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S U M M A R Y 
(Chapter 1) This thesis addresses four questions relevant to the behavioural teratogenicity of 
medical drugs: 
ι. Which medical drugs are used most frequently during pregnancy? 
2. What drugs can be expected to produce effects and what effects can be expected? 
3. What are the best design strategies to study the behavioural teratogenicity of medication 
during pregnancy from a theoretical and methodological point of view? 
4. Are these studies possible in practice and do they provide useful information about the 
effects of specific groups of drugs? 
(Chapter 2) Studies carried out all over the world including the Netherlands, on drug use 
during pregnancy show that many women use medical drugs during pregnancy. 
Exact figures are difficult to obtain because the studies employed different design 
characteristics (definition, methods of data collection and study population). Chapter 2.2 
shows that fifty per cent of the variation in study results can be explained by differences in 
methods of data collection. Differences between definitions (types of drugs studied) and 
the type of (sub) population included in the study also introduced large discrepancies 
(5-40%) in the results. 
Chapter 2.3 describes a prospective study on the use of medication during low-risk 
pregnancy in a cohort of women supervised by specialist obstetricians at a university 
hospital («=332) and a cohort of women supervised by midwives in private practice 
(«=250) in the Netherlands in 1984-85. Drug use was measured through several interviews 
during pregnancy. Women under the supervision of obstetricians used medication more 
frequently than women supervised by midwives (nearly ninety per cent versus sixty per 
cent, respectively). Iron supplements and local anaesthetics for episiotomy were excluded 
from this study. From a medical point of view the fact that medication is used during 
pregnancy is of more interest than the frequency of drug use and the amount of drugs 
used. The most interesting question from a pharmaco-epidemiological point of view is 
which medical drugs are used during pregnancy. The top-five medications were 
analgesics, antacids, vitamins, antibiotics and dermatological preparations. 
To investigate the variation over time of the amount and the type of drugs used 
during pregnancy, we studied data on drug use during pregnancy obtained in Sweden 
between 1980 and 1983. Drug use was estimated on the basis of the answers to a few 
questions asked once during and once after pregnancy in a study on occupation and 
pregnancy outcome. We compared the results to drug use during pregnancy which had 
been measured in earlier periods (1963-65 and 1979-80) in Sweden (chapter 2.4). In the 
most recent period, it was found that two thirds of the women had taken at least one drug 
during pregnancy, excluding iron supplements and drugs taken at delivery. Analgesics 
were used most commonly, followed by antibiotics. The amount of drug use (and 
especially the use of analgesics and psychopharmaceuticals) was smaller than in 1963-65, 
and similar to that in 1979-1980. In the early eighties, pregnant women in Sweden were 
encouraged to take 'simple' drugs for common disorders, such as analgesics for common 
colds and anti-emetics for nausea. Therefore, further limitation of the use of drugs to those 
strictly necessary for the health of the mother or child would be possible. 
(Chapter 3) The second question dealt with the teratogenic potential of the drugs that were used 
most frequently during pregnancy. Emphasis was laid on behavioural effects, as these 
might occur in situations where morphological congenital abnormalities do not occur. 
A review of the literature on the behavioural teratogenicity of medical drugs 
showed that the behavioural teratogenic potential of many of the drugs on the market has 
never been studied in humans Drugs for which an association can be expected with 
behavioural or functional effects in exposed offspring were psychopharmaceuticals, 
especially anti-epilepbc medication, and hormones No information was found about the 
effects of antacids, antibiotics, dermatological preparations and most vitamins on the 
functional development of the prenatally exposed child (chapter 3 1) 
With such a limited body of knowledge, there is a need for more explicit studies on 
the functional sequelae of prenatal exposure to medical drugs in humans As Post-Market-
ing Surveillance is not adequate and registries of congenital anomalies do not include 
functional developmental problems, these studies have to have an ad hoc character 
(Chapter 4) The third study question was What are the best design strategies to study the 
behavioural teratogenicity of medication during pregnancy7 
To study the effects of prenatal exposure using epidemiological methods, two designs can 
be considered case-referent studies and cohort studies Randomized trials would be the 
most useful design, but they are considered to be unethical for the investigation of side-
effects 
The case-referent approach is only valid if exposure (use of medical drugs during 
pregnancy) and confounder information can be measured accurately at the time the out-
come is measured We therefore studied the completeness and the accessibility of various 
retrospective sources of data on drug use during pregnancy Information was returned on 
request by the CP and the pharmacy which supplied the drugs during the ïndex-preg-
nancies and was obtained from the hospital records and during a structured interview 
with the mothers of mentally retarded or physically disabled children The information 
from the mothers was the most extensive Pharmacists and GPS did not agree with each 
other on the type of drugs used Furthermore, many pharmacists were unable to provide 
the requested information because they had not kept the records (chapter 4 2) In another 
study, we sent a questionnaire on medical drug use during pregnancy to women who had 
participated in a study on drug exposure during pregnancy seven and eight years earlier 
Exposure recall was found to be imprecise seven and eight years after pregnancy The 
sensitivity for anaesthetics was the highest with eighty per cent, while for most drug groups 
a maximum of half of the exposed subjects could be identified with the questionnaire filled 
in by the mother (chapter 4 3 and 4 4 ) A questionnaire on the behaviour of the child was 
also filled in, so we had the opportunity to evaluate the existence of differential recall in this 
study There were indications that the error in the exposure measurement depended on the 
outcome under study and this led to recall bias Spurious associations of some drugs with 
the outcome under study could be the result (chapter 4 4 ) 
The cohort design is valid if a reference group is chosen which resembles the ex-
posed group as closely as possible for the relevant characteristics This is not easy because 
treatments vary over time and, more importantly, they depend on the exact indications for 
treatment, such as the seventy of the disease (chapter 4 6 ) Cohort studies are feasible in 
principle, but long-term follow-up and outcome measurement are often expensive and 
impractical Historical cohort studies can only be conducted for drugs whose use during 
pregnancy has been adequately documented m the past Both study designs were 
investigated for their practical feasibility 
SUI 
(Chapter5) In a follow-up study on 1000 children born at an obstetrics department of a 
university hospital, a questionnaire on the behaviour of the child ('CBCL', Child Behaviour 
Checklist) was filled in by the parents Associations were found between prenatal exposure 
to analgesics and behavioural deviations in boys and in girls, while exposure to hormones 
was associated with depressive behaviour in girls However, follow-up of this cohort was 
of limited value because only a small number of children had been exposed to specific 
drugs Thus, a survey-type of cohort study will have to be very large to provide enough 
information on the less frequently used medical drugs 
(Chapter 6) In a case-referent study on prenatal exposure to medication and mental retardation 
among cases with an IQ ot below 80 and referents with an IQ of over 90 from a patient 
population at a children's neuropsychological department, an association was found 
between mental retardation and exposure to antibiotics in children with highly educated 
mothers Information on exposure was collected from the parents, GPS, pharmacies and 
hospitals The association between mental retardation and exposure to antibiotics in 
children with highly educated mothers may well be an artifact The findings in case-
referent studies should be interpreted with caution because of uncertainty about the 
accuracy (of recall) of the information on exposure 
10 (Chapter 7) A historical cohort study showed that children prenatally exposed to the anti­
hypertensive medication labetalol had worse concentration scores as compared to children 
prenatally exposed to melhyldopa Moreover, children exposed to labetalol were more 
often classified as inattentive by their teachers None of the other developmental 
assessments differed between the children exposed to labetalol and the children exposed to 
methyldopa Historical cohort studies are practicable, although it can be expensive to 
ascertain the outcome and administratively labour-intensive if a large proportion of the 
mothers have moved house during follow-up, making retrieval of new addresses 
complicated 
(Chapter 8) Although epidemiological studies on behavioural teratology may be conducted, 
more emphasis should be laid on improving Post-Marketing Surveillance activities 
Improvement of Post-Marketing Surveillance would be the most direct if at least the first η 
children exposed to a new drug were to be followed-up for life, и depending on the max­
imum acceptable risk Better recording of exposure to medical drugs would improve the 
possibilities for non-expenmental studies on behavioural teratology Computerized 
administration of dispensed drugs at pharmacies is expected to play an important role m 
future studies It is suggested that follow-up can be carried out through existing pathways, 
such as infant welfare programmes and school health programmes 
C H A P T E R 
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Since the discovery that thalidomide exposure during pregnancy induced dys-
melia in the fetus in the early sixties [1], drug exposure during pregnancy has been viewed 
as a potentially harmful event which should be prevented as much as possible. However, 
views and practice are not always compatible. In box i, a striking example is presented of a 
woman who took as many as 33 different preparations during pregnancy. This case report 
may signal that excessive drug use does occur in isolated pregnancies, but it does not 
provide any quantitative estimates of the frequency and character of drug use during 
pregnancy on a population level. Surveys should provide information about drug use in a 
particular situation defined in terms of time and location. Although such studies have been 
conducted [2-6], they differ with regard to methods of data collection, type of study 
population and the definition of drugs and drug groups. Their results, therefore, cannot be 
combined into an overview of actual drug use during pregnancy and its variation over 
time and location [2]. However, the frequency of medical drug use during pregnancy was 
high in all these studies. Apparently, many pregnant women need drugs. It is important to 
know the risks associated with drug use during pregnancy in order to be able to make a 
rational choice of treatment if necessary. 
The thalidomide drama drew attention to the possibility that the use of drugs dur­
ing pregnancy could lead to anatomical defects in the offspring. Since then, the conviction 
Box 1 Drug use during pregnancy ' 
PCM Pasker-de long, TKA8 fides, Щ van Dongen, KL Bos 
Pharmacotherapy during pregnancy should be as restricted as 
possible since the teratogenic properties of most drugs are unknown. 
Furthermore, pregnant women may be more prone to side-effects of 
drugs. 
Recently, a 33-year old pregnant woman, gravida 3, para 2, 
35 weeks pregnant, was referred to our Obstetrical Department be­
cause of pancytopenia and anticipated complications after premature 
contractions earlier in pregnancy. She complained of fatigue after an 
influenza-like illness. At physical examination we saw a woman in gen­
eral distress, very anaemic (Hb 3.6 mmd/l) and with an underfilled 
vascular system. She said that she had not eaten for a month. Her 
nutritional status was bad and she was depressed. Folate deficiency 
and pneumonia were diagnosed. Pancytopenia was present 
On admittance she brought with her a plastic bag full of medical 
drugs, prescribed to her by her general practitioner from whom she 
had received the prenatal care up to then. We checked the prescrip­
tions with her pharmacist who confirmed - on a computer outprint -
that during her pregnancy 61 prescriptions had been dispensed to 
her. Among the 33 preparations prescribed were S antacids, A benzo­
diazepines, 7 antibiotics - local as well as systemic - and some other 
drugs, №e paracetamol, iron tablets and a corticosteroid. The drugs 
had been prescribed because of nervousness, fears, depressions, 
'hysteric syndrome', frequent headaches, genital infections and an in­
fluenza-like disorder. At 30 weeks of pregnancy, threatening premature 
labour was treated in another hospital. On admittance, all medications 
were discontinued. 
Of the drugs the patient had taken, propranolol, nitrofurantoin 
Cimetidine, Indometacin, paracetamol and butylscopolamine may in­
terfere with the folate metabolism. The pancytopenia was thought to 
have been of toxic origin, and to be a result of the folate deficiency. 
The patient was treated with folic acid, with pepcldin because she had 
intestinal bleedings and with amoxycillin because of the pneumonia. 
She recovered slowly. At 37 weeks, labour started and was supported 
with oxytocin. A healthy girl weighing 2,900 ς was bom, with Apgar 
scores of 5 at one min and 8 at five min. Although no adverse effects 
on the neonate were apparent, the medical drugs that had been pre­
scribed and issued to this pregnant woman were not without risks. 
We thought that nowadays the knowledge of teratogenic prop­
erties of medications and the computerized dispensing of the prescribed 
medications by pharmacists would make the present case impossible. 
We seem to be wrong. Although it is known that pharmacotherapy 
should be limited during pregnancy, neither physician nor pharmacist 
did attend sufficiently to avert this extensive and irrational therapy. 
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CHAPTER 1 INTRODUCTION 
has grown that other health outcomes, such as behavioural characteristics, may also be 
sensitive to prenatal drug exposure [7] The study of teratological effects should therefore 
be focused on all defects in the offspring 
In the premarketing phase of every drug that appears on the market, animal 
experiments, mostly in rats and mice, are conducted to study the potentially harmful effects 
of medical drugs on the fetus The results of these animal experiments may provide useful 
indications of the teratogenic potential for inducing morphological effects, but their 
extrapolation to the human fetus is not always straightforward For example, m the 
standard experiments on rats, thalidomide did not show any teratogenic potential at the 
doses studied In some rabbits, which arc not routinely studied, a dose which was five times 
larger than the teratogenic dose for humans had to be given to induce the characteristic 
phocomeha [8] Inversely, caffeine is highly teratogenic for the fetuses of the rat as it induces 
skeletal malformations and abortions [9] and behavioural disturbances [10], while in 
humans the teratogenic potential of caffeine has not (yet) been established [11,12] 
It will be even more difficult to predict the effects of exposure in utero on human 
functions from the results of animal experiments For instance, the reproductive 
performance of exposed offspring is usually measured by the number of resorptions or the 
number of fetuses per pregnancy The implications of these findings in the rat for human 
reproductive function after prenatal exposure are unknown, as humans usually have only 
one child at a time The interpretation of functional developmental disorders of the central 13 
nervous system (CNS) in animals in relation to human functions is even more difficult [7, 
pp 197-198] For instance, the equivalents of dysfunction of the offspring of exposed 
animals on 'maze-learning' tests or 'active avoidance conditioning' are not intuitively clear 
m the human fetus Furthermore, more complicated functions of the human brain do not 
occur in animals and therefore cannot be studied in them Moreover, it is thought that 
functional effects on children may occur predominantly after exposure in the second 
and/or third trimester, when the brain has its second growth spurt and differentiation of 
most of the cells in the CNS takes place This period does not occur during pregnancy in the 
rat, which is the animal used most frequently for teratology studies It is only recently that 
studies on the effects of early neonatal exposure in rats have become usual 
In the premarketing phase, there is no alternative for animal experiments to study 
the (behavioural) teratogenicity of medical drugs before they are marketed Too few 
humans participate in studies on the intended and unintended effects of a drug m the 
premarketing phase to detect infrequent side-effects, and if the drug is not expressly 
developed for use during pregnancy, pregnant women are excluded completely from these 
studies Thus, many possible teratogenic side-effects will not have been studied in humans 
before a drug is admitted to the market, which emphasizes the need to study the side-
effects of new drugs once they are on the market This is the intention of Post Marketing 
Surveillance (PMS) Nowadays, PMS in most countries is based on the voluntary reporting 
of perceived side-effects If Post-Marketing Surveillance is to add to the safety of new 
drugs, it should be carried out systematically for all new drugs, with follow-up of the first 
и exposed in utero, и depending on the maximal acceptable risk 
Until systematic Post-Marketing Surveillance is introduced on a larger scale for 
teratogenic as well as other side-effects, information about the teratogenicity of drugs for 
human fetuses can only come from epidemiological studies The drugs that are presently 
being used during pregnancy should therefore be evaluated thoroughly and priority should 
be given to the drugs used most frequently and to those for which alternative treatments exist 
CHAPTER 1 INTRODUCTION 
Knowledge about (the absence of) mapr teratogenic effects of medical drugs based 
on epidemiological studies is growing but it is far from complete New evidence, even 
related to drugs that have been on the market for many years [e g box 2], is still being 
added Information on functional sequelae is even more scarce A growing number of 
epidemiological studies on the behavioural teratogenicity of medical drugs have been 
published, but no consensus has been reached - or aimed at - about outcome measures and 
ways of collecting data, so the results seem to be inconsistent An even larger problem is 
the lack of knowledge on the best way to collect information about exposure To increase 
our knowledge about the impact of methodology on the results, more methodological 
epidemiological studies should be undertaken and consideration should be given to the 
end points to be studied It is necessary to reach agreement on a study design and ways to 
measure exposure and outcome 
Box 2 Psychopharmaceuticals and perinatal deaths * 
KM Pasker-de long, С Ahlborg ¡r, L Bodin, CA Zielhuis 
Re Uegreid L, Conradi N, Hagberg G, Hedner T, Psychotropic drug 
use, including benzodiazepines, in pregnancies resulting in perinatal 
death Acta Obstet Gynecol Scand 1992,71 451-457 
Laegretd et al reported the results of a case-referent study on psycho-
tropic drug use during pregnancy and perinatal deaths They found a 
statistically significant Odds Ratio of 3 1 for the use of psychopharma 
ceubcals in perinatal deaths as compared to live births They state that 
this is a 'noteworthy finding' We found a nearly thirteenfold increased 
nsk of pennatal death for women using psychopharmaceuticals dunng 
the first trimester of pregnancy in a secondary analysis of a dataset 
originally collected to study occupational hazards for reproduction 
The design of our study has been published elsewhere [1 ] In short, all 
women registenng at pregnancy care centers in Orebro county from 
October 1980 through Jury 1983 were asked to fill In a setf-
admimstered questionnaire before the first prenatal health check-up, 
1 e mostly in the second or third month of pregnancy Among others, 
questions were asked about the intake of medical drugs Midwrves 
collected information from hospital records and from the women 
themselves several months after pregnancy The midwrves asked about 
pregnancy outcome, illnesses dunng pregnancy, and drug intake 
related to these illness Only singleton pregnancies in non-chromcally 
iH women (n=4701) were included in the analyses Analyses were done 
on several relationships between aght groups of drugs and 5 
pregnancy outcomes thought to be of interest. Out of twelve risk 
ratio's calculated, four showed to be different from unity 
The most stnking result was a relative nsk of 12 7 (test-based 95% 
confidence limits 5 0, 32 4) for pennatal death with the use of psycho-
pharmaceuticals dunng the first trimester The psychopharmaceuticals 
used were mostly benzodiazepines and phenothiazines The relative nsk 
was higher for regular users (RR=24 0, 6 2 92 2) than for occasional 
users (RR=5 4, 0 8-38 5) but numbers were very small No specific type 
of drug could be held responsible for the increased nsk 
In our study, there were only three exposed cases and 25 non-exposed 
cases so that, even though the result was highly significant, chance may 
have played a rôle If one case less had been found, the relative nsk 
would have been 8 5 (test based 95% confidence limits 2 6, 28 2) 
Now that two studies have yielded a similar relationship, the possibility 
cannot be excluded that the use of psychopharmaceuticals increases 
the risk of pennatal death m children exposed in utero Since some 15% 
of pregnant women use psychopharmaceuticals [2,3], the question is of 
major importance There is an urgent need for larger studies to be 
earned out on this subject 
иееолпсеа 
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CHAPTER 1 INTRODUCTION 
This thesis was written in this context and focussed on the following questions: 
ι. Which medical drugs are used most frequently during pregnancy? (chapter 2) 
2. What drugs can be expected to produce effects and what effects can be expected? 
(chapter 3) 
3. What are the best design strategies to study the behavioural teratogenicity of medication 
during pregnancy from a theoretical and methodological point of view? (chapter 4) 
4. Are these studies possible in practice and do they provide useful information about the 
effects of specific groups of drugs? (chapters 5,6 and 7) 
In the light of our findings, the feasability, directions, strengths and weaknesses of 
pharmaco-epidemiological studies on behavioural teratology are discussed in chapter 8. 
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2.1 Introduction 
Monitoring drug prescription and drug utilization patterns during pregnancy is 
important for several reasons. Firstly, it may lead to interventions if medical drugs which 
are contra-indicated during pregnancy are found to be used or prescribed (too) frequently. 
Appropriate steps may then be taken to prevent the use of these drugs in future 
pregnancies. Secondly, it may lead to research into the drugs used most frequently for 
which (teratogenic) safety has not yet been established. If these drugs should prove to be 
hazardous to the fetus, prevention of their use might have the greatest effect on a 
population level. 
The frequency and character of medical drug use during pregnancy has been, and 
still is, the subject of many studies. The results suggest that the use of medical drugs is not 
limited to drugs that are thought to be medically necessary for the mother and/or child. 
The use of medication varies over time and between geographical locations 
because new drugs are introduced onto the market, new indications materialise for 
existing drugs and legislation is not uniform over the world. Time and geographical 
location therefore restrict the utility of the results of pharmaco-utilisation studies; this 
means that the monitoring of drug use should remain an area for continued research. So 
far we do not know the extent of variation in time and location and what factors are likely 
to determine drug use. Moreover, these variations in time and over geographical location 
cannot be studied easily from previously published material because the study designs 
vary considerably with regard to the definition of 'drugs' and 'drug groups', methods of 
data collection and type of study population. The results of utilization studies may well be 
biased by these design characteristics. 
This chapter describes these methodological fallacies in relation to comparing 
figures on drug utilization, provides some insight into temporal and geographical 
differences and presents an overview of figures with respect to the frequency of medical 
drug use by pregnant women at low risk for pregnancy complications in the Netherlands 
in 1983. 
CHAPTER 2 1 FREQUENCY AND CHARACTER Of DRUG USE DURING PREGNANCY 
2.2 Medical drug use during pregnancy; 
a review of methodological fallacies* 
PCM de long, CA Zielhuis, WS Nijdam, TKAB Eskes 
Abstract Many women use drugs during pregnancy. Almost all the studies on drug use 
during pregnancy have shown that 70% or more of pregnant women take at least one drug. 
The results of these studies, however, are not directly comparable because the study 
designs vary to a large extent with regard to the definition of drugs, methods of data 
collection and study population. In this paper, the effect of these characteristics (definition, 
methods of data collection and study population) on the results is evaluated on the basis of 
data from three studies on drug use during pregnancy. The methods of data collection had 
the most influence on the results: fifty per cent of the variation could be explained. 
Differences between definitions also introduced large discrepancies {5-40%) in the results. 
There is an urgent need for a standard study protocol. In the meantime, detailed informa­
tion about the methods and definitions used should be given when presenting the results 
of studies on drug use during pregnancy. 
Introduction Many studies have been published on drug use during pregnancy [1-14]. Several of 19 
them [1,7,8] were carried out shortly after the thalidomide drama at the beginning of the 
1960s. They showed that a fairly large proportion of women use drugs during pregnancy. 
Later studies [5,8,11,13,14] showed a small decrease in the number of drugs per woman 
and the proportion of women taking drugs during pregnancy. A summary of the study 
results is shown in table 1. As can be seen, there is wide variation in the proportion of 
pregnant women who took drugs. For example, Hill [10] (prior to 1973) and Doering and 
Stewart [4I (1974-76) found that 100% of the pregnant women in their study populations 
used at least one type of drug. The mean number of different drugs per woman was 10.3 
and 18 respectively. On the other hand, Rubin et al. [13] (1984-1986) and Simpson et al. [14] 
(1980-85) concluded that the use of drugs during pregnancy had diminished, because only 
34.8% and 56.4% of the women took at least one type of drug, respectively. The results of 
all the other studies fell in between, with a predominance of about 70-80% of women 
taking at least one drug during pregnancy. The mean number of different types of drug 
reported in the various studies varied between 1.3 and 18 per woman. 
In several reports, researchers have tried to compare the results, however this is 
difficult because of the large difference between the methodologies, a factor which is often 
overlooked. Only Brocklebank [3] made restrictions in his comparison. He split up the 
results of studies according to differences in the definition of drugs, because he assumed 
that these differences were responsible for much of the variation in the results. Studies 
have been found to differ as to whether or not certain types of drugs are included, such as 
iron and vitamin supplements, non-prescription drugs (отс), drugs given at delivery 
and/or drugs for local application. 
Comparing the different study results also involves other problems. Study 
methods and especially methods of data collection, may influence the results to some 
extent. It is likely that a prospective study in which pregnant women are interviewed each 
•Publlihcd In I PharmacoepMcfflM 1990;1:61-75. 
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Table 1. Summary of 
studies on drug use during 
pregnancy 
Author 
Heinonen (13) 
RCCP (*2) 
Forfar (10) 
Harjulehto(H) 
Hill (15) 
Eskes(8,9) 
Doering (7) 
Brocklebank (4) 
Meire (20) 
Eskes (8,9) 
Simpson (24) 
Rubin (23) 
De |ong (17) 
Country 
USA 
UK 
UK 
SF 
USA 
NL 
USA 
USA 
В 
NL 
USA 
Yean of 
study 
59-65 
63-65 
63-65 
64-84 
<1973 
74-75 
74-76 
75-76 
1977 
78-79 
80-85 
Women with diabetes 
UK 
NL 
82-84 
87-88 
* RCCP= Royal College of Cenerai Practitioners 
η = no. of study subjects 
π 
50282 
500 
911 
659 
156 
1000 
168 
2528 
500 
1000 
387 
342 
2765 
1000 
% Users 
94.2% 
82.0% 
82.1% 
66.0% 
100.0% 
82.7% 
100.0% 
62.0% 
98.6% 
71.7% 
56.8% 
65.8% 
34.8% 
86.0% 
Mean No. 
Drugs p/p 
3.8 
1.9 
4.2 
? 
10.3 
2.0 
18.0 
? 
4.4 
1.7 
1.3 
1.7 
7 
? 
month about their use of drugs and are requested to write down every drug used in a 
diary, will produce quite different results from a retrospective study performed on 
hospital records. In between these extremes, there are a variety of study methods available, 
such as data collection through records, questionnaires or interviews with open or 
multiple choice questions, data collection before or after delivery, or several times during 
pregnancy or only once. Abstracting medical or pharmacy records will miss most of the 
over-the-counter (отс) drugs because these are not recorded [2,15]. It is well-known that 
medical records are often inaccurate [16], but these are still being used for drug utilization 
research. Interviews and questionnaires may involve recall errors [17,18]. A questionnaire 
design also influences the results. Open ended questions will not give as much information 
about drugs taken for specific complaints as explicit questions [19]. Data collection through 
interviews held some time after delivery may give highly inaccurate information, 
especially about the use of drugs early in pregnancy [20]. A combination of records and 
interview is probably the best approach [21]. 
A third point (after the definition of drugs and the method of data collection) may 
be the selection of the study population. Depending on the method of subject recruitment, 
bias may occur towards selecting women with high or low-risk pregnancies. This problem 
is especially prevalent in the Netherlands where high-risk pregnancies tend to be delivered 
in hospitals, whereas low-risk pregnancies are often delivered at home. But in any study 
population, the possibility exists that health-conscious women will be selected who follow 
a different drug-consumption pattern. 
There is a vague possibility that these three factors are of relevance to the inter­
pretation of the results presented in the literature, but it is not obvious what the relative 
importance is of these methodological factors. We estimated the relative impact of the 
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three factors (definition, method of data collection and study population) in three Dutch 
surveys on drug use during pregnancy 
Populations and Information was available from three different studies, all earned out in the 
methods catchment area of one University Hospital In all three studies, the drugs were coded ac­
cording to the same classification system, which was based on the Dutch Pharmaco-
therapeutical Compass, 1984 I22I 
1 The first study was carried out in 1984 with a group of 1,007 pregnant women 
who were consecutively registered for prenatal care and delivery at the university hospital 
Seventy per cent of these had medical risk factors [23] which formed an indication for 
specialist obstetrical care Twenty-nine twin pregnancies were excluded from the analyses 
One of the authors (WSN) kept a record of the drugs and the period of use, which was 
updated at each prenatal visit to the obstetrical care unit After delivery, an in-depth 
interview was conducted, in which the record was checked, completed and corrected 
Whenever there was doubt about the name of a drug, it was checked with the pharmacy 
Iron supplements were excluded because at our hospital it was given routinely to all the 
women Routine information on delivery and pregnancy outcome was available for the 
total group of 978 women 
2 The second study was performed from 1984 to 1985 [24] on 1,034 low-risk 21 
pregnancies They were selected from a group of 1,503 women with virtually no nsk 
factors The women had chosen to be supervised either by a midwife (п=6з8), or by their 
General Practitioner (GP) (n=i28) or by an obstetrician (n=268) A structured interview was 
held within nine days after delivery Various questions were asked, including details about 
the pregnancy outcome, complications during delivery and drug use during pregnancy 
The information was not checked with the pharmacies or GPS 
3 The third study (carried out in 1985) investigated drug use in 251 low-risk 
pregnancies The women were supervised by a midwife in private practice Drug use was 
recorded by the midwife at each prenatal visit A check-up after delivery was not carried 
out and no information was available on the pregnancy outcome 
The comparison of subsets from these three studies enabled us to estimate the impact of 
differences between the definition of drugs, the methods of data collection and the study 
populations 
a The impact of differences between définition was evaluated by calculating the 
proportion of medications excluded when changing the definition and by comparing the 
effect of changing the definition within study 1 
b The impact of method of data collection was studied in each population of 
women without a medical indication who were under the supervision of either a 
gynecologist or a midwife Two 'prospective' studies (numbers 1 and 3 with interviews 
during each prenatal visit and an in-depth interview after delivery, supplemented by 
checking the hospital and pharmacy records) were compared to a 'retrospective' study (no 
2, with a questionnaire filled in within nine days of delivery) 
с Differences between study populations which led to differences in outcomes 
were estimated on the basis of data from study 2, by comparing the women who were 
supervised by a gynaecologist to the women who were supervised by a midwife or GP 
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Most of the results are shown as frequency plots, because the distribution of the 
number of drugs per woman is skewed. Although the mean number of drugs per woman 
is not a very appropriate measure, the value has been shown for reasons of comparison to 
the data reported in the literature. 
Results Definition of dnjgs 
Figure ι lists all the drugs used, divided into differing groups. The figure shows the 
proportion of drugs which would be missed if one or more of the groups were excluded 
from the definition. 
Figure 2 is an example of the effect of excluding different groups of drugs used in 
study ι. It shows the frequency distribution of the number of drugs taken per woman 
using the different definitions and their effect on the mean number of drugs taken. The 
frequency distribution of number of drugs per woman excluding iron supplements is not 
shown, because they were already excluded from study ι. 
22 
Method of data collection 
There were large differences between the results of the 'prospective' and 
'retrospective' studies, as can be seen in Figures ja and jb. Assuming that the actual use of 
drugs was similar m all the studies, about half of all the drugs (excluding iron supplements 
and delivery drugs) were not identified in the 'retrospective' study. 
Population 
The women in study г who visited the hospital prenatal care centre, took 15% more 
drugs than those who were supervised by their GP and 30% more than those supervised by 
a midwife (figure 4). None of the women had a medical indication for hospital delivery. 
Discussion Our results indicate that the study design of studies on drug use can greatly 
influence the results. According to our data, differences in definition may very easily 
account for some 5-40% variation in the results. A superfluous method of data collection 
may overlook more than 50% of the drugs taken. Variation in the results because of patient 
tigure 1 Distribution of 
all drugs used over the 
various groups 
100% 
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Figure 2. Example of the 
impact of changes m 
the definition of drugs in 
study I on the frequency 
vlot and the mean number 
of drugs per woman. ORIGINAL DEFINITION 
3 21 (100%) 
" I 
10 • 
" I 
12 I 
EXCLUDING DELIVERY 
2 AS (76%) 
23 
ι 
J 
10 
ι 
15 
EXCLUDING V I T A M I N S 
3 00 (93%J 
» I . 
EXCLUDING OTC DRUGS 
2 48(22%) 
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Figure 3 Impact of data 
collation method 
Frequency distribution of 
drugs taken per woman m 
different studies, assuming 
similar populations and 
similar definitions 
Gynaecologists 
24 
Midwwes 
3 4 5 
retrospective 
selection of study populations may be of relevance, as according to our analyses, it may 
distort the results by 15-30% 
These quantitative results should be generalized with caution for the following reasons 
ι The impact of definition differences on the study outcome depends on the pre­
valence of the drugs excluded from the definition m the study population ( e g , if iron 
supplements are hardly ever being used by pregnant women, excluding them from the 
study will not materially change the results) 
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Figure i. Frequency 
distribution of number of 
drugs per woman in 
different populations, 
assuming similar studies 
and simitar definitions. 
2 Î 4 S 6 
gynaecologists 
2 3 4 S 
nildwlv« 
2. The impact of the study methods depends on the definition of drugs. If simple 
analgesics are included in the study, an examination of the hospital and pharmacy records 
will probably yield incomplete results, whereas if only prescription drugs are of interest, 
this may be a valid method. Furthermore, the methods of data collection may differ to a 
much larger extent in the literature than they did in our three studies. 
3. The impact of population selection may never be as large in other countries as it 
is in the Netherlands, where high-risk pregnancies are supervised by a gynaecologist and 
low-risk pregnancies are often completed without any contact with a hospital. In the 
Netherlands, hospital-based studies may select high-risk patients with a high intake of 
drugs. 
25 
Despite these problems, we believe that our results can be interpreted at least 
qualitatively, i.e., our study supports the idea that methodological factors may explain a 
considerable part of the variation in the results of studies on drug consuming behaviour in 
pregnancy. 
It may therefore be concluded that the differences between the results reported in 
Table 1 reflect the differences in study design and the definitions used. Table 2 shows the 
relevant design characteristics of the studies mentioned in table 1. Some studies excluded 
many drugs from their inquiry [13,14,17]. Studies in which the definition of drugs was very 
broad, reported a high proportion of users [4-6,12]. In other studies which reported a high 
use of drugs, data collection occurred several times before delivery, through interviews 
and verification in the medical hospital and GPS records. 
Owing to the fact that many pregnant women are still using medical drugs, some 
of which are contraindicated during pregnancy, monitoring drug taking behaviour should 
be continued. There is an urgent need for standardisation of the study method and the 
definition of drugs for future monitoring. A suitable standard method should preferably 
be a prospective study with interviews at frequent intervals (e.g., each month) and perhaps 
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Table 2 Methodology of the 
studies shown in table 1 
Author 
Heinonen (13) 
RCCP (*2) 
Forfar (10) 
Har|ulehto(11) 
Hill (15) 
Eskes (8,9) 
Doenng (7) 
Brocklebank (4) 
Meire (20) 
Simpson (24) 
Rubin (23) 
De Jong (17) 
Drugs Excluded 
iron, delivery 
iron, delivery 
iron, delivery 
delrvery7 
iron, vitamins 
iron 
none 
OTC, delivery? 
delivery 
iron, vitamins, delivery 
iron, vitamins, delivery 
OTC 
Data Collection 
interview, records 
CP records 
interview, records 
interview, records 
interview 
interview, hospital 
+ CP records 
interview, hospital records 
Medicaid 
interview 
interview 
questionnaire, records 
pharmacy records 
Measurements 
several, before delivery 
several, before delrvery 
after delivery 
after delivery 
once, before delivery 
several, before and after 
delivery 
several, before delivery 
after delivery 
after delivery 
once, before delivery 
several, before delivery 
after delivery 
* RCCP= Royal College of Cenerai Practitioners 
26 a diary, completed by verification of the information with physician and hospital records. 
Information about the prevalence of high-risk pregnancies should be included in the 
results. Consensus should be reached on what drugs should be included and excluded 
from the definition. In the meantime, complete information about the study and especially 
about the definition of drugs are necessary to draw conclusions about drug taking beha­
viour in pregnant women in different countries. 
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2.3 Medication during low-risk pregnancy * 
PCM de¡ong, WS Nijdam, CA Zielhuis, ТКАВ Eskes 
Abstract The use of medication during low-risk pregnancy was studied prospectively in a 
cohort of women supervised by specialist obstetricians at a university hospital (n=332) and 
a cohort of women supervised by midwives in private practice (n=25o). More women 
under supervision of obstetricians/gynaecologists used medication (87.7%) than women 
supervised by midwives (59.87c). The top-five of medication were analgesics, antacids, 
vitamins, antibiotics and dermatologie preparations. More research is needed to establish 
the risks of these medications to the offspring. 
Introduction Every handbook on Gynaecology and Obstetrics advises against drug use during 
pregnancy, because the effects on the developing fetus and infant are usually unknown. 
Numerous effects may be expected, depending on the drug taken, the dose and the gesta­
tional age. Theoretically, they range from embryonal death (drugs taken during the first 
2 weeks) to minor functional disturbances. 
Except for the well-known teratogenic effects of, e.g., diethylstilboestrol [1], 
28 thalidomide [2] and isotretinoin [3], most modern drugs are not thought to have any 
significant negative effect on fetal development. Occasionally, a publication appears in 
which the name of a drug is connected with some sort of adverse pregnancy outcome, for 
example, bendectin with major malformations [4], Clonidine with functional disorders [5] 
and clomiphene with neural tube defects [6]. 
After the thalidomide drama in 1961-62, drug use during pregnancy was expected 
to diminish abruptly. However, studies showed that pregnant women were still using 
many drugs. Table 1 shows a summary of the results of various studies. 
From the Perinatal Project carried out from 1959 to 1965 in the USA, Heinonen et al. 
[7] concluded that 94.2% of 50 282 pregnant women used medication (mean 3.8), excluding 
iron supplements and medication taken at delivery. There was an upward trend in the 
number of drugs per woman after 1962. Forfar and Nelson [9] conducted a study from 1963 
to 1965 in the UK, in which they found that 82.1% of 911 pregnant women used medication, 
excluding laxatives and dermal preparations. The average number of drugs used was 4.2 
per person. More recently, reports in the literature claim that drug use during pregnancy 
has diminished. Simpson et al. [14] conducted a study from 1980 to 1985 in the USA. Fifty-
seven per cent of the women used medication and the mean number of drugs was 1.3 per 
person. Methodological differences between the studies may have played an important 
role [17]. Harjulehto et al. [13] published a study based on the Finnish registry of birth 
defects over the period 1964-1984. Of the 659 women in the study, 66% reported drug use 
during pregnancy. A diminishing trend in time could only be found for analgesics and 
tranquilizers. In 1990, the Collaborative Study on E>rug Use in Pregnancy published a 
preliminary report [16]. Drug use varied in 17 countries between 61 and 100% of the 
women. Mean number of drugs was 2.2 per person. The categories of drugs most often 
used in the studies mentioned in table 1 were vitamins, analgesics and iron. But other drugs 
were also frequently used. 
* Submitted as a letter to the editor 
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In the Netherlands, two studies comprising 1000 women each were performed in 
1974 and 1978. Eskes et al. lio] reported that drug use diminished from 82.7% to 717% and 
that the mean number of drugs diminished from 2.0 to 1.7 per person. The studies were 
carried out at a university hospital in which women at high risk for pregnancy 
complications were overrepresented. Among these women were those who were treated 
for chronic or life-threatening diseases. Some risk for adverse effects of the medication 
used on pregnancy outcome has to be taken in these cases. Women with low-risk preg-
nancies are more likely to only use drugs to treat minor conditions such as headache. 
Furthermore, from the point of view of prevention, the safety of drugs used by many 
pregnant women should be assured. Medical drugs which are hardly ever used in 
pregnancy give less reason for public health concern. 
We studied the drug use in two groups of low-risk pregnancies in the Eastern part 
of The Netherlands. One of the two groups was supervised by obstetricians/gynae-
cologists and the other by midwives in private practice. We evaluated what drugs were 
used, how many women used them and at what stage during pregnancy. 
Populations and 
methods 
Table Ì. Summary of 
studies on drug use during 
pregnancy. 
Author [Ref] 
The use of medication during pregnancy was investigated prospectively in women 
at low risk for pregnancy complications. Those women could choose for prenatal care and 
delivery at a university hospital (group 1: gynaecologists) or for prenatal care and home 
delivery (group 2: midwives). In both groups, the medication was coded in accordance 
with one classification system, which was based on the Dutch Pharmacotherapeutical 
Compass, 1984 [18]. 
Group 1 was part of a study carried out on 978 pregnant women who were con-
Country Study Period Usen (%) Mean no Super-
drugs p/p visor 
Including 
F V Ρ 
29 
Heinonen [7] 
RCCP [8]* 
Forfar [9] 
Eskes [10] 
Doering [11] 
Brocklebank[12] 
Eskes [10] 
Harjulehto [13] 
Simpson [14] 
Rubin [15] 
CGDUP[16J" 
USA 
UK 
UK 
NL 
USA 
USA 
NL 
SF 
USA 
diabetic women 
UK 
13x@ 
1950-1965 
1963-1965 
1963-1965 
1974-1975 
1974-1976 
1975-1976 
1978-1979 
1964-1984 
1980-1985 
1982-1984 
77 
50282 
500 
911 
1000 
168 
2528 
1000 
659 
387 
342 
2765 
9714 
94.2 
82.0 
82.1 
82.7 
100.0 
62.0 
71.7 
66.0 
56.8 
65.8 
34.8 
85.0 
3.8 
1.9 
4.2 
2.0 
18.0 
? 
1.7 
? 
1.3 
1.7 
7 
2.2 
any 
CP 
any 
hosp 
any 
any 
hosp 
hosp 
any? 
any? 
any 
any? 
* RCGP = Royal College of Cenerai Practitioners 
" CCDUP = Collaborative Croup on Drug Use in Pregnancy 
@ 13x=13 countries all over the world 
η = no. of study subjects 
F = Iron supplements, V = Vitamins, Ρ = Parturition. 
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Women supervised by a gynaecologist (group 1) 
Number 
of drugs 
0 
1 
2 
3 
4 
5 
6 
7+ 
Moan 
SEM 
Trimester 
1 
60.2 
25.6 
10.5 
2.4 
0.9 
0.3 
0.6 
0.05 
2 
59.0 
23.8 
10.5 
3.9 
0.3 
0.3 
1.2 
1.0 
0.7 
0.07 
3 
42.2 
259 
16.3 
6.0 
6.0 
2.1 
1.5 
1.3 
0.08 
1-3 
23.5 
25 3 
18.4 
13.9 
7.5 
3.6 
3.0 
4.8 
2.1 
0.11 
Delivery 
53.3 
19.9 
13.6 
8.1 
4.5 
0.3 
0.3 
0.9 
0.17 
Total 
12.3 
21.4 
18.4 
14.5 
11.4 
6.6 
4.5 
10.9 
3.0 
0.13 
Women supervised by a midwife (group 2) 
Table 2. Number of drugs 
per xvoman. 
Number 
of drugi 
0 
1 
2 
3 
4 
5 
6 
7 
Mean 
SEM 
Trimester 
1 
73.3 
20.3 
5.2 
1.2 
0.3 
0.04 
2 
71.7 
17.9 
7.2 
1.6 
1.2 
0.4 
0.4 
0.05 
3 
59.4 
26.7 
10.8 
2.8 
0.4 
0.6 
0.05 
1-3 
42.6 
25.5 
19.5 
5.2 
4.8 
1.6 
0.4 
0.4 
1.1 
0.08 
Delivery 
94.8 
1.6 
1.6 
0.8 
0.8 
0.4 
0.1 
0.03 
Total 
40.2 
25.9 
18.7 
6.0 
5.2 
2.0 
0.6 
1.2 
1.3 
0.09 
SIM = standard error of the mean 
secutively registered for prenatal care and delivery at a university hospital in 1984. Only 
low-risk pregnancies (without a medical indication for hospital delivery, η = 332) were 
included in this report. One of the authors (WN) kept a separate record of the drugs used 
and the period of use, which was updated at each prenatal visit. After delivery, an in-depth 
interview was conducted in which the record was checked, completed and corrected. 
Whenever there was doubt about the name of a preparation, it was checked with the 
pharmacy. Iron supplements were excluded, because at this hospital they were given 
routinely to all pregnant women. 
Group 2 consisted of 250 low-risk pregnancies who were supervised in 1985 by one 
of five midwives in private practice in the vicinity of the university hospital. Drug use was 
! 
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recorded by Ihe midwife at each prenatal visit No check-up was done after delivery but 
delivery medication was included in the record 
Results In group 1,64 5% of the women were Primigravidae The women delivered after a 
mean duration of pregnancy of 38 9 weeks (681% between 38 and 42 weeks) The mean 
birthweight was 3085 gr and 47 9% of the children were female There were 21 congenital 
malformations m 14 children (4 2%) Five of the children had multiple congenital anom­
alies The most frequent anomaly was a missing cord artery (гх) and a congenital anomaly 
of the tractus digestivus (гх) or urogenitals Ux) 
In group 2,37 9% of the women were Primigravidae The women delivered after a 
mean duration of pregnancy of 39 6 weeks (84 3% between 38 and 42 weeks) Eleven per 
cent (n=27) of the women were referred to the hospital outpatient clinic, 7 of whom during 
delivery The mean birth weight in this group was 3285 g and 54 3% of the children were 
girls There were five congenitally malformed children (2%), all with another anomaly 
Table 2 gives the distribution of the number of drugs per woman (iron supplements 
excluded) for the trimesters of pregnancy and for delivery The distributions were skewed 
and the mean number of drugs was therefore not an appropriate summary statistic 
Medication was used by 87 7% of the women under the supervision of a gynaecologist and 
by 59 8% of the women under the supervision of a midwife When the delivery medication 
was excluded, the rates were 76 5 and 57 4%, respectively 31 
Figure 1 shows the difference in the use of various categories of drugs in the two 
groups The women under the supervision of a gynaecologist used more drugs from the 
various categories Only antibiotics were used with equal frequency in both groups In 
group one, obstipation and heartburn were the most common indication for drug use 
Nineteen women (5 7%) had 'chronic' disorders (mostly coded as 'circulatory diseases') In 
group 2, infections accounted for most drugs taken 'Chronic' disorders existed in 17 
women (6 8%), (eczema in 7 of them) Figure 2 shows the distribution of consumption of the 
various categories of medications over the trimesters of pregnancy for both groups 
In group ι, 60 women had a caesarean section The medication for these women 
consisted of a general anaesthetic and muscle relaxants Three of the women under the 
supervision of a midwife had an emergency caesarean section requiring epidural (local) 
anaesthetic For the vaginal deliveries, prenatal care in hospital was associated with the 
more frequent use of local anaesthetics (for episiotomy) and oxytocics than delivery at 
home Most tocolytics were used in the ceasarean section deliveries 
Of the women under the supervision of a gynaecologist who only used one drug, 
most women used oxytocin Folic acid was the most common single drug used by the 
women under the supervision of a midwife 
Discussion The number of drugs used by the pregnant women in group 1 were similar to the 
rates found m the literature Of all the women without a medical indication for delivery in 
hospital but who delivered in hospital, 76 5% used at least one drug dunng pregnancy 
(mean number of drugs 21 per person) For the women supervised by a midwife in private 
practice, this figure was 57 4% (mean 11 per person) The difference between these two 
figures is striking, because none of these women had a medical indication for delivery in 
hospital It is ofcourse possible that the difference is (partly) an artifact, caused by differing 
methods of data collection The most important difference was that in group one only one 
person collected the informa hon, whereas in group two, five mid wives collected the data 
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Figure 1. Proportion of 
women attending a 
gynaecologist (group 7) or 
a midwife (group 2) 
that used the categories of 
drugs during pregnane}/. 
proportion of women 
analocsks antacid» vitamin» tocolytics oxytocics 
categorie« of drugs 
Another difference was that in group one, all information was checked and completed 
after delivery, while in group two, information was only completed for medications that 
were used in hospital. This may have caused some difference in the results, but it is 
unlikely that it caused all. Against it is the fact that antibiotics were used with equal 
frequency in both groups. Three other factors may have played a role: (ι) women with a 
more difficult pregnancy require more drugs and may be overrepresented in a hospital 
population (which is supported by the distribution of the few obstetric variables presented 
in the results section: more Primigravidae, more extreme pregnancy lengths and lower 
birthweights); (2) anxious or women in doubt possibly take drugs more easily and go to an 
outpatient clinic for their antenatal care without a medical indication; and (3) women 
supervised at an outpatient clinic may have easier access to drug prescriptions because the 
gynaecologists prescribe drugs themselves, whereas a woman supervised by a midwife 
has to go to her GP for a prescription because midwives are not allowed to prescribe drugs 
except for iron supplements (which were excluded from this study). The use was higher 
for all drugs in group 1 (except for antibiotics), but the excess in the women under the 
supervision of a gynaecologist was mostly due to antacids, folate supplements (routine), 
local anaesthetics (episiotomies) and tocolytics (short pregnancies). 
Our data do not completely agree with other reports on the kind of dmgs being 
used. Anti-emetics, which according to other authors are taken by some 16% of all 
pregnant women, were only used by 3.6% and 1.6% in group 1 and 2, respectively. None of 
the drugs (except for iron supplements) were used by more than 20% of the women. The 
top-five drugs used in our groups comprised: analgesics (mostly acetylsalicylic acid and 
paracetamol); antacids (containing magnesium and/or calcium); vitamins (especially 
vitamin в), minerals and folate supplements; antibiotics (most frequently amoxycilline); 
and dermatological preparations (soothing creams). 
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Figure 2. Proportion of 
women attending 
a gynaecologist (group I) 
or a midwife (group 2) 
that used the categories of 
drugs m a trimester. 
proportion of women 
Gynaecologists 
Midwives 
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Groups of drugs, trimester of use 
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Croups of drugs, trimester of use 
We examined the literature for reports on the teratogenic hazards of the drugs in 
our top-five. As a great many women use these drugs, small relative risks may result in a 
large group of affected infants in the population. Any excess risk will show up quickly in 
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the case of a rare pregnancy outcome, but increments may not attract much attention at all 
in the total group of more common adverse pregnancy outcomes Very few studies in the 
literature are large enough to detect more common risks, so they cannot be used to provide 
a correct full-scale picture of the risks involved, at least not in our view 
In this study, the groups were too small to explore the congenital anomalies and 
their relation with the medication used A listing of the few anomalies can be obtained 
from the authors 
Conclusion More research is needed on the effects of these commonly used drugs on the more 
prevalent adverse pregnancy outcomes, such as cleft palate, spontaneous abortion, low 
birth weight, functional disorders, mental retardation, etc The effects of drugs on rare out­
comes can be detected quite easily (e g, thalidomide), but the effects of drugs on common 
adverse outcomes need to be studied more thoroughly in order not to be missed 
Therefore, large studies should be undertaken involving large groups of affected children, 
with extensive data collection on drug use and other risk indicators during pregnancy 
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2.4 Medication during pregnancy in Sweden 
over the years* 
PCM de jong, С Ahlborg ¡τ 
Although most textbooks on Gynaecology and Obstetrics dissuade medical drag 
use during pregnancy, many studies have shown that drug use is common in pregnant 
women (1) Recently, it has been suggested that drug use during pregnancy has diminished 
(2) We analysed the use of medical drugs in a population based prospective study in 4701 
pregnant women, earned out in Orebro countv in Sweden in 1980-83 (3) and compared the 
results to those of Kullander and Kallen (4) who studied drug use in 1963-65, and to the 
results of Sandahl (5) who studied drug use in the first trimester of pregnancy m 1979 1980 
All three studies were population based, and used questionnaires and interviews to collect 
the information In the most recent study, 4701 women from Orebro county filled in an 
extensive self-administered postal questionnaire m the first trimester of pregnancy, before 
their first visit to the maternity care unit All these women were interviewed by a midwife 
within three months after delivery with the help of a short questionnaire Kullander and 
Kallen (4) had questionnaires filled m several times during pregnancy by 6376 women 
pregnant m 1963-65 They checked the information in hospital records Sandahl (5) 
interviewed 2436 women in the 17th week of their pregnancy otcuring in 1979 or the first 
part of 1980 Before the interview, the women were informed about the purpose of the 
study and were asked to write down the drugs thev used during the first trimester The 
study only covered first trimester use 
Table 1 lists the proportion of women that took a drug from the various groups in the 
three studies In the most recent study, the most frequently reported drugs were analgesics, 
vitamins and antibiotics However, some remarks are due The gestational age at first visit 
(and thus the duration of the first trimester) varied Most of the women entered the study in 
their second (37%) and third (46%) month Furthermore, the questions about drug use were 
not similar in the first measurement and the second (after pregnancy) This mav hamper 
comparisons between the two periods In comparison with the earlier study of Kullander 
and Kallen, the use of analgesics during the entire pregnancy was lower This is probably the 
result of underassesment in our study because occasional tablets were not included in the 
second part of the study Sandahl reported a higher use of analgesics in the first trimester of 
pregnancy than Kullander and Kallen and the present study In Sweden in the study period, 
pregnant women were encouraged to take the common drugs they thought they needed, like 
analgesics or anti-emetics Anti-emetics were reported more often in the second part of the 
pregnancy than in the first trimester in our study because most women started using them 
only after their first prenatal visit In comparison with Kullander and Kallen the use of anti­
emetics had decreased Antibiotics were used more often in our study than twenty years 
earlier In the beginning of the eighties, pregnant women were screened for sub-clinical 
unnary tract infections and were treated if diagnosed This mav also explain the rise m use of 
antibiotics after the first questionnaire Psychopharmaceuhcals were reported far more often 
in the study of Kullander and Kallen The results of Sandahl were intermediate The use of 
psychopharmaceuhcals seems to have diminished m twenty years 
* Submitted as a letter to the editor 
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Table 1. Proportion of 
women having had al least 
one preparation from the 
various drug groups. 
Drug group 
None 
Analgesics 
Anti-emetics 
Psychopharm. 
Antibiotics 
Vitamins 
Entire pregnane) 
De Jong 
80-8} 
36.6 
37.1 
9.4 
1.8 
14.9 
9.5 
r 
Kullander 
61-65 
_ 
55.4 
14.0 
14.6 
1.3 
_ 
First trimester 
De Jong 
80-81 
46.1 
35.5 
3.1 
0.9 
6.4 
9.5 
Kullander 
61-6S 
_ 
27.0 
12.0 
12.0 
7.1 
34.8 
Sandahl 
79-80 
6.6 
60.0 
12.0 
3.0 
10.0 
74.7 
- Not calculable trom the reports 
We conclude that drug use during pregnancy diminished in Sweden between 1963 
and 1983. However, two-third of all pregnant women still used a drug. Since the safety of 
most drugs with respect to teratogenicity is not established and not all of the drugs used 
are considered necessary, drug use during pregnancy should be as restricted as possible. 
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2.5 Comments on chapter 2 
From the studies on drug use during pregnancy published until now and reviewed 
in this chapter, it can be concluded that 70% or more of pregnant women take at least one 
drug Despite the uniformity of the overall results, the individual studies are far from 
comparable The study designs vary to a large extent with regard to the definition of drugs, 
methods of data collection and characteristics of the study population These variations in 
population and methods should be kept m mind when interpreting the results It was 
shown m this chapter (2 2) that these three important features of a study could account for 
considerable vanation in the study results even if there was no difference in drug 
utili7ation in the populations studied As most studies on drug use (during pregnancy or 
otherwise) are set up with a specific aim and with specific practical constraints, it may be 
concluded that the generalizabihty of the results of these studies to drug utilization 
patterns in other populations is very limited If the variation in results is a consequence of 
differences m design, it is possible to study differences m drug use over time, population 
and /or geographical location only if these design differences are accounted for In our 
study in the Netherlands we found that for similar pregnancies, drug use depended on the 
type of prenatal care provider In contrast, the variation over time in Sweden was less easy 
to summarize on the basis of published material because of the great differences between 
the study methods The Dutch survey on drug use during pregnancy m the Netherlands m 
1983 disclosed that analgesics, antacids, antibiotics, dermatological preparations and 
vitamins were used most frequently Because of their high utilization frequency, these 
drugs should be given priority in studies to provide definite proof of teratogenic safety, 
especially in view of the fact that these drugs are not medically necessary in general 
and/or there are several alternative treatments available A review of the present state of 
knowledge about the safety of drugs is presented in chapter 3 
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H A P T E 
The Literature 
3.1 Potential effects of medical drug use during pregnancy on the functional 
development of the central nervous system: a review 
3.1 Potential effects of medical drug use during 
pregnancy on the functional development of the 
central nervous system: a review" 
PCM Pasker-de long, CA Zielhuts, f ¡M Cabreéis, YA Hekster 
Introduction At least 70% of women are exposed to some medication during pregnancy [54] In 
1983, the drugs used most often during pregnancy included vitamins, analgesics, anti-
biotics, ferro and dermatological preparations [54] There is no 100% guarantee that any 
medication used will not interfere with the anatomical and functional development of the 
fetus Thus, many children were exposed to potentially noxious chemicals in utero The 
effects of the most frequently used drugs on anatomical development have been studied 
fairly extensively [12] However, very little is known about the effects on functional 
development of exposure during pregnancy These functional effects are likely to be 
associated with lower levels of exposure to drugs and exposure at other moments during 
pregnancy than anatomical developmental disorders The few studies that have been 
published to date indicate that it is reasonable to assume that functional effects of prenatal 
exposure to medical drugs do exist 
Most of the studies were earned out on animals, but these involve some major 
problems The development of the fetal rat or mouse brain is different from that of the 
human brain For instance, the phase of development of the human brain in the third 
trimester matches that of the rat after birth Furthermore, there may be considerable 
differences in metabolism between the rat or mouse and the human, which may alter the 
teratogenic potential of drugs Finally, there may not be a suitable animal model to test for 
disorders of the higher functions of the central nervous system (CNS) in the human because 
these do not occur in animal brains Similarly, functional tests in the rat or mouse, such as 
'maze learning' or 'avoidance conditioning', do not have any intuitive equivalents in 
human functioning so the consequences of dysfunction of the animal on these tests is not 
clear in the human Extrapolation of the results is therefore difficult [1,28,88] Studies on 
humans are another possibility, but these also involve some major problems However, 
efforts have been made to study the relation between exposure to medical drugs m utero 
and the functional status of the CNS in the human 
To give a meaningful overview of the information from animal experiments and 
studies on the human, it would be useful and logical to take into account the possible 
working mechanism behind the observed effects Although the functional effects may 
differ between animals and humans, the mechanism through which the brain develops 
and some basic functions of the brain may be similar enough to be able to extrapolate some 
findings in animals to human functions [57,70,97] 
The present review therefore discusses the risks of medical drugs reported in the 
literature in the light of their possible interference with processes involved m the 
development of the CNS and its functions First, we discuss the basic processes involved in 
the development of the brain 
* Submitted for publication 
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The developmental In both animal and human embryos and fetuses, the brain is the organ that 
processes to the brain undergoes the longest period of development. The development of the CNS starts with the 
induction of the neural groove and continues after birth. It is therefore vulnerable to 
damaging influences almost throughout pregnancy and after birth {figure 1). In short, the 
following phases can be distinguished [22,35,74,102]: 
Induction 
In the human fetus, induction of the central nervous system takes place with the 
formation of the neural groove in the third week post-ovulation (5 or 6 weeks after the 
LMP). It is not known exactly how induction occurs; it may be initiated by chemicals. In 
animal experiments, for example, it has been shown that mesoderm is necessary for the 
induction of the neural groove in newts and that if mesoderm is transplanted to another 
site, the neural groove will develop there as well [96]. For this effect to occur, the 
mesoderm did not have to be in direct contact with the ectoderm, but induction could be 
prevented by a non-permeable membrane. For induction to take place, the inducer had to 
be present in a sufficiently high concentration for several hours. Therefore, it is dubious 
whether single low-dose exposures would interfere with the induction process. It is far 
more likely that interference with induction from chemicals will inhibit the formation of 
the neural groove or its closure than enhance induction. If formation of the neural groove 
is inhibited, this will probably lead to an abortion, while failure of the neural tube to close 41 
will result in a dysraphia defect (spina bifida or anencephaly). In either case, the effects of 
interference with induction will be major and recognizable as anatomical abnormalities. 
Proliferation 
The brain goes through one period of neuronal proliferation (human: weeks 3-25) 
in which most of the neurons are formed [1,74]. The proliferation of glial cells continues 
throughout pregnancy and later life [35]. In the first twenty weeks of gestational life, 
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150,000 cells per minute are formed in the brain In total, 10 to 15 billion cells are formed [11 
Cell division starts before the neural tube has closed (wk 4) The number of resulting cells 
depends on the number of precursor colls, the duration of the proliferation period and the 
length of the cell cycle [1,22] Interference can therefore occur through inhibition of cell 
division, prolongation of the cell cycle time and destruction of the precursor pool For 
chemicals to be able to interfere with this process, they would have to be present in the first 
half of pregnancy to be able to Proliferation ends during different periods in the various 
areas of the brain the 'long distance' neurons are formed earlier than the 'small-axon' 
neurons, deeper layers of the brain are formed before the superficial layers, and the 
hemispheres are the last to form The glial cells are mainly formed in the second growth 
spurt, from the 20th gestational week onwards For proliferation to take place, enough 
nutrients have to be present If inhibition of proliferation is caused by elimination of the 
precursor cells, this might result in microcephaly (radial microbrain) [35] If the interference 
occurs later in the process, the resulting damage may be far more focal 
Migration 
In week 4 of the human gestation, cell migration is responsible for formation of the 
peripheral ganglia from neural crest cells Later in the development of the brain (weeks 12 
through 26, and most importantly in weeks 15-25), neurons move from the mantle of the 
neural tube towards the neocortex [22,35,74] I '1S likely that cells are prompted to start 
moving in a certain direction through chemical migration factors, although the destination 
is probably genetically determined [74] The neuroblasts move along pathways which are 
marked by radial glial cells I98I Migration disorders are the most common cause of brain 
disorders If interference with migration occurs through interaction with the pathway cells 
or filaments or through delay of migration, it might be impossible for the correct nerve 
connections to form, which might change the organization of the brain (e g lissencephaly), 
thus leading to subnormal function [1,35,74] m m e F e t a ' Alcohol Syndrome, a pattern of 
overmigration seems to exist [35] Mental retardation, epilepsy, learning disabilities, 
cerebral palsy and impaired co-ordination are some of the functional defects which result 
from migration disorders 174] 
Aggregation 
Aggregation (or pattern formation or determination) occurs between the third and 
ninth week of gestation in the human Groups of cells become committed to a certain goal 
The location of cells in the brain determines their aggregational goal A chemical 
(morphogen) which shows a concentration gradient over the tissue gives information about 
the position of the cell and thus determines the final function of a cell These morphogens 
seem to act through genetic control It is possible that their receptors are present in the 
nucleus and they may regulate DNA transcription [1] The patterns formed are of major 
importance The early commitment of cells to a specific function and site simplifies the 
processes of migration and differentiation [1] Interference with aggregation may dis-
organize migration and subsequent differentiation This may manifest itself in various ways 
Differentiation 
Neuroblasts differentiate into the two major cell types of the brain neurons and 
glial cells In the human, this occurs from gestational week 18 and continues after birth 
Neurons receive, process and transmit information During the differentiation from 
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neuroblast to neuron, an axon and dendrites are formed. The axon is the efferent part of the 
neuron, the dendrites are the afferent part. The number of dendrites per neuron is of major 
importance for the capacity of the brain. The second growth spurt of the brain, which 
occurs from the 31st week of pregnancy onwards, is mainly due to the sprouting of axons 
and dendrites and the proliferation of glial cells [1,35,74]. The dendrites form the millions 
of contacts (synapses) between the neurons. Glial cells protect and nourish the neurons. 
Neurons do not grow in the absence of glial cells [55]. Interference with differentiation may 
cause the cells to differentiate prematurely or may postpone or inhibit the process. 
Differentiation does not occur simultaneously in all parts of the brain, so the effect of 
interference will depend on its timing. In mental retardation, the number of dendrites per 
neuron is often decreased [1]. 
Programmed cell death and synapse elimination 
Cytocide does not occur on a large scale in the brain, but cells that are no longer 
necessary or functional will die eventually. Cell death occurs mainly in gestational weeks 
18 through 36 in the human. Synapse elimination also occurs in the last few weeks of 
pregnancy [351, which provides the opportunity to correct errors and to finetune the 
contacts made between neurons [1]. In this way, the process of cell death forms a very 
important 'repair' mechanism. The trigger for cell death may be genetic in origin. Neuronal 
axons which have not made correct contact with their goal are also known to trigger cell 43 
death [83]. Interference in selective cell death may make the process less selective or 
enhance cell death rates. It may also stop cell death from occurring, thus leaving aberrant 
connections intact. In both cases, a variety of effects may emerge. 
Synaptogenesis 
Synapses are the junctions between neurons which transmit electrical pulses 
(mostly chemically). It has been hypothesized that many connections are formed but that 
only the connections which are being used remain intact [1]. The formation of synapses is 
probably guided by neurotransmitters and other specific chemicals (possibly proteins). In 
the human the process starts in gestational week 14, is most active after the 28th week and 
continues after birth. The formation of synapses is also thought to continue throughout life, 
thus creating the opportunity to leam (i.e. use new connections) after birth [74]. The 
number of synapses is believed to depend (in part) on the number of neurons and on the 
number of dendrites per neuron. These are to some extent genetically determined [1]. 
Chemicals which interfere with this process are likely to cause slower development, 
epilepsy, mental retardation, learning disorders, etc. [74]. 
Myelinization 
Oligodendrocytes (glial cells) form several layers of myelin around the axons of 
neurons in the central nervous system. Myelinization improves the conduction of pulses 
along the axon, so the pulses arc passed on more rapidly and the axons are protected 
against damage. In the human, myelinization starts in about week 20 of pregnancy, is most 
active from week 30 onwards and continues after birth. Myelinization occurs in phases, 
from the cord up to the hemispheres. Interference with this process may lead to the loss of 
motor and learning abilities [74]. 
Interference with the processes discussed above can occur directly or indirectly [70,107]. 
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Indirect effects may result from the interference of medical drugs with the environment in 
the mother and fetus, through their physiological action For example, interference with 
the blood flow through the placenta and/or uterus and/or fetus may hamper the flow of 
nutrients, the metabolism of the fetus and/or its mother may be altered, e g the fetal liver 
may be induced to break down chemicals into toxic substances, hormone equilibrium may 
be disturbed [5], and the homeostasis of the mother and /or fetus may be changed As the 
metabolism and homeostasis of the fetus are not established until the second half of 
pregnancy, disruption of these two mechanisms is most likely to occur after exposure in 
the second half of pregnancy I70] 
Materials and The literature about the functional effects of prenatal exposure to medical drugs on 
methods the central nervous system over the years 1980-1992 was reviewed after conducting a 
thorough search in Medline using CD-Rom with the search strategies 'prenatal exposure, 
delayed effects' and 'neonatal diseases and abnormalities, chemically mduced' Any 
potentially relevant literature was selected on the basis of the language (English, German, 
French or Dutch), the exposure (only medical drugs, no drugs of abuse), the outcome 
under study (only functional defects associated with the CNS) and the species (only studies 
on humans, rats, mice and primates) The references in the papers selected using this 
mechanism were searched for any additional publications and any interesting papers were 
also reviewed Drug groups for which no data were found are not discussed 
The literature The long-term effects of exposure in utero to many medical drugs have never been 
studied in the human In addition, research has not always addressed similar outcomes in 
human studies, or the same exposure period or population in which the exposure took 
place, so the results of the studies cannot be easily compared Knowledge is therefore 
scanty and fragmentary Below we discuss the effects reported in the human and various 
animals for several groups of drugs and the processes which may be involved in the 
etiology of the effects 
Psycho- Psychopharmaceuticals are used occasionally by five to fifteen per cent of pregnant 
pharmaceuticals women [13,54] 
Hypnotics and sedatives 
These drugs which depress the central nervous system, to achieve deep sleep and 
calmness, are used frequently There are two main groups of hypnotics/sedatives the 
benzodiazepines and the barbiturates In humans, no relation was found between benzo­
diazepine exposure and the ЪеЬа юигаІ score' of children at the age of nine years [99] 
Laegreid [60,61] reported on a BZD syndrome similar to the fetal alcohol syndrome High 
doses of BZD in labour diminished the Apgar score and the maintenance of homeostasis in 
the neonate [23,34] m r a t i< benzodiazepine exposure was associated with developmental 
delays and the drug group has been shown to influence fetal heart rate variability and 
REM-sleep (57,113] The animals showed impaired sexual behaviour and lower brain 
weights in adulthood [70] A modification in the monoammergic regulatory functions 
would account for the profile of the prenatal drug effects in mice, including impairment of 
adult active avoidance performance and no impairment of passive avoidance performance 
[4] Exposure of rats to a benzodiazepine receptor antagonist seemed to decrease the 
emotional responsiveness to environmental challenges [16] 
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Barbiturate use during pregnancy led to abstinence symptoms m the child [26] 
Phénobarbital given to prevent neonatal jaundice seemed to be associated with a higher IQ 
in the treated group than m the non-treated group [109I Rats [6,36! and mice [67] prenatally 
treated with barbiturates were easily distracted, slower to learn and slower to habituate to 
stimuli The behaviour of both animal species was also impaired Rats had lower levels of 
sex hormones [661 and their EEG was less variable after exposure in utero [65I Chronic 
exposure of rat tissue culture to barbiturates showed slower growth of neurons [36] 
Both drug groups may interfere with differentiation [113] and synaptogenesis or 
may influence the internal milieu of the fetus The effects of interference depend on the 
dose and timing of use Benzodiazepines affect the limbic system, the substantia reticularis 
and the catecholamine producing cells in the hypothalamus [19,57] Benzodiazepine use 
during pregnancy is therefore likely to affect the integration function and the behaviour 
function of the brain 
Antipsychotics 
These block the dopamine receptors in the brain Antipsychotic medication is not 
used very often during pregnancy There are two major groups the phenothiazines which 
are also used as antiemetics and the butyrophenones, lithium forms a third group, but it is 
contra-indicated during pregnancy because of associated malformations In a study on the 
effects of exposure to psychopharmaceuhcals in utero on school behaviour in children, it was 45 
concluded that phenothiazine exposure was not related to a lower behavioural score' [99] 
However, there was a difference m the behavioural scores between the exposed and non-
exposed subjects It was not possible to correct for confounding by socio-economic status in 
this comparison, but an effect seemed to be present Use of phenothiazines in weeks 4 
through 10 of gestation seemed to be related to mental retardation and congenital anomalies 
[32] In the Collaborative pennata! project, phenothiazines were not found to have any effect 
on the IQ of the offspring [95] Lithium did not seem to have any functional effects [17,26,52] 
Haloperidol interfered with the development of the dopamine receptor in the rat 
brain [38], which resulted in a lower intensity of apomorphine-mduced stereotyped 
behaviour [24] Reflexes were delayed and learning ability was impaired in rats treated 
with either phenothiazines or butyrophenones [110,112] Phenothiazines increased cell 
death m the rat brain, while butyrophenones slowed down cell proliferation [77,78] 
Exposure to bendectin, a combination of doxylamine succinate and dicyclomine hydro-
chloride used as an antiemetic, was not associated with IQ at the age of four years [91] 
Anaesthetics 
Anaesthetics are administered frequently during labour They are usually used for a 
short period only, so their effect should be small Children exposed to anaesthetics and 
analgesics during labour showed delayed motor development, language development and 
acquisition of cognitive skills at the age of seven years [7] However, these children formed a 
selection of all the children born, and there may have been more pregnancy complications, so 
that their development would have been delayed even without the use of anaesthetics 
during delivery 
Nitrous oxide seemed to influence motor development in rats after multiple 8-hour 
exposure to mimic occupational exposure [104] Halothane decreased the synaptic density in 
rats, which was associated with delayed behavioural development [108] Hollenbeck 
hypothesized that anaesthetics disrupt the calory supply to the fetal brain [50] 
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The opiate-like pethidine is sometimes used to allay pain during labour The use of 
opiates and opiate-hkc substances during pregnancy may lead to hyperactivity in the 
children exposed in utero [50] Use during delivery may not produce such effects The 
combination of pentazocine (a benzomorphan analgesic) and tnpelennamine (an anti-
histamine drug) which has a subjective effect similar to heroin and morphine, seemed to 
be associated with some long-term behavioural teratogenic risk in rats, but the effect was 
fairly small [30] 
Analgesics 
Simple analgesics are used very frequently during pregnancy Most usage 
comprises a single tablet now and again A recent review summarized the literature on 
aspirin (acetylsahcyhc acid) I47I Two cohort studies have been published to date which 
investigated the behavioural consequences of prenatal exposure to these drugs One of 
these studies found an association between prenatal exposure to aspirin at least twice a 
week in the first five months of pregnancy and a lower IQ and attention disorders [100] No 
association was found for acetaminophen in the same study, which suggested that there 
may not have been any confounding by the indication for use In another study which 
compared subjects who had been exposed to aspirin at some time during the first 20 weeks 
of pregnancy to subjects who had never been exposed, no differences were found in the 
level of intelligence at the age of four years [59] The difference in results may reflect a 
difference in exposure classification In rats, prenatal exposure to acetylsahcyhc acid 
affected learning [15,58] and behaviour [58,111] Aspirin affected prostaglandin synthesis 
and seemed to affect the fetal circulation to the brain [48] Acetaminophen may also be a 
potent inhibitor of prostaglandin function [79] 
Anti-depressants 
These are not used very often during pregnancy There were several case reports of 
prenatal exposure to clomipramine which led to abstinence symptoms in the neonate 
[11,89] m a small study on the pregnancy outcome of depressed women with or without 
treatment with tricyclic drugs, all the children examined showed normal development 
[71] 
Imipramine altered the functional development of rats in a complex manner [3] 
Inhibition of open held behaviour and the acquisition of active avoidance responses resulted 
from subchronic prenatal exposure in rats [29] Mono-amineoxidase inhibitors had more effect 
than the re-uptake blockers [29] Locomotor activity was enhanced at 23 and 60 days of age in 
treated animals [25] Another study reported that Imipramine decreased the locomotor 
activity of treated rats, but enhanced the locomotor response to apomorphine [18] The striatal 
dopamine receptors were more sensitive to dopamine after exposure to antidepressants [18] 
Prenatal exposure to tricyclic antidepressants in rats was found to lead to profound 
neurobehavioural and neurochemical changes [25] Anbdepressant drugs inhibited REM sleep 
in rats, which is known to be important for the functional development of the brain [70] They 
also interfered with the re-uptake of monoaminergic neurotransmitters and may thus 
interfere with differentiation and with synaptogenesis, which may lead to cell death 
Anti-epileptic medication 
The effects of prenatal exposure to anti-epileptic medication have been studied 
fairly extensively A fetal hydantoin syndrome (FHS) has been described on analogy with 
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the fetal alcohol syndrome [27], although the inheritance of traits has been implicated as 
the causal pathway [27]. The FHS has been associated with phenytoin, carbamazepine and 
other hydantoin drags [2146,53] and consists of craniofacial defects, fingernail hypoplasia 
and developmental delay. Valproic acid seems to be associated with an increased risk of 
anencephaly in the fetus [42I. Many studies have shown an increased risk of 
developmental delay in the children of epileptic mothers [43,49,64,81]. 
There is much debate about the contribution of antiepileptic medication to the 
enhanced risk of congenital malformations in the children of mothers with epilepsy, 
because the epilepsy itself may also play a role [41,43]. Furthermore, epileptic women seem 
to have lower IQS than non-epileptic women with the same socio-economic status and 
seem to have a smaller head circumference [39,40,46]. A review of the developmental 
neurotoxicity of phenytoin which integrated the results from human and animal studies 
was published in 1990 [2]. It was concluded that phenytoin is a behavioural teratogen both 
in animals and in humans at doses well within the therapeutic range. 
Hormones Corticosteroids 
These can be divided into two subgroups: mineralocorticoids and glucocorticoids. 
Mineralocorticoids regulate the mineral and water homeostasis and can therefore be 
expected to have an effect on water retention in the fetus when administered during 
pregnancy. This may interfere indirectly with brain development. 47 
The glucocorticoids have a catabolic effect. They stabilize the blood glucose level 
and suppress the reactivity of tissues. In pregnancy they are administered to enhance lung 
maturation and are thus specifically used in the latter part of pregnancy if delivery is 
imminent [8]. The administration of dexamethasone to rats depleted the number of 
receptors in the hippocampus and cerebellum, and influenced their motor co-ordination 
and behaviour [8,9]. Glucocorticoids may influence cell proliferation indirectly through 
their effect on the blood glucose level and directly through interference with DNA synthesis 
and protein metabolism [7]. In the human, they may also directly influence the 
differentiation and synaptogenesis in the hippocampus, cerebellum and the hypo-
thalamus, as in the rat [9]. 
Sex steroids 
The sex steriods are necessary for the sexual differentiation of the fetus [102,103]. 
There are three groups of sex steroids: the androgens (testosterone and anabolic steroids), 
the oestrogens (female hormones) and the progestagens. Progestagens are used to prevent 
a threatened abortion from occurring, especially in the early stages of pregnancy. 
Oestrogens were also used for treating threatened abortion until it was proved that they 
were not effective. Androgens themselves arc not often used during pregnancy, but some 
progestagens have androgenic properties [19]. 
Children treated with progestagens were found to be physically more aggressive, 
especially when treated with androgenic progestagens. This was true for girls and for boys 
[84]. Reinisch concluded that male behaviour depends on the presence of androgens in the 
first part of pregnancy, just as it does in animals [85]. 
Oestrogens may feminize the behaviour of children exposed in utero [85]. DES is 
the best known synthetic oestrogen that was used during pregnancy. Girls, but not boys, 
who were prenatally exposed to progestagens and/or oestrogens showed feminized 
behaviour as compared to non-exposed matched controls from the same collaborative 
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perinatal study [33]. Prenatal exposure to sex hormones may be expected to affect 
differentiation, aggregation and synaptogenesis in the fetal brain. 
Androgens may masculinize the behaviour of female fetuses. 
Anti-hormones 
Anti-hormones are not generally used during pregnancy. Examples of anti-hor-
mones are bromocriptine which is used to stop lactation, and clomiphene which is used to 
induce ovulation. They usually are not used during pregnancy. Clomiphene may influence 
the fetus because it is present in the follicular fluid and may be connected with neural tube 
defects [69]. 
Thyroid hormones and anti-thyroid hormones 
These drugs influence the metabolism of the mother and probably that of the fetus 
as well. The use of thyreostatics during pregnancy was related to the presence of struma in 
the child at birth [19]. Children seem to be able to deregulate or upregulate their thyroid 
function if necessary so it has always been presumed that thyroid dysfunction during 
development docs not have any extra effect [19]. However, whether this is true in the 
human remains to be studied. Thyroid hormones were found to play an important role in 
the formation of synapses in the cerebral cortex [7]. In pre-adult rats, they diminished 
dendritic branching in the caudate nucleus [20]. 
Insulin and oral anti-diabetics 
Antidiabetic drugs regulate glycogenesis and thus the blood glucose level in the 
mother and fetus. Through this mechanism they might have an indirect influence on brain 
development in the fetus. However, insulin itself does not cross the placenta because the 
molecule is too large so it will not influence the fetal blood glucose level; it does regulate the 
maternal blood glucose level to keep it within the normal range. It is therefore unlikely that 
the use of insulin during pregnancy will have any effect on the development of the fetal brain. 
Oral anti-diabetics are seldom used during pregnancy and are contra-indicated 
because of their teratogenic properties. They cross the placenta readily, may deregulate 
fetal metabolism having an indirect effect on brain development and may also have a 
direct effect on any of the processes. 
Circulatory drugs Circulatory drugs (mainly antihypertensive medication) are used by about five per 
cent of pregnant women, especially in the latter part of pregnancy. 
Anti-hypertensive medication 
For anti-hypertensive treatment, beta-blocking agents are the treatment of choice, 
although centrally acting agents are also used. Ten out of 14 children exposed to labetalol 
were found to be developing normally at 6 months of age [63]. In a study on prenatal 
exposure to Clonidine, more of the children in the exposed group were hyperactive and 
they had significantly more sleeping disturbances than the non-exposed children [51]. 
Maternal pre-edampsia was not associated with the intelligence scores of the offspring at 
the age of seventeen years [90]. No information about the treatment administered for pre-
eclampsia was mentioned in the report. 
The follow-up of children born after participation in a trial on methyldopa versus 
no treatment, revealed that the developmental score was higher in the exposed children 
CHAPTER 1 THE LITERATURE 
than in the non-exposed children, but lower than in the children born to normotensive 
women [76] In the past few years, several trials showed that the treatment of hypertension 
did not improve the pregnancy outcome [80,92,93,94] 
The beta-blocking agents propranolol and atenolol and the centrally active 
Clonidine did not alter the behavioural development of rats [87], whereas losulazine did 
impair their functional development [72] Reserpine affected the dopamine receptor 
binding and the dopamine and serotonin concentrations in the caudate nucleus and 
reduced the response amplitude and rate of habituation (learning) to auditory startles [14] 
Antihypertensive medication may act indirectly through altering the blood flow through 
the placenta and fetus It has been suggested that the placental vascular resistance is 
increased after labetalol, while it is decreased after methyldopa [86] The birth weight of 
labetalol-exposed children was lower than that of bed rest controls [93] It was also found 
that prenatal exposure to Clonidine or propranolol was associated with lasting changes in 
the turnover of norepinephrine in several bram areas in the rat [10] Exposure to these 
drugs may therefore have a direct effect on synaptogenesis 
Antibiotic medication No studies were found on functional development after exposure to antibiotic 
medication m the human Two reports were available on premarketing tests in rats of a 
new antibiotic 'Lomefloxacin' This was not found to have any behavioural teratogenic 
effects [105,106] 49 
Tocolytic medication Children prenatally exposed to tocolytic medication were found to have statis-
tically non-significant IQ decrements [82], poorer school performances [44] and an 
increased risk for complications m the first eighteen months of life [56] Other studies did 
not reveal any effects of tocolytic medication on the development of the child [37,101] It 
was not clear whether the drug itself or the premature birth associated with its use was 
responsible for a possible delay in development 
Antlcoogulatlve Prenatal exposure to coumann derivatives was associated with mental retardation 
medication in 5 out of 16 patients and with blindness in a number of cases [45] 
Vitamins Retinoids (vitamin A and derivatives) are teratogenic in the human The pattern of 
malformations associated with exposure to retinoids includes craniofacial, cardiac, thymic 
and central nervous system malformations (hydrocephalus, microcephaly) [21,62] There 
was only one report on the prenatal exposure of rats to retinoids and their effect on 
functional development Maze performance was impaired at doses lower than the no-
effect level for morphological defects [75] 
For other vitamins, the effects of deficiencies have been studied in humans (107] 
Evidence suggests that minor deficiencies in the folate level at the time of conception may 
impair the closure of the neural tube [31] and that supplementation may prevent some of 
the neural tube defects from occurring [68,73] 
Discussion The processes involved m the development of the brain are not only influenced by 
external factors but they are also modified by each other For example, if (inadvertent) cell 
death occurs of the target or initiating cells, synaptogenesis will be impaired [36] 
Similarly, if migration fails, pattern formation and synaptogenesis may also be impaired 
Of all the processes involved, synapse formation seems to be affected the most However, 
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impaired synaptogenesis may not lead to any measurable behavioural effects because of 
the compensatory potential (plasticity) of the developing brain [74] 
For many medical drugs, no studies were found on their potential behavioural 
teratogenicity in the human For instance, no human data are available on the behavioural 
teratogenicity of antibiotic medication Data were also scarce for most self medication This 
is not equivalent to "probable safety", although positive studies are more likely to be 
published than negative ones It can be concluded from the studies which have been 
published that many drugs and drug groups are potential behavioural teratogenic 
substances Especially psychopharmaceuhcals (benzodiazepines and barbiturates, general 
anaesthetics, anti-epileptic medication and analgesics) have been implicated in the etiology 
of functional developmental disorders Other groups which are of potential danger to the 
fetus may be antihypertensive medication and hormones It was difficult to combine and 
interpret the results of the studies we reviewed because the outcome measures and the 
designs varied greatly Some of the conflicting results may have been the result of 
differences in exposure or outcome measurements The results of animal experiments 
cannot always be extrapolated towards humans because the mechanism of action of a 
behavioural teratogen is not always clear in animals In future research, studies should 
address the mechanism of action of drugs It is also important to evaluate the best way to 
study associations between exposure to medical drugs, changes in brain composition and 
SO function, and developmental characteristics in the exposed child Standard long-term 
follow-up studies on exposed children should be earned out and the results published, and 
outcome measures should be standardized to increase our knowledge on the lasting side-
effects of prenatal exposure to medical drugs 
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4.1 Introduction 
Behavioural teratology is the study of functional abnormalities resulting from 
prenatal or early postnatal exposures [1]. If exposure to medical drugs is being studied, 
(behavioural) teratology is in fact the study of side-effects of prenatal exposure to these 
drugs. From the epidemiological literature it is known that when studying side-effects, it is 
helpful to distinguish between side-effects which are predictable based on knowledge of 
the working mechanism of the drug and side-effects which are unexpected, and usually 
rare. Predictable side-effects cannot usually be studied in non-experimental research 
because of bias from contra-indications: the drug will be withheld from persons who arc 
sensitive to the side-effects. Non-experimental designs are suitable for studying un­
predictable effects which are not related to the indication for treatment [2]. In general, 
confounding by contra-indications is not likely to occur in teratology: medication will not 
be withheld or prescribed because of demonstrated or assumed sensibility of an individual 
fetus to specific side-effects. It can thus be deduced that in general, non-experimental 
epidemiological methods are appropriate to study the risk of (behavioural) congenital 
defects associated with prenatal exposure to medical drugs if the maternal illness which 
formed the indication for the use of the specific drug during pregnancy, is not related to 
the defect under study. 
Epidemiological studies describe the frequency of health outcomes such as 
congenital anomalies, as a function of the presence of possible determinants (i.e. medical 
drugs) in a specific time period (i.e. during pregnancy) which is relevant from an 
etiological point of view [3]. As developmental disorders are multifactorial in origin, it is 
likely that other internal or external factors are necessary to contribute to the occurrence of 
the side-effects under study [4]. Factors that determine the susceptibility of an individual 
to the effects of a particular exposure should be included as effect modifiers in the study 
design and analysis. Factors which do not add to the susceptibility to the effects of the 
exposure but are independent determinants of the disease, should also be included as 
(potential) confounders and their distribution should be similar over the exposure groups. 
Thus, in valid epidemiological research, information not only has to be collected about 
exposure and health outcomes, but also about confounders and effect modifiers. 
In non-experimental research it is important to study non-exposed subjects who 
are otherwise comparable to the exposed subjects, as is also the procedure in clinical trials. 
It is thus theoretically incorrect (although sometimes tempting) to regard all the non-
exposed subjects as referents in a study population. For instance, not all the subjects 
without disease (and therefore without exposure) are eligible for being a referent in a study 
on side-effects of medical drugs. Once the exposed and non-exposed subjects have been 
defined, information about the frequency of the outcome under study in both groups has 
to be collected. 
There are two ways to collect information on the occurrence of disease as a 
function of a set of determinants. The first option is to study all exposed and comparably 
non-exposed subjects in the study base (census of the base). The incidence rate of the 
outcome event over a specified period of time τ in the exposed and non-exposed subjects 
can be estimated. Relative measures of effect (RHS) can be calculated [3]. 
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The second option is to include a sample of the study base and all the cases 
(outcome events) which arise from the study base. The relative frequency of exposure and 
comparable non-exposure among cases and the base sample can be estimated and the 
relative estimates of effect (ORS) can be calculated from the Odds of exposure for the cases 
and base sample [3] (figure 1). 
Either of these designs, generally known as cohort studies and case-referent 
studies, respectively, are suitable to study behavioural teratogenicity of medical drugs. 
Case-referent studies are an efficient way of studying associations between one 
outcome and several exposures, because only a sample of the population from which the 
cases have arisen has to be studied to collect reference information. For a case-referent 
study to be valid, it is necessary to be able to retrieve valid information about exposure in 
the past. This requirement cannot always be fulfilled. Exposure information may be biased, 
e.g. because of knowledge of the outcome (differential misclassification) or may be 
imprecise (random misclassification). 
The advantage of Cohort studies is that more outcome variables can be studied in 
relation to the same drug exposure in one study. Furthermore, exposed and non-exposed 
subjects can be chosen who have similar characteristics with respect to extraneous factors, 
which makes confounder control easier. An efficient way to analyse the information from a 
cohort study is to collect all the cases after follow-up and to sample the cohort for a base 
sample. This variant is referred to as a nested case-referent design or a case-base or case-
cohort design, depending on the criteria for the base sample. The major disadvantages of 
cohort studies are related to practicality. If there has been a long time interval between 
exposure and the occurrence of the illness, follow-up will be cumbersome and selective 
drop out may occur. Furthermore, the measurement of functional development with 
specific selected outcomes is generally difficult and expensive and, if the outcome is a rare 
condition, large numbers of exposed and non-exposed subjects may have to be studied. 
59 
Figure 1. Standard table to 
be filled with information in 
epidemiological research on 
teratology. Exposed 
Non-exposed 
Total 
Affected 
A 
В 
Non-affected 
С 
0 
Total 
N1 
NO 
T 
•• Collection of dato In a cohort study 
<!> Collection of data in a case-referent study 
Modified from Strohm, Pharmacoepidemiology, New York 1989 
Cohort study: Risk Ratio = A/NI I B/NO 
Risk Difference = Α/ΝΊ • B/NO 
Case-Referent study Odds Ratio = MB I CIO = A'D / B'C 
note. N ì and NO are not relevant for the calculation of risks in case-referent studies 
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Other study designs are less suitable for studying behavioural teratogenicity 
- Case series (case-referent studies without a base sample) may provide the first 
indications of possible associations between exposure to a specific drug and a certain 
pregnancy outcome and are therefore extremely important from an explorative point of 
view However, they cannot estimate excess risks associated with the exposure of interest, 
because no reference can be made to the exposure status in a base sample Moreover, most 
case reports are published because of the unexpected co-occurrence of exposure and 
outcome Exposure is therefore likelv to be overrepresented among these cases 
- Cross sectional studies or surveys (studies in which exposure and outcome 
information refer to the same moment in time) can only be used for studying side effects of 
drugs if exposure at the moment of measurement of the outcome is a good proxy of the 
exposure at the time of induction of the illness In studies on behavioural teratogenicity, in 
which outcomes cannot be measured until school age, this would imply that the 
consumption of specific medical drugs by the mother at the time of outcome measurement 
was similar to the consumption of these drugs during pregnancy This is not probable 
Similarly, it is theoretically impossible to measure teratogenic effects at the time of the 
relevant exposure From a theoretical point of view, cross-sectional studies therefore 
cannot give valid answers to questions related to behavioural teratology 
- The use of trials (cohort studies in which the allocation of exposure and com-
parable non-exposure is realized through a (modified) randomization procedure) to study 
side-effects alone is ethically untenable Side-effects of exposure to medical drugs can only 
be studied m trials that were set up to study the intended effects of treatment In general 
these study populations are not large enough to be able to estimate the rate of occurrence 
of side-effects Most importantly with a view to studying the teratogenic effects of drugs, it 
should be noted that pregnancy is almost always an exclusion criterion for trials intended 
to study the efficacy or effectiveness of a medical drug In addition, trials have the same 
problems as non-expenmental cohort studies 
Thus, epidemiological studies on behavioural teratogenicity should be designed as 
case-referent studies or cohort studies For case-referent studies to be valid, exposure to 
medical drugs (and other determinants) has to be accurately measurable after several 
years For cohort studies to be practicable, the outcome must be measurable with a 
reasonable degree of ease and validity 
In this chapter we present the results of studies on the validity and accessibility of 
several potential sources of information on medical drug use during pregnancy to be used 
in case-referent studies In addition, we discuss ways to select tests to obtain outcome 
measurements in cohort studies if the outcome is 'functional development/ Finally, the 
choice of reference groups in cohort studies is discussed in the context of a specific example 
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4.2 Accessibility and validity of data on medical 
drug use during pregnancy collected from 
various sources* 
PCM de jong, MIL Prevoo, CA Zielhuis, N Roeleveld, F Cabreéis 
Abstract In studies on the relationship between drug use during pregnancy and congenital 
defects in offspring, data on drug use often have to be collected m retrospect We studied 
the completeness and accessibility of various retrospective sources of data on drug use 
during pregnancy Information returned on request by the GP and pharmacy which 
supplied drugs during the index-pregnancies was compared to information obtained 
during a structured interview with the women involved and from hospital records both 
collected in a previously conducted case-control study on mental retardation and parental 
occupation The accessibility of GP and pharmacist information was moderate to low 
although 78 5% of the pharmacies and 78% of the GPS returned the questionnaire, only 29% 
and 77% of the questionnaires were informative about drugs used during pregnancy, 
respectively Hospital records did not contain standard information on drugs used during 
pregnancy The interview was taken as the standard and the completeness of the other 
sources of data was calculated in relation to the interview data The mean number of 61 
groups of drugs used per person was 1 7 according to the interview The GPS and 
pharmacists reported an average of only one group of drugs The data from hospital and 
GP record combined agreed best with the drug use reported during the interview The 
sensitivity was 69% The sensitivity of GP records m relation to the interview for some 
frequently used groups of drugs was low between 31% and 47% for antibiotics, vitamins 
and iron As only twenty-five pharmacists returned the questionnaire on drug pre-
scriptions, it was not possible to calculate the sensitivity of this source of data for groups of 
drugs We conclude that neither the hospital records nor pharmacy or GP records form a 
good alternative to a structured interview in studies on the relationship between medical 
drug use during pregnancy and congenital defects in offspring However, the information 
obtained from pharmacies with an automated record system agreed better with the results 
from the interview Thus in future research this source of data may prove to be useful 
Introduction Since the discovery of the teratogenicity of Thalidomide [1] and DES [2], there has 
been great interest in exposure to medical drugs during pregnancy and its possible effects 
The best way to measure drug use during pregnancy is to conduct a prospective study m 
which the women are followed carefully throughout pregnancy [3] However, this is not 
feasible if we wish to study the effects of drugs on specific pregnancy outcomes, and it is 
all the more impractical where functional disorders m offspring are concerned, because too 
many women would have to be followed for a very long time The most feasible design for 
studying the effects of drugs used during pregnancy on functional disorders, is the case-
referent design [4] Therefore, information on the use of medication during pregnancy 
must be collected retrospectively 
The retrospective information is usually collected from one or more of the 
following sources 
• Publlihcd In I Pharmacocpldemlol 1991 2(2) 45 57 
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ι Personal interviews with the mothers This source was used in the study on Bendectin® 
use and congenital heart disease by 7ierler and Rothman [5I 
2 The medical records kept at the hospital This source was used in the study on the 
teratogenicity of DES [6] 
3 The medical record kept by the general practitioner (cv) The Royal College of General 
Practitioners conducted a study using this source of data [7] 
4 The medical records kept by the pharmacist A study using this data source was 
conducted in the Netherlands by de Jong-van den Berg [8] 
None of the sources mentioned above is even conceptually perfect In an interview, 
recall error and recall bias may occur, distorting the picture of drug use dunng pregnancy 
and any relationship with developmental disorders that may exist [9] In hospital records, 
the information is mostly collected in a nonstructured interview in which the emphasis 
may have been laid on certain drugs suspected to be relevant to the etiology of the disease 
CPS do not usually record the drugs prescribed by specialists or those received in hospital 
Furthermore, self-medication will be missed when only this source of data is used [10] 
Finally, pharmacists do not record the drugs received in hospital, or those obtained from 
other pharmacies, or by self-medication [n] 
Although it is vital to know how complete each of these sources of data is when 
62 studying the effects of drugs used during pregnancy, few studies have actually addressed 
this question 
We studied the relative accessibility and validity of data on drug use collected 
from hospital records, CP records and pharmacy records and compared the results to 
information collected dunng an interview The data were partly obtained from a study on 
the relationship between parental occupation and mental retardation [12] and were partly 
new We also studied the suitability of CP and pharmacy records for future research and 
their accuracy in relation to automation of the administration of CPS and pharmacies 
Population and This report is based on the data from a sample of participants in a case-referent 
methods study on mental retardation and parental occupation carried out by Roeleveld et al [12] 
Cases (subjects with mental retardation with an unknown cause) and referents (subjects 
with a congenital physical handicap with a known cause not related to parental 
occupation) were selected using hospital records from the paediatnc departments of a 
university hospital and two rehabilitation centres in the eastern part of the Netherlands 
For the majority of the cases and referents, the hospital records registered some 
information on drug use in the relevant period The parents of these children (»=628) were 
interviewed thoroughly with respect to exposure to occupational hazards as well as to 
several other factors in the period from three months before conception to six months after 
birth The "other factors" included ten groups of medical drugs which were considered to 
be relevant to the etiology of mental retardation or were added as pseudo-exposures Table 
3 lists the ten groups 
In the present study, only pregnancies in which the child was bom after 1979 
(«=207) were included, to reduce recall error in the interview information and erroneous 
information from the other sources Information from the interview and the hospital 
records was used The 207 parents were asked to provide the name and address of the 
general practitioner (CP) and the pharmacy from which they obtained drugs dunng the 
index pregnancy A total of 159 parents responded, but not all the answers were complete 
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In this way, 150 GPS (answered by 157 parents) and 93 pharmacies (answered by 111 
parents) were identified and sent a questionnaire which consisted of two parts The first 
part contained an open question about the drugs prescribed for the pregnant woman 
during the relevant period The second part contained multiple-choice questions about the 
possibility of using the data for future research Nonresponding CPS and pharmacists were 
reminded once, by telephone The accessibility was measured as the response of the CPS 
and pharmacists and the completeness of the answers on the returned questionnaires 
Validity was expressed as the sensitivity and specificity of the GP, pharmacy and hospital 
records in relation to the information obtained during the interview The interview was 
taken as the standard, because all medications, including over-the-counter (отс) drugs, 
were supposed to be included in the ten groups of drugs Furthermore, compliance is 
included if information about drugs used is collected from the user instead of from the 
prescnber or the issuer Sensitivity was defined as the proportion of users m the interview 
identified by the other source and was calculated as the proportion of positive answers 
from the interview that were also positive m the other source Specificity was defined as 
the proportion of nonusers in the interview identified by the other source and was 
calculated as the proportion of negative answers from the interview that were also 
negative in the other source Ninety-five percent confidence intervals were calculated for 
the proportions or, for low numbers, were read from the appropriate table in Geigy [13I 
Kappa coefficients were not calculated, because there was too much missing data 63 
The second part of the questionnaire included questions on the automation of the 
administration systems, the availability of information on certain patient characteristics 
and the possibility of selecting specific patients The answers to this part were used to 
assess the suitability of GP and pharmacy records for future research on the effects of drug 
use during pregnancy on the development of the offspring 
Results Accessibility 
In total, 785% of the 93 pharmacies and 78% of the 150 CPS returned the 
questionnaire The responding pharmacies represented 85 participants (76 5% of 111) and 
the CPS represented 121 participants (77% of 157) Of the 73 responding pharmacies, nine 
had to be reminded first Of the 121 responding GPS, 25 returned the questionnaire after the 
reminder, whereas three GPS could not be reached because they had moved or had no 
telephone Although the response rate was high, only 29% and 77% of the returned 
questionnaires were informative about drug use during pregnancy, respectively The 
others were left blank or featured 'unknown' In total, we received information from the 
GPS of 93 parents (59% of 157) and from the pharmacy of 25 parents (22 5% of 111) 
Validity 
Figure 1 shows the number of drugs used according to the different sources The 
hospital records did not contain information on the number of drugs used In the 
interview, a mean number of 1 7 drugs per person was reported In GP and pharmacy 
records, the mean number of drugs was 1 
Table 1 lists the sensitivity of the various sources regarding drug use in cases where 
information on the pregnancy was available Sensitivity was low for all the individual 
sources, but was highest for GP information When two sources were combined (ie 
a positive answer in one of the sources was regarded as evidence of use, and missing 
values of one source were replaced by information from the other), the sensitivity was 
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highest for CP and hospital information together (sensitivity 690%) Contrary to our 
expectations, when nonprescription (отс) drugs were excluded, the sensitivity decreased 
in most cases {table 1) 
When the missing data were regarded as being a negative response (which is done 
in some studies, especially if hospital records are the source), the sensitivity for drug use in 
relation to the interview, was 8 4% for pharmacies, 32 8% for crs and 481% for hospital 
records The combination of pharmacy and hospital records had an overall sensitivity of 
53 4% and the combination of CP and hospital record 67 9% 
In the Netherlands, pharmacies are required by law to keep prescriptions for six 
years Therefore we calculated the sensitivity of drug prescription information during 
pregnancies occurring before and after 1983 {table 2) The information for those which 
occurred after 1983 led to a slightly higher sensitivity, but the confidence intervals over­
lapped completely Finally, we compared the sensitivity of information obtained from 
pharmacies with automated and nonautomated administration systems {table 2) 
Pharmacies with an automated administration system produced higher sensitivities There 
were not enough GPS with automated administration system at the time of the pregnancy 
to calculate the separate sensitivities for GPS 
I able 3 lists the number of women who used drugs in the various groups according 
to the individual data sources As the numbers were very low, we only calculated the 
sensitivity of the GP information for the use of antibiotics, vitamins/fluoride and iron 
Sensitivity was low for antibiotics 47% (24-72), for vitamins/fluoride 31% (14-52) and for 
iron 41% (26-58) 
Table 4 lists the possibilities of the CP and pharmacist to select patients on various 
criteria GPS and pharmacists with automated administration systems had more pos­
sibilities for selecting patients and had information on more patient characteristics than GPS 
and pharmacies with nonautomated administration systems 
Figure Ì The number of 
drugs from different groups 
used during pregnancy 
according to the various 
sources 
proportion of mother ι 
Interview 
General Practitioner 
Pharmacist 
number of group· of drug· 
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Int+ ( 9 5 % Cl) tat spec 
Table 1. Sensitivity (sens) 
and specificity (spec) of the 
various sources regarding 
drug use during pregnancy 
and regarding drug use 
when OTC drugs were 
excluded. 
1. Pharmacy 
OTC excl. 
2. General practitioner 
OTC excl. 
3. Hospital Record 
OTC excl. 
4. 1.and3. 
OTC excl. 
5. 2. and 3. 
OTC excl. 
25 
93 
153 
154 
157 
22 
19 
78 
69 
126 
114 
127 
115 
129 
117 
50.0% 
42.1% 
55.1% 
55.1% 
50.0% 
39.5% 
55.1% 
44.4% 
69.0% 
60.7% 
(28-72) 
(20-67) 
(43-66) 
(43-67) 
(41-59) 
(31-48) 
(46-64) 
(35-53) 
(61-77) 
(52-70) 
3 
6 
15 
24 
27 
39 
27 
39 
28 
40 
66.7% 
66.7% 
73.3% 
66.7% 
85.2% 
97.4% 
81.5% 
92.3% 
75.0% 
80.0% 
int+ = number of positive answers in the interview 
int- = number of negative answers in the interview 
OTC = over-the-counter drugs 65 
Table 2. Sensitivity of 
plmrmacist information* for 
interview data: period in 
which pregnancy occurred 
and automation at the time 
of pregnancy (which was 
between 1979 and 1987). 
Baby bom before '84 
Baby born after '83 
Automated 
Non-automated 
π 
5 
20 
12 
13 
lnt+ 
5 
17 
10 
12 
sensitivity 
40.0% 
52.9% 
80.0% 
25.0% 
(95% CI) 
( 5-85) 
(28-77) 
(44-97) 
( 5-57) 
'CPs keep their information for longer than six years and there were too few CPs automated at the time of 
pregnancy to make a comparison of the sensitivity of automated and nonautomated CP information. 
Discussion Our results indicate that the accessibility and validity of GP records and pharmacy 
records as a source of data on drug use during pregnancy were rather low. Firstly, the 
information was difficult to obtain. Although we had the permission of the parents, many 
cps and pharmacists would not provide the information for reasons of privacy. 
Furthermore, the information from the GPS and pharmacies had low sensitivities in relation 
to the information obtained during the interview, as well as in relation to each other (not 
shown). There was a wide range of sensitivities for the various types of drug. Antibiotics, 
for instance, appeared to be registered better than vitamins. For most of the drugs, too few 
users were present to calculate valid figures. 
Some critical remarks can be made about the validity of the study itself. We 
regarded the interview data as the 'golden' standard. It is likely, however, that the 
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Table 3 Use of the groups 
of drugs according to the 
апоич sources 
Drug Croup 
N5AID 
Antibiotics 
Cardiovascular medication 
Gastrointestinal medication 
Tranquilizers/sedatives 
Hormones 
Vitamins/lluonde 
Iron 
Cytostatic drugs 
Miscellaneous 
Interview 
(n=1S8) 
л(%) 
21(13 2) 
25(15 7) 
5( 31) 
21(13 2) 
15 ( 9 4) 
61 (38 4) 
35 (22 0) 
71 (44 7) 
0 
16(101) 
CP 
(if=91) 
n<%) 
2( 22) 
19(20 4) 
3 ( 3 2 ) 
9 ( 9 7 ) 
0 
8 ( 8 6) 
11 (11 8) 
23 (24 7) 
0 
13(14 0) 
phinnaclit 
(n=2i) 
n ( % ) 
3(12) 
5(20 
0 
3(12) 
1 ( 4 ) 
2( 8) 
1( 4) 
5(20) 
0 
4(16) 
NSAID = Non steroidal anti inflammatory drug 
66 
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interview data were incomplete -and incorrect in some cases [9] Nevertheless, we feel that 
the thorough interview of the parents involved gave the best results, which was supported 
by the fact that the interview gave the most information about the drugs used From other 
studies we know that about 80% of all pregnant women use medical drugs during 
pregnancy, with a mean of about two drugs per person [14] This was also found in our 
interview data (figure 1) 
Although we received the address of the GPS of 157 parents and of the pharmacy of 
111 parents, we only received pharmacy information for 25 pregnancies and GP informa­
tion for 93 pregnancies We checked the possibility of selective response, 1 e, whether drug 
use was more or less common among the women for whom no information was returned 
The mean number of drugs used according to the interview was the same for the women 
for whom information was returned by the GP and pharmacy and for whom no 
information was returned 
We also checked whether the data recorded from 1983 onwards were more 
accurate than those recorded before 1984 Although the sensitivity of the information 
recorded in the period from 1983 onwards was higher, the number of children born before 
1984 for whom information was still available was so low that exclusion did not affect the 
sensitivity (table 2) This was to be expected, because most of the pharmacies had destroyed 
the information recorded before 1983 and therefore did not complete the questionnaire 
This study comprised small numbers of users of specific drug groups We could therefore 
not calculate the sensitivity for several groups of drugs separately 
In conclusion, this study does not support the idea that GPS and/or pharmacies are 
relevant sources of information for studies on the effects of medical drug use during 
pregnancy The increase in sensitivity found for automated pharmacy administrations is 
promising for future research, because at the time of the pregnancy, only 38% of the 
pharmacies had an automated administration system, whereas at the time of the 
questionnaire, 90% of the pharmacies had Future research should therefore reassess the 
validity of pharmacy record data by comparing the information from this source to data 
from a study in which drug use is/was recorded prospectively during pregnancy 
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Table 4 Proportion of the 
GPs/pharmacies able to 
select patients on various 
criteria and able to select 
patient* on these criteria at 
the time of the questionnaire 
(1990) 
Criteria 
Selection of patients 
by use of groups of drugs 
by use of specific drugs 
Availability of information on 
chronic diseases 
mortality (1) 
pregnancy (1) 
civil status (1) 
age(1) 
gender (1 ) 
Willing to co-operate 
CP 
automated 
I I = 1 7 
39% 
54% 
77% 
-
-
-
-
— 
45% 
not 
ii*SO 
10% 
7% 
27% 
-
-
-
-
— 
pharmacy 
automated (2) 
n=63 
64% 
80% 
84% 
47% 
56% 
44% 
100% 
100% 
38% 
(1) Information on these items was assumed to be known by the CP 
(2) There were only four pharmacies with non automated administration systems 67 
Finally, although the data indicate that epidemiological follow-up studies based on 
pharmacy or GP record data are possible m principle, most pharmacists and CPS will 
probably not be willing to give the names of eligible subjects for reasons of privacy (table 4) 
However, we found that they would be more inclined to co-operate if they could approach 
the eligible subjects themselves 
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4 3 Validation of a questionnaire on medical drug use 
during pregnancy* 
PCM de long, AA Huijsmans, HE Nienhuis, WS Nijdam, CA Zielhuis, TKAB Eskes 
Abstract The validity of a questionnaire on medical drug use during pregnancy was tested 
against information collected 7 years previously (in 1983-1984) at the University Hospital 
of Nijmegen, The Netherlands. The study population consisted of women with high-risk 
pregnancies. The sensitivity for drug categories varied between 0% and 8o%. The sens­
itivity was highest for drugs used during labour (77%) and was extremely low (0%) for 
some drug categories. Personal characteristics thought to influence the sensitivity, such as 
parity of the mother and method of data collection (mailed questionnaire or personal inter­
view), showed no statistically significant effect. The newly developed questionnaire needs 
further improvement. 
Introduction The majority of pregnant women use one or more drugs [1-3], the effects of which 
are unknown. A case-referent design is the most efficient way to study the relation of 
drugs used during pregnancy with congenital malformations, since specific malformations 
are rare [4]. 69 
For reduction or prevention of recall errors, which may occur in determining drug 
use during pregnancy іл retrospect, a valid and reliable instrument is needed [5,6]. 
Previous research showed only moderate associations between prospectively and retro­
spectively collected data, indicating low validity [7,8]. Differences in the recall interval, 
ranging from 9-24 months to 30 years, and the variation in the study populations and types 
of medication examined make it difficult to compare the results of the published studies. 
The design of a questionnaire greatly determines the validity of the measurements: 
More specific questions lead to more valid answers [4,9,10]. Furthermore, the results of a 
mailed questionnaire seem to be less valid than those obtained via a questionnaire which is 
part of a personal interview [11]. We developed a questionnaire characterised by a 
"personal time calendar" to focus the participants' memories and thus improve the quality 
of retrospectively collected data on drug use during pregnancy. The validity of this 
questionnaire was studied in women who participated in a prospective study on drug use 
during pregnancy 7 years ago. 
Materials and The questionnaire consisted of a time schedule and an additional list of questions. 
methods The time schedule asked for life-events and illnesses that occurred during the index preg­
nancy. The list of questions included specific questions about drugs taken for pregnancy-
related conditions such as anaemia and emesis. The names of some drugs for these con­
ditions were listed, but no pictures were shown. No specific efforts were made to help the 
women remember the names of the preparations. 
Data on drug use during pregnancy were collected prospectively by Eskes and 
Nijdam [3I from 978 women with high-risk pregnancies who delivered at the University 
Hospital in Nijmegen in 1983. Information on drug use during pregnancy was collected 
through an interview at each prenatal visit, and the women were requested to write down 
• P u M i M In Am I Epidemiol 1991; 114:99·-1002 
ι 
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all drugs they used in the period between the visits. After delivery, the women were 
interviewed again to complete the information. For drugs that could not be identified 
through the interview the prescriptions were requested at the pharmacies. Local 
anaesthetics for episiotomy, as well as iron supplements, were excluded from the study. 
The questionnaire was presented to 488 women randomly selected from the 978 
participants of the previous study. To mask the purpose of the study, we presented it as a 
study on the effects of drugs on the development of the child. Of the 488 selected women, 
the women with addresses in the city of Nijmegen ( η = 53), received an invitation for a 
personal interview. The other women ( и = 435), living in the Nijmegen area, received the 
questionnaire by mail. In addition, all of the women were asked to fill out a Child Behavior 
Checklist (CBCL) [12] for the index child. 
A reminder was sent to the women who had not returned the mailed questionnaire 
within 4 weeks. A fortnight later, nonresponders were reminded by telephone. Drugs were 
categorised in accordance with the classification system used in 1983. 
The agreement between the prospective and retrospective information was 
estimated by means of sensitivity and specificity analyses. Because of the limited number 
of women who could recall the exact names of the preparations (9 per cent of the 
preparations used), calculations were performed per drug category. For sensitivity, 95% 
confidence intervals were calculated. 
We distinguished five personal characteristics which we anticipated would 
influence the sensitivity: 
1. Questionnaire circumstance (personal versus mailed); 
2. Number of children (one versus more than one); 
3. Interval between the index pregnancy and the nearest pregnancy before or after (1 year 
versus more than 1 year); 
4. Birth order (eldest or youngest versus other); and 
5. Length of gestation (shorter than 38 weeks versus 38 weeks or longer). 
Table 1. Recall of use of 
various drug categories by 
women followed in 1983 
during their high-risk 
pregnancy in the Nijmegen 
University Hospital and 
questioned in 1S90. 
Drug category 
Anaesthetics 
Hypnotics/sedatives 
Analgesics 
Local anaesthetics 
Antacids 
Oxytocics 
Tocolytics 
Antibiotics 
Total 
Users' 
η 
32 
40 
61 
77 
55 
66 
42 
36 
409 
Correct* 
answers 
« (%) 
24 (75) 
12 (30) 
26 (43) 
13 (17) 
19 (35) 
53 (80) 
29 (69) 
17(47) 
193 (47) 
* according lo the prospectively collected Information 
# in the questionnaire 
Answers with 
timing correct 
% 
100 
58 
54 
92 
42 
100 
100 
71 
82 
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Figu re 1. Recall of use of 
various drug categories by 
women followed in 1983 
during their high risk 
pregnancy in the Nijmegen 
University Hospital and 
questioned in 1990. 
Sensitivity for drug 
categories. 
D r u g c a t e g o r i e s 
musei« reluants ^ 
nasal medications 
mouth/throat med 
antlhcmorrtioldallcs 
vaginal antllnfect 
dermatologies 
cough medications 
folk acid 
local anaesthetics 
corticosteroids 
tranquilizers 
vitamins/minerals 
antacids 
analgesics 
laMatlves 
antibiotics 
tocolytics 
general anaesthetics 
ojrjrtocks 
f*H 
I· 
0 % 1 0 % 2 0 % 
·—< »S% Confidano InttrMl 
4 0 % 50% 60% 
Sensitivity 
* used during labor 
70% 80% 90% 100% 
D sperifk questions 71 
For each characteristic, sensitivities with 95 per cent confidence intervals were calculated 
for any drug use. 
Results The response to the mailed questionnaire was 68 per cent. Of the 296 returned 
mailed questionnaires, 246 (57 per cent of the original population) gave information about 
drug use during the relevant pregnancy. For 50 women, the questionnaire was not 
readable, information was given about the wrong pregnancy, or vital information was 
missing. For the personal interviews, the response was 68 per cent ( и = 36). 
In the prospective survey, the mean number of drugs used per woman was 3.1 [3]. 
In the retrospective study, 1.4 drugs per woman were reported and of these, 0.3 pre­
parations per woman were correctly recalled. 
For the separate drug categories, the specificity was 90 per cent or more (not 
shown). The specificity therefore proved to be a less important component of reporting 
accuracy than sensitivity and was not studied further. The sensitivity for any drug use was 
80 per cent. The sensitivity ranged from о to 80 per cent for the various categories, as 
shown in ßgurei. 
The extent to which the women who correctly reported the drugs they used could 
also remember the time of use is shown in table 1. Recall of the time of use was good for the 
drug categories with a high sensitivity. 
Figure 2 shows the sensitivity for any drug use in various periods of pregnancy 
and for drugs used throughout pregnancy. For drug use during labour, the sensitivity 
was the highest (77 per cent). For drugs used throughout pregnancy, the sensitivity was 
55 per cent. 
The results of the analyses per characteristic are shown in table 2. Only the length of 
gestation had a statistically significant effect on the sensitivity. 
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Figure 2. Recall of drug use 
and trimester of use by 
women followed in 1983 
during tlieir high-risk 
pregnancy in the Nijmegen 
University Hospital and 
questioned m 1990. 
Sensitivity for drugs used in 
one of the various periods of 
pregnancy. 
sensit iv i ty 
72 
Discussion 
J 9S% CI 9 5 % CI = 9 5 % Confluence Interval 
3rd 
trimester 
period of use 
ы 3rd 
trimester 
This study showed only moderate agreement between the retrospective question­
naire data and the prospective information collected η years previously. The mean number 
of preparations reported exactly by the women was very low (0.3 drugs, 9 per cent of the 
drugs used). The specificity for the drug categories was high (90 per cent or more for all 
categories) because of large numbers of nonusers and few overreported drugs. The 
sensitivity for the drug categories ranged from 0 to 80 per cent. 
These figures are fairly similar to those found in the literature. Klemetti and Saxén 
[7] reported a sensitivity of 70 per cent for drugs used in a representative group of 
pregnant women. The interval between the two interviews (before and after delivery) was 
short. This may have improved recollection. Feldman et al. [13] reported a sensitivity 
(recall rate) of 62 per cent in an interview after delivery compared with before delivery. 
The study group consisted of women who contacted the investigator for information about 
risks from drugs to which they had been exposed. 
The sensitivity varied between 0 and 80 per cent for the various drug categories. 
A number of factors seemed to explain this variation, at least in part. The sensitivity for 
drug categories used at delivery, a major life-event, was high (figures 1 and 2). The sen-
sitivity was low for drug categories with many over-the-counter drugs. Feldman et al. [13] 
reported a sensitivity of 31 per cent for over-the-counter drugs and 55 per cent for 
prescription drugs. The sensitivity was lowest for drugs for which no specific questions 
were included in the questionnaire (figure 1). Mitchell et al. [4] showed that specific 
questions lead to higher sensitivities. A short pregnancy duration (less than 38 weeks) was 
the only personal characteristic that had a statistically significant influence on the sensitivity 
(table 2). The women who delivered prematurely often used general anaesthetics and 
tocolytics. For the other characteristics, the differences (although not statistically significant) 
were in the expected direction. 
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Some specific features of this study should be kept in mind when interpreting the results. 
ι. The population was not representative for all pregnant women. Whereas about 30 per 
cent of Dutch women deliver at home, the study population comprised only hospital 
deliveries. Drug consumption during pregnancy is higher in the latter group [14], which 
may influence recollection. Furthermore, specific drugs these women may have used for 
complications might be easier to remember. 
2. The response was low. The main reason for nonresponse was that the women had 
moved (36 per cent of the nonresponders). It is not likely that this introduced a bias. 
3. The women who were interviewed lived in the city of Nijmegen. Differences might exist 
in access to hospital and socioeconomic status between these women and the women 
who received the questionnaire by mail. The access to hospital is presumed to be equal 
for all women as a result of the organization of Dutch health care. There was no 
indication for differences in socioeconomic status. 
4. The recall time was long. The influence of recall time could not be assessed in this study 
because all the women delivered in the same year. 
Adding a time schedule to the questionnaire did not improve the quality of the 
data on drug use during pregnancy collected in retrospect. The time schedule was not 
filled in by the majority of women who received the questionnaire by mail. It was filled in 
during the personal interview, but this did not seem to improve the sensitivity. We have to 
conclude that this questionnaire with a time schedule needs further improvement in order 
to meet the requirements for use in case-referent studies on the effect of medical drugs 
during pregnancy on congenital defects that appear in childhood. 
73 
Table 2 Recall of drug use 
by women followed m 1983 
during their high-risk 
pregnancy m the Nijmegen 
University Hospital and 
questioned in 1990 
Personal characteristics of 
the participants and 
sensitivity for any drug use. 
Characteristic 
Interview 
Mailed questionnaire 
One child 
More than one child 
Child in '82/'84 
No child in '82/'84 
Eldest child in '83 
Eldest child not in '83 
Youngest child in '83 
Youngest child not in '83 
<38 weeks pregnant 
38 weeks and longer 
Sensitivity 
% 
88 
78 
89 
77 
86 
76 
80 
75 
75 
79 
88' 
74* 
(95% CI) 
(76-99) 
(72-84) 
(79-99) 
(71-83) 
(73-99) 
(70-82) 
(72-88) 
(67-83) 
(65-85) 
(72-86) 
(81-95) 
(67-81) 
'p<0,05 difference in sensitivity 
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4.4 Recall of medication during pregnancy; validity 
and accuracy of an adjusted questionnaire* 
PCM Pasker-de ¡ong, MPH Berns, YTHP van Duynhoven, WS Ni/dam, TKAB Eskes, CA Zielhuis 
Abstract Objective To study the validity and accuracy of an adjusted questionnaire on 
medical drug use dunng pregnancy eight years after the pregnancy 
Methods An (adjusted) questionnaire on medication used dunng pregnancy was tested 
against information collected 8 years previously (in 1983-1984) from 473 women with high-
risk pregnancies who delivered at the University Hospital Nijmegen, the Netherlands 
Results For separate drug groups, the sensitivity varied between 5% and 91% The timing 
of use was recalled moderately well Although specific questions on drug groups did 
improve the sensitivity as compared to an earlier questionnaire, the improvement was not 
enough to make the questionnaire valid High maternal education, low birth weight, low 
gestational age and a low 5-min Apgar score were related to better recall The validity of 
the questionnaire depended on the behavioural score of the child, implying recall bias 
Conclusions Questionnaire data on drug use during pregnancy obtained eight years after 
delivery are not a valid source of information 
Introduction Relatively little clinical epidemiological research has addressed the adverse effects 
of drug use dunng pregnancy on fetal development The rare occunence of specific 
congenital disturbances is partly responsible for this The most feasible epidemiological 
approach to identify potential functional teratogens seems to be the case-control design 
[1,2], which requires complete and accurate data on medication during pregnancy [3-6] 
One way of collecting data on drug use during pregnancy is via a questionnaire Most of 
the studies which evaluated the validity of questionnaires to measure exposure in 
retrospect showed only moderate agreement between the data obtained using the 
questionnaire and the data obtained prospectively [7-14] These questionnaires were 
mostly been tested within 1 year after pregnancy [11-14] I' n a s been suggested that the 
measurement error of questionnaires on medication is related to the recall time, the 
prescription status of drugs and the methods of data collection [2,12,15-18] Some studies 
have shown that the design and formulation of the questions in mailed questionnaires are 
of crucial importance for the amount of information collected For instance, specific 
questions on specific medical therapies seem to improve the validity [6,19] 
We developed a questionnaire to be administered m a study on the effect of drug 
use dunng pregnancy on the functional development of children As developmental delay 
cannot always be diagnosed until school age, the questionnaire was intended to measure 
drug exposure some five to ten years previously with reasonable precision In 1990, we 
conducted a validation study on this questionnaire in a subgroup of 495 women from a 
population of 978 who had participated m a drug consumption study in 1983 The validity 
of this first questionnaire was unsatisfactory, because 20 to 100 per cent of the users of 
specific drug groups were missed [20] 
We extended and adjusted the questionnaire by adding more specific questions on 
indications and drug groups The validity of this adjusted questionnaire was studied in a 
> Submitted for publication 
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second subgroup from the population of 978 women who participated in the drug 
consumption study in 1983 [21] This paper presents the results of this second validation 
study and compares the results of both evaluations Furthermore, we discuss the effect that 
the questionnaire data would have had on the outcome of case-referent studies if they had 
been used instead of the original data 
Materials and In 1983, a population of 978 women who delivered at the University Hospital 
methods Nijmegen provided detailed information on drug consumption during pregnancy (Golden 
Standard) I21] Information was collected at each prenatal visit via an interview on the 
medication used between the last menstrual period and delivery, including the medication 
used during labour The women were requested to write down all the drugs they had used 
m the period between the visits After delivery, the information about drug use was 
completed In cases where the type of prescription drug was unclear, the prescriptions 
were requested from the hospital pharmacy Iron preparations as well as local anaesthetics 
for episiotomy were excluded from the study In 1990, a random sample of 488 of the 
participants were invited to participate in the validation study of the first questionnaire 
The remaining 473 women whose child had survived the neonatal period, were eligible for 
participation in the present study The methodology of this validation study was similar to 
that of the previous study [20] 
The adjusted questionnaire on medical drug use consisted of a list of questions and 
an additional time schedule The time schedule enquired about life events and illnesses 
that occurred during the index pregnancy and was meant to help the women remember 
the pregnancy concerned A similar schedule had been used in the previous study, but 
, extensive instructions for filling in the schedule were added The adjusted questionnaire 
was longer and included questions about maternal demographic factors, factors that 
possibly influenced maternal reporting and several more questions on drug use during 
pregnancy and labour, especially on the timing of use, indications for use and prescription 
status No lists or pictures of medications were shown The questionnaires can be 
requested from the first author 
The 473 eligible women were sent the questionnaire by mail If an address proved 
to be incorrect, we approached the municipal registries for the new address but we were 
not always successful A reminder was sent to the women who did not respond within 
three weeks A fortnight after this reminder, the remaining nonresponders were contacted 
by telephone, as far as possible The study was presented as a study on the influence of 
medication during pregnancy on the behaviour of the child, so a Child Behavior Checklist 
[22] was bent with the questionnaire, as in 1990 The CBCL is a questionnaire to be filled m 
by the parents and collects data on the behavioural problems and competencies of children 
aged 4 to 16 years The CBCL does not diagnose aberrant behaviour but may signal clinical 
behavioural problems 
Data collected with the questionnaire were compared to the data collected m 1983 
Sensitivity and specificity with a 95 per cent confidence interval (CI) were used as 
measures of reporting accuracy as before [20] Drug groups used by a minimum of 20 
women (as recorded in the prospective study) were included in the analyses The number 
of correctly reported trimesters of use was estimated for some groups on the basis of the 
agreement about the drug group The influence of differences between the results of the 
first questionnaire and those of the adjusted one were studied m relation to the change in 
the type of questions 
Ì 
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The following personal characteristics were examined for possible influence on the 
estimated sensitivity of reported drug use (considered as no use at all during pregnancy 
versus any use during pregnancy): number of children, number of pregnancies, interval 
between the index birth and the nearest birth before or after, birth order, gestational age, 
maternal age, birth weight, maternal education (based on the educational level and 
profession), address (rural or urban), 5-min Apgar score (<8 or 8-10) and the indication for 
a hospital delivery (none, primary or secondary). 
Finally, to identify potential recall bias in the data, associations were compared 
between frequently used drug groups and the behavioural score for both sources of 
information about drug use. 
Results A total of 259 (55 per cent of 473) questionnaires were returned completely filled in 
for the correct pregnancy. Comparison of the number of medications used, maternal age, 
5-min Apgar score, indication for a hospital delivery, birth weight of the child and 
gestational age, showed no differences between the responders and non-responders (table 1). 
The 259 responders used an average of 3.3 medications. In the questionnaire, an 
average of 2.0 drugs per woman were reported. Of all the drugs used, the women recalled 
only 9 per cent (0.3/3.3) w ' t n t n e correct drug names. The overall sensitivity for drug use 
(identification of users of any drug) was 88.2 per cent. The overall specificity (identification 
of non-users) was 74.2 per cent. The influence of some characteristics of the women on the 77 
sensitivity is shown in table 2. Maternal education, gestational age and birth weight of the 
child, Apgar score at five min, number of children and birth order of the index child were 
statistically significantly associated with the sensitivity. 
Table 3 presents the sensitivity of the questionnaire for users of any medication in a 
specific trimester. Sensitivity was highest for medication during labour. The figures were 
higher than those obtained in 1990. 
The sensitivity for the separate groups varied between 5 and 91 per cent (table 4). 
Sensitivities for over-the-counter drugs were much lower than for prescription drugs. The 
specificity was over 95 per cent for most of the drug groups and was therefore not consid-
ered further. Table 4 also specifies the way the information was obtained. The recall per-
centages of drugs for which the indication as well as specific questions had been asked were 
not significantly higher than those for drugs for which only one enquiry method was used. 
Table 1. Comparison of 
maternal age, birth weight 
of the child, gestational age, 
5-minute Apgar score, 
indication for hospital 
delivery and number of 
drugs used by responders 
and non-responders 
followed at the University 
Hospital Nijmegen, the 
Netherlands, in 1983 
during high-risk pregnancy 
and contacted in Í991. 
— 
Maternal age in years (sd) 
Birth weight in g (sd) 
Gestational age in weeks (sd) 
Number of drugs used (sd) 
Medical indication for delivery % 
Primary 
Secondary 
None 
5-minute Apgar score <8, % 
Responden 
(л = 2S9) 
28.6 (4.4) 
3226 (750) 
39.4 (2.6) 
3.3 (3.0) 
69.0 (3.5) 
24.4 (5.4) 
6.6 (6.0) 
3.2 (6.2) 
Non-responden 
(и = 214) 
28.5 (4.8) 
3223(586) 
39.4 (2.3) 
3.0 (2.6) 
67.0 (3.9) 
25.1 (5.9) 
7.9 (6.5) 
2.8 (6.7) 
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Table 2 Vic influence of 
some personal 
characteristics on the 
estimated sensitivity of drug 
use (no use at all versus any 
use) m women followed at 
the University Hospital 
Nijmegen, the Netherlands, 
m 1983 during high-risk 
pregnancy and questioned 
m 1991 
Characteristic 
Number of pregnancies 
one pregnancy 
more pregnancies 
Number of children 
one child 
more children 
Interval between pregnancies 
> 1 5 year 
< 1 5 year 
Birth order 
youngest child 
other 
eldest child 
other 
Gestational age 
< 38 weeks 
> 38 weeks 
Birth weight 
< 2500 g 
>2500 g 
S-minute Apgar score 
<B 
>8 
Medical indication for delivery 
primary 
secondary 
Maternal age 
> 30 years 
< 30 years 
Maternal education 
high education 
low education 
Address 
urban 
rural 
(") 
(") 
(224) 
(25) 
(224) 
(71) 
(188) 
002) 
(157) 
(109) 
(150) 
(43) 
(209) 
(32) 
(220) 
(B) 
(240) 
(178) 
(63) 
(96) 
(163) 
(28) 
(97) 
(101) 
(157) 
sensitivity 
089 
0 88 
0 96 
0 87 
0 89 
084 
0 83 
0 91 
0 92 
0 84 
0 97 
0 86 
0 97 
0 87 
1 00 
086 
0 87 
088 
0 92 
086 
100 
0 83 
090 
0 87 
difference In sensitivity 
95% confidence Interval 
001 
-018-020 
0 09* 
0001 -018 
0 05 
-004-014 
0 08 
-0005-017 
0 08* 
0 002-016 
011* 
0 05-018 
010* 
003 018 
014* 
010-018 
0 01 
- 0 04 - 0 06 
0 06 
-0 02 014 
017-
ОЮ-024 
0 03 
-005-011 
'p<0 0S 
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Table 3 Estimated 
sensitivity of the recall of 
the tnmester(s) of drug use 
(considered as no drug at all 
m a particular trimester 
versub any use in that 
trimester) m women 
followed at the University 
Hospital Nijmegen, the 
Netherlands, m 1983 
during high-risk pregnancy 
and questioned m 1991 
trimester(s) of use 
first trimester 
second trimester 
third trimester 
during labour 
during whole pregnancy 
95% C/ = 95 per cent confidence interval 
sensitivity 
0 64 
0 50 
0 73 
084 
0 55 
95% CI 
0 48 - 0 80 
0 33 - 0 67 
0 63 - 0 83 
0 77 - 0 91 
0 38 - 0 72 
Table 4 Estimated 
sensitwity of the recall of 
the use of various drug 
(sub)groups subdivided into 
groups with over-the-
counter drugs and groups 
with only prescription 
drugs by women followed at 
the University Hospital 
Nijmegen, the Netherlands, 
m 1983 during high-risk 
pregnancy and questioned 
in 1991, and the method of 
data collection 
Name of group 
Croups with only prescription drugs 
folic acid 
local anaesthetics 
hypnotics / sedatives 
cardiovascular medications 
antibiotics 
hormones / metabolic drugs 
vaginal anti-mfectrves 
tocolytics 
oxytocics 
general anaesthetics 
overall prescription 
Groups with over-the-counter drugs 
nasal medications 
dermatologies 
vitamins / minerals 
cough medications 
analgesics / antipyretics 
antacids ** 
overall OTC 
sensitivity 
0 20 
0 25 
0 27 
0 33 
0 51 
0 56 
0 59 
0 70 
0 78 
0 91 
0 50 
0 05 
013 
0 24 
0 30 
0 34 
0 44 
0 28 
95% CI 
0 09-031 
0 15-035 
0 10-044 
017 - 0 49 
0 35 - 0 67 
0 37 - 0 75 
0 38 - 0 80 
0 55 - 0 85 
0 67 - 0 89 
0 83 - 0 99 
0 45-055 
000-014 
0 01-025 
0 09 - 0 39 
0 10-050 
0 22 - 0 46 
0 30 - 0 58 
0 22 - 0 34 
specificity 
1 00 
0 96 
0 98 
0 99 
0 97 
0 97 
0 97 
0 95 
0 95 
0 95 
0 97 
1 00 
0 98 
0 96 
0 99 
0 92 
0 96 
0 97 
method1 
* 
# 
# 
# 
# 
#* 
# 
* 
* 
# 
# 
# 
* 
# 
#* 
#* 
' # question retened to indication of use 
' question referred to specific group 
#· question referred to indication afuse and specific group 
95% О =95 per cent confidence interval 
79 
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Figure 1. Recall of use of 
various drug groups by 
women followed at the 
University Hospital 
Nijmegen, the Netherlands 
in 1983 during their high-
risk pregnancy and 
questioned in 1990 or 1991. 
Change in sensitivity 
according to the change in 
the type of questions asked. 
sensitivity 
a. Similar questions 
b. More specific questions 
8 0 % 
laaatlves tocolytics gen anaesthetics oavtoclcs 
3 0 % 
2 0 % 
1 0 % 
0 % 
1 0 0 % 
Τ 954» CI 
50% 
: 4 0 % 
3n( 1 0 % 
nasal antl 
medication hemorrh 
vag 
antiinfect 
dermato­
logies 
cough local tranquilizers antibiotics 
anaesthetics 
0 % 
Table 5 shows the sensitivity of the questionnaire for some types of medication if 
the use and the timing of use had to be correctly recalled. As expected, these proportions 
decreased considerably if timing was involved, and the sensitivity varied between 6 per 
cent (folic acid) and 71 per cent (oxytocics). 
Figures ία and lb compare the sensitivity of the adjusted questionnaire to the 
sensitivity of the previous version. For most groups, the adjusted questionnaire was more 
sensitive if the questions had been formulated in a more detailed manner. 
CHAPTER 4 WLICHINC THE RESEARCH OPTIONS IN EPIDEMIOLOGICAL STUDIES ON BEHAVIOURAL TERATOLOGY 
Table 5 Recall of trimester 
of use conditional on the 
recall of use of a drug 
(sub)group by women 
followed at the University 
Hospital Nijmegen, the 
Netherlands, in 1983 
during high-risk pregnancy, 
and questioned m 1991 
drug group users (в) 
% users correctly recalling 
use вт trimester 
folic acid 
antacids 
analgesics 
vaginal anti-infectives 
antibiotics 
tocolytics 
local anaesthetics 
oxytocics 
50 
48 
59 
22 
39 
37 
68 
51 
20 
44 
34 
59 
51 
70 
25 
78 
6 
17 
15 
36 
33 
49 
18 
71 
Discussion 
Tabic 6 presents the sensitivity and specificity of some frequently used groups of 
drugs according to the behavioural status of the child at the time of the questionnaire In 
the same table, the Odds Ratios are given for the association between the behavioural score 
and the consumption of these drugs as estimated from the original data and from the 
questionnaire, respectively 
Despite the efforts to improve the questionnaire, its validity was still 
disappointing The agreement between the data on medication collected with the adjusted 
questionnaire and the prospective data was only fair The extension of the questionnaire by 
87 
Table 6 Sensitivity and 
specificity of some groups of 
drugs frequently used by 
toornen followed at the 
University Hospital 
Nijmegen, the Netherlands, 
in 1983 during high-risk 
pregnancy, according to the 
behavioural status of the 
child at the time of the 
questionnaire (1991) and 
Odds Ratios for the 
association between drug 
groups and aberrant 
behavioural score according 
to the original data and 
according to the 
questionnaire 
Sensitivity 
Behavioural score of the child normal high 
86 6 58 8 
50 5 40 0 
Psychopharmaceuticals 
Analgesics 
Local anaesthetics 
Folic acid 
Digestive tract medication 
Genital tract medication 
Antibiotics 
Vitamins 
32 7 15 0 
133 818 
62 5 54 5 
38 2 55 6 
314 14 3 
119 00 
Specificity 
normal high 
94 3 84 0 
94 5 81 2 
94 7 95 5 
619 48 4 
87 6 93 5 
85 4 79 2 
983 1000 
96 3 97 4 
Odds Rath» 
original collected 
data data 
09 1 5 
11 2 4' 
15 12 
16 2 0* 
10 10 
13 12 
10 0 4t 
0 9 0 4t 
'p<0 0S 
Г There was only one 'exposed' case according to the questionnaire 
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including specific questions on drug groups or questions about indications for use, only 
slightly improved the validity compared to the previous questionnaire without these 
specific questions In the previous study, the women used 3 1 drugs and reported 1 4 drugs 
per woman In the present study, the women used 3 3 drugs and reported 2 0 drugs 
Sensitivity had improved by 8 2 per cent (95% confidence limits 1 8 , 14 6 per cent) as 
compared to the previous study Specificity did not improve significantly (difference 5 2 
per cent, 95% confidence limits -2 7 ,13 1 per cent) The proportion of correctly recalled 
specific preparations was similar for both questionnaires The proportion of correctly 
recalled groups of drugs was higher for the adjusted questionnaire 
The results presented in this paper should be interpreted in the light of the quality 
of the underlying study Some remarks should be made on this subject 
1 The non-response rate was 45 per cent We were unable to obtain the present address of 
at least 15 per cent of the population However, there was no reason to assume that 
response was related to the recall of drug use, because the non-responders were 
comparable to the responders on most of the characteristics related to sensitivity We 
had no information on the level of maternal education of the non-responders 
2 The women to whom we sent the questionnaire had participated in a prospective study 
eight years previously Some of the women remembered that their drug use had been 
recorded We tried to prevent bias by presenting the questionnaire as a study on the 
relation between drug use during pregnancy and the behaviour of the child 
3 The women all delivered at the University Hospital Nijmegen As the Dutch obstetric 
health care system encourages women with uncomplicated pregnancies to deliver at 
home, the women in our study population were not representative with respect to 
pregnancy complications, associated drug use and events, such as caesarean section [24] 
These may have improved the recall 
From the characteristics studied, maternal education, birth weight, gestational age, 
5-min Apgar score, number of children and birth order of the child, were associated with 
the sensitivity Birth weight and gestational age were associated with frequent drug use 
during labour and the sensitivity for these drugs was high This effect was independent of 
maternal education The number of pregnancies was not associated with the sensitivity, 
whereas the number of children was Apparently, uncomplicated first pregnancies do not 
make any more impression than later ones, whereas the pregnancies from the first child 
after one or more spontaneous abortions, are better remembered 
Over-the-counter drugs had lower sensitivities than prescription drugs (table 4) 
Bryant and Feldman [12,14] reported similar results The women seemed to remember 
drug use better if it had been labeled as a drug by a prescription or if the reason for taking 
the drug was important enough to visit a doctor 
The tnmester-specific recall percentages were higher than those obtained m the 
previous study, but the accuracy of this questionnaire for identifying the users of spécifie 
drug groups in a particular trimester was only fair (table 5) 
Despite the findings m the previous study that an added time schedule did not 
improve the quality of the questionnaire data, we added such a schedule to the current 
questionnaire, but it had been slightly adjusted and included an extensive introduction 
Once again, most of the women had not filled in the time schedule, confirming the 
statement that it does not give any important additional information and can be aban-
doned m this type of study 
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The validity and accuracy of the questionnaire evaluated in the present study was 
better than that of the previous one. Statistically significantly better results were obtained 
from the extended questions. Although almost any type of drug use was covered by this 
questionnaire, its sensitivity for the use of specific groups of medication was only 
moderate. It may be concluded, therefore, that questionnaires cannot provide information 
with sufficient validity and precision about drug use during a pregnancy that occurred 
several years previously. Moreover, this study suggests that recall bias does occur despite 
the prevailing idea that it is just a text-book problem! Part of the questionnaire may prove 
useful in studies on specific drugs, such as general anaesthetics. For other medications, we 
recommend combining the questionnaire (if any) with other sources of information, such 
as medical records or records at pharmacies. 
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4.5 Evaluation of Standard developmental tests 
to be used in epidemiological follow-up studies 
Introduction Epidemiological studies on the functional teratogenicity of medical drugs can be 
earned out in various ways In a case-referent study, the outcome is usually some clinical 
disorder which was diagnosed beforehand If, on the other hand a cohort study is 
conducted, functional development must be measured by the investigator In this case, the 
investigator need not focus on the clinically evaluated functional disorders of the child 
after prenatal exposure, but can concentrate on the functional status of the child 
Functional development as such is not defined Without a clear definition of the outcome 
under study in the context of a research hypothesis, it is impossible to choose a correct 
measurement instrument The first thing to do, therefore, is to define the outcome to be 
studied The choice and definition of the outcome should be based on information from the 
results of previous research into humans and in animals Then the choice of a suitable way 
of estimating this outcome can be den ved 
When planning a study on the functional sequelae of prenatal exposure to 
medication during pregnancy one may be interested specifically in the development of the 
central nervous system without knowing which particular function may be important In 8S 
this situation, a battery of tests which measure a broad spectrum of the functional 
development of children has to be selected To be able to select the tests m an objective 
way, we formulated a list of entena which should be met by the tests if they are to be used 
Materials and On the basis of the following requirements, we selected ten tests for evaluation 
methods ι There had to be a Dutch version of the test and sufficient expenence with its use As a 
proxy, we required that the tests had been used frequently in the Netherlands 
2 The test had to have been developed for use on individuals Group tests were excluded 
3 As epidemiological cohort studies involve a general population, the test had to be 
suitable for use on a general population, and not only on children with brain function 
disorders 
Information about the tests was collected from the manuals of the vanous tests and 
from the NIP (Dutch Institute for Psychologists) [16] The literature about the tests was 
researched back to 1980, but little additional information was obtained Information was 
also collected in interviews with experts in the field 
The entena were formulated on the basis of our understanding of the 
requirements The list of entena is given below 
Content/Intention Does the test intend to measure what we are interested in7 
Validity Does the test measure what it intends to measure7 
Precision!Accuracy Is the random error in the test results suitably limited7 
Gender specificity Are there differences in the interpretation of test results obtained from 
boys and girls7 If so, the two sexes have to be dealt with separately 
Robustness Is the test sensitive to differences in testing circumstances7 
Age and geographic range For what age group is the test suitable7 
Price What is the pnce per participant for admirustenng and evaluating the test7 
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Qiialißcation of the administrators: Do you need schooled professionals to administer the test? 
Time: How long does it take to test a participant? 
Results 
Table 1. Evaluation often 
tests for neurodevelopment '. 
The tests we evaluated had various measurement intentions. The tests were: RAKIT 
(Revised Amsterdam Children's Intelligence Test), LOT (Leiden Diagnostic Test, Intelli-
gence), Kaufmann-лвс (Assessment Battery for Children, Intelligence), WPPSI (Wechsler 
Preschool and Primary Scale of Intelligence), DOS (Denver Developmental Screening Test, 
DDST), MOS (McCarthy Scales of Children's Abilities), τνκ (Language Test for Children) 
UTANT (Utrecht Language Level Test), LOS-KF (Lincoln Oseretsky Skala - Kurzer Form, 
Motor development) and CBCL (Child Behavior CheckList). Some of these tests were of 
Dutch origin, while a Dutch version had been developed for the others. Not all the tests had 
been studied for validity in the Netherlands. If a version of a test is available in a specific 
language this does not necessarily mean that the performance of the test at issue has been 
studied in the population with that language. Choosing a frequently used test in the 
appropriate language therefore does not imply that the test has been validated and that the 
results are interpretable. The results of the evaluation are given in the table. 
Intention 
Intelligence 
Language 
Motor development 
Behaviour 
Validity 
Accuracy 
Sex differences 
Robustness 
Age range (months) 
Price' purchase 
Test forms 
Administrator 
Proteuional 
Ыипе 
Teacher 
Parenti 
Duration 
References 
RAKIT 
short 
+ 
-
-
-
+ 
++ 
no 
+ 
50-134 
1100 
2.70 
+ 
-
-
-
45-60 mm 
2,3,17 
IDT 
+ 
-
-
-
+ 
+ 
no 
+ 
48-96 
365 
1.50 
+ 
-
-
-
50-75 mm 
14,17,20 
Kauf­
mann 
+ 
-
-
-
? 
? 
no 
± 
30-150 
1175 
4 
+ 
-
-
-
45 mm 
15 
WPPSI 
+ 
-
-
-
7 
? 
no 
+ 
48-78 
1075 
4 
+ 
-
-
-
50-75 mm 
1,17,18 
DOS 
+ 
+ 
+ 
+ 
-
+ 
no 
++ 
0.5-78 
165 
1.30 
-
+ 
-
-
5-20 mm 
6,7,17 
MOS 
+ 
+ 
+ 
+ 
•> 
? 
no 
± 
30-102 
68.75 
2.05 
+ 
-
-
-
45-60 min 
17 
τνκ 
-
+ 
-
-
++ 
++ 
no 
-
48-108 
675 
4.10 
+ 
-
+ 
-
9-15 min 
4,5,17 
UTANT 
-
+ 
-
-
+ 
+ 
no 
+ 
48-84 
729 
0 65 
+ 
-
+ 
-
25-40 min 
10,17,20 
LOS-KF 
-
-
+ 
-
? 
f 
no 
++ 
60-168 
95 
0 
+ 
+ 
-
-
30 mm 
19 
CBCL 
-
-
-
+ 
++ 
++ 
yes 
++ 
48-192 
0 
0.60 
-
-
-
+ 
20 mm 
16,17 
' *+ = Ixcellent, + = Good, ± = fair, 
- - Poor, ? = Not enough information for rating available 
' Pnce level 1992 in Dutch guilden 
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Discussion Many standardized tests are available to study neurodevelopmenlal issues in 
children Each of these tests has specific advantages and disadvantages The choice of the 
test (combination) to be used in an epidemiological study depends on the specific aim of 
the study, its design characteristics and the resources available To be able to make a 
rational choice, one needs a systematic overview of the pros and cons For this purpose we 
developed a list of entena These entena greatly facilitated the actual choice of a test 
battery in a specific explorative study on central nervous system development after m 
utero exposure to specific anti-hypertensive medication 
References 1 Berger H¡C, Creuwels LMP, Peters HFM Nederlandse handleiding bij het gebruik van 
Wechslers Intelligentieschaal voor kleuters, de WPPSI AMSTERDAM, SWETS к ZEULINCER, 
1973 
2 Bleichrodt N, Drenth PjD, Zaal ¡N, Resmg WCM Revisie Amsterdamse Kinder 
Intelligentie Test Instructie, normen, psychometrische gegevens LISSE, SWETS к 
ZEITUNGER, 19B4 
3 Bleichrodt Ν, Drenth P¡D, Zaal ¡Ν, Resmg WCM Handleiding bij de Revisie 
Amsterdamse Kinder Intelligentie Test LISSE, SWETS к ZEÍTLINGER, 1987 
4 Van Bon, WHI Taaltest voor kinderen Handleiding USSE, SWETS к ZEÍTLINGER, 1982 
5 Van Bon WH¡ Aspekten van taalvaardigheid Een onderzoek naar de validiteit van de 87 
Taaltest voor kinderen Proefschrift LISSE, SWETS & ZEÍTLINGER, 1984 
6 Coo/s ATM, Hermanns ¡MA Vroegtijdige onderkenning van problemen in de 
ontwikkeling van kinderen Constructie en toepassing van de DOS USSE, AMSTERDAM, 
SWETS & ZEITLINGER, 1977 
7 Cools ATM, Hermanns ¡MA Handleiding bij de DOS USSE, SWETS к ZEITUNGER, 1976 
8 Drenth PjD Inleiding in de testtheorie DEVENTER, VAN LOGHUM-SLATERIUS BV, 1975 
9 Duit M, Ceerlmgs С Motoriek van kleuters Scriptie NIIMEGEN, INSTITUUT SOCIALE 
GENEESKUNDE, 1984 
10 Kohnstamm CA, Sanavro F De Utrechtse Taalniveau Test voor 4-7 jarigen UTANT 
Handleiding USSE, SWETS к ZEÍTLINGER, 19B0 
11 Van Krogten AMHI Hersenorganiciteitstests USSE, SWETS & ZEÍTLINGER, 1979 
12 Oudenhoven D Problematiek van in hun ontwikkeling bedreigde kleuters Scriptie 
NIJMEGEN, VAKGROEP ORTHOPEDAGOGIEK, K U , 1986 
13 Scfiroots ЦТ, Van Alphen de Veer RJ Leidse Diagnostische Test (LDT) Deel 1 
Handleiding USSE, SWETS к ZEÍTLINGER 1976 
14 Schroots ЦТ Leidse Diagnostische Test (LDT) Deel 5 Cognitieve ontwikkeling, 
leervermogen en schoolprestaties USSE, SWETS к ZEÍTLINGER, 1979 
15 Testklapper NIIMEGEN, AFDELING PSYCHOLOGIE, к и NIIMEGEN, 1983 
16 Verhulst FC, Koot IM, Akkerhuis CW, Veerman ¡W Praktische handleiding voor de CBCL 
(Child Behavior Checklist) ASSEN, VAN GORCUM & COMP BV, 1990 
17 Visser RSH, Van Cliet-Mulder, \C, Evers A, Ter Laak \ Tests en testresearch -1982 N I P , 
1982 
18 Wechsler D Manual for the Wechsler Preschool and Primary Scale of Intelligence NEW 
YORK, THE PSYCHOLOGICAL CORPORATION, 1967 
19 Wiegersma PH Motonsche diagnostiek evaluatie van lichamelijke vaardigheden Ц 
kinderen LISSE, SWETS к ZEÍTLINGER, 1986 
20 De Zeeuw I Algemene psychodiagnostiek deel 1 USSE, SWETS к ZEÍTLINGER, 1981 
CHARTE* 4 WEIGHING THE RESEARCH OPTIONS IN EPIDEMIOLOGICAL STUDIES ON BEHAVIOURAL TERATOLOGY 
4.6 On the choice of a reference group in 
a pharmaco-epidemiological cohort study 
on behavioural teratology* 
PCM Pasker-de ¡ong, CA Zielhuis, ¡EMC Pellegrino 
Abstract Background In pharmaco-epidemiological studies the choice of a reference group is 
not self-evident Various reference groups have been suggested 
Question Which reference group should be included in a pharmaco-epidemiological study 
on the functional development of children prenatally exposed to labetalol7 
Methods In a historical cohort study on the functional effects of prenatal exposure to 
labetalol three reference groups were included children exposed to another antihyper-
tensive drug (methyldopa), children exposed to hypertension but not labetalol or methyl-
dopa Cbed rest'), and children exposed neither to hypertension nor to antihypertensive 
medication ('norm') 
Results The methyldopa group was most comparable to the labetalol group in terms of 
population and information The information was comparable for all four groups, the 
populations of the bed rest and norm groups differed from the labetalol group especially in 
respect to the seventy of the disease, while the exposure protocol was dissimilar for all 
groups 
Conclusion In studies on behavioural teratogenicity of medical drugs, the group of children 
prenatally exposed to the medication under study is best contrasted with a group of 
children exposed to another medication as these groups show the best comparability with 
respect to underlying disease, population characteristics and pregnancy complications As 
treatment protocols differed not only in the specific chemical used but also in other 
aspects, the exposure contrast still is not unidimensional 
Introduction The choice of a reference group in epidemiological research on side-effects of 
medication has been, and still is, the subject of some confusion As in all epidemiological 
studies, bias in pharmaco-epidemiological studies is prevented by comparability of 
information, comparability of populations, and comparability of exposure [1, pp 30-31] 
The first two have been recogni7ed widely No confusión has ansen from them For the 
third, some authors suggest that exposure should be contrasted with a situation of absence 
of all exposures [eg 2, ρ 59] Miettinen, however, showed on theoretical grounds that 
exposure should be contrasted to comparable non-exposure (1 e placebo-exposure), in 
which the distributions of factors associated with exposure are similar over the groups 
[3,4] In pharmaco-epidemiological research this difference in choice is particularly 
relevant as the reason for exposure (the indication) may in itself be a determinant of the 
outcome Exposure and population characteristics are closely related Two options for the 
choice of a reference group exist a reference group consisting of subjects with the disease, 
but not exposed to any drug for the indication, and a reference group consisting of subjects 
who have the disease and are treated for it with another type of medication Carson, 
Strohm and Maishn state that if diseased persons without exposure are chosen to be the 
reference, it is the association of the drug with the outcome that is studied, if, on the other 
* Submitted for риЫкаНол 
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hand, diseased persons with exposure to another drug for the same indication are taken as 
the reference, one studies whether the drug is associated with the outcome more strongly 
than a similar drug for the same indication І5,р 295]. Logically, both are partially correct: 
So long as the non-exposed and the exposed are equally diseased or the severity of the 
disease is unrelated to the outcome, a non-treated reference group may be chosen. On the 
other hand, so long as the treatment chosen as referent is unrelated to the outcome under 
study, it is a placebo treatment with respect to the association between the exposure and 
outcome under study and the effect measured is unbiased by an effect of the placebo. 
With a primary interest in the functional development of children prenatally 
exposed to labetalol because of maternal pregnancy hypertension we conducted a 
historical cohort study. Both reference groups were equally (un)acceptable: Women treated 
with bed rest only for their pregnancy hypertension are likely to be less severely diseased 
than those who are being treated medically. On the other hand, the effects of other 
pharmaceuticals used for treatment of pregnancy hypertension on the functional 
development of the child at school age are not well known. We therefore included both 
reference groups, together with a 'norm' group, to evaluate the effects of prenatal exposure 
to labetalol and of pregnancy hypertension on the functional development of the child. 
In the period between 1983 and 1987, the situation with respect to PIH and PAH 
treatment in the Netherlands had many characteristics of a natural experiment. Dutch 
gynaecologists switched from methyldopa as treatment of first choice to labetalol because 
methyldopa (a centrally active antihypertensive drug) had several side-effects to the 
mother that were absent with labetalol (a combined alpha and beta-blocking agent). It took 
some four years before the majority of gynaecologists had switched from methyldopa to 
labetalol. Whether a hypertensive pregnant woman received treatment with methyldopa 
or with labetalol in this period depended on the attending gynaecologist. 
Methyldopa has a working mechanism that differs from the mode of action of 
labetalol. Furthermore, methyldopa is generally regarded as a safe drug for the fetus. 
Functional development was similar at four year follow-up of children born in a large 
clinical trial on the effectiveness of methyldopa versus no anti-hypertensive treatment [6]. 
Materials and The departments of Obstetrics and Gynaecology of twelve hospitals in the Nether-
methods lands participated in the study. The hospital records of all women whose diastolic tension 
had exceeded 90 mmHg at least once during pregnancy and who delivered in one of these 
hospitals between 1-1-1983 and 31-12-1987 were reviewed for the study (и = 4000). They 
were selected via the hospital registry or via the files of the Dutch Obstetrics Registry. All 
women treated with methyldopa (Aldomet ®) or labetalol (Trandate ®) for PIH or PAH were 
included in the study together with a sample, matched on delivery date, of the women 
treated with clinical bed rest because of hypertension. Finally, a group of women without a 
medical indication for hospital delivery was selected from the hospital files, matched on 
delivery date as well. Only women aged between 20 and 35 years, with singleton preg­
nancies who delivered from a livebom child after at least 32 weeks gestation and who had 
not suffered from diabetes or epilepsy in this pregnancy were eligible. Finally, 540 mother-
child pairs were selected for inclusion in the study: 99 labetalol, 102 methyldopa, 154 Bed 
Rest, and 184 pregnancies without a medical indication for obstetric supervision (Norm). 
1 
C H A T T E ! 4 j WEIGHING THE RESEARCH OPTIONS IN EPIDEMIOLOGICAL STUDIES ON BEHAVIOURAL TERATOLOGY 
The 540 women were sent a letter from the department where they had delivered, 
with a request to participate in the study. One reminder was sent to all non-responders and 
addresses were traced (if possible) when a letter was returned as being undeliverable. 
Women who agreed to participate were contacted by telephone to make an 
appointment. All children whose parents agreed to participate were tested at the children's 
home address by one of six trained child-psychologic test-assistants. The following devel-
opmental aspects were assessed: 
The child's Concentration (Bourdon-Vos [71), IQ (Shortened RAKIT [8]), Memory (visual 
memory: subtest of RAKIT [8], verbal memory: ten-words-test [9], associative memory: 
verbal word pair associations [9]), Gross motor development (subtest of Hamm Marburger 
Körper Koordinationstest für Kinder [10]), Fine motor development (prick-test [9]), and 
Language development (Mommers one-minute test [11]). 
In addition, the parents were asked to fill in a questionnaire about the pregnancy 
and the early development of the child, as well as about the behaviour of the child (CBCL). 
The teacher of the child also filled in a questionnaire on behaviour (TRF). 
Analyses comparing the outcome in the Iabetalol group with each of the reference 
groups were carried out with t-tests or χ2. The assessment of confounding and the 
correction for it were done with linear or logistic regression analysis as appropriate. 
Results Some information about the responders and non-responders is given in table 1. 
More 'norm' and bed rest mothers refused to participate. The participation rate was similar 
for Iabetalol and methyldopa mothers. For the four groups of participants in the study, 
comparability on the three points was evaluated. 
Comparability of information 
All medical records were reviewed twice: first to identify potential participants 
and later, by another person, to collect information on the pregnancy, hypertension and 
treatment, and the delivery. Both times the reviewers were blinded as to the outcome 
status of the children. Similarly, the psychological testers were blinded as to the exposure 
status of the child at the time of testing. There seems to be no possibility for systematical 
differences between groups in measurement error of the outcome parameters. 
Participants 
295 
2908 (53) 
38.2 (0.2) 
27.7 (0.2) 
60.2 
60.4 
53.6 
50.0 
6.7(0.1) 
Refuten 
119 
3093(85) 
39.0 (0.2) 
26.9 (0.4) 
18.4 
15.8 
24.8 
25.3 
6.9(0.1) 
Non-responders 
124 
3142(77) 
38.6 (0.2) 
26.1 (0.4) 
21.4 
23.8 
21.6 
24.7 
7.1 (0.1) 
Table 1 Characteristics of 
participants, non-particip­
ants and nmi-responders. 
Mean and (standard error). 
Number 
Birth Weight 
Gestational age 
Maternal age 
Group: 
Iabetalol (n = 98) 
methyldopa (n = 101) 
Bed reu (n = 153) 
Norm (n = 186) 
Age of the child on Jan. 1,1993 
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Labetalol Methyldopa Bedrest Norm 
Table 2 Characteristics 
of the four populations m 
the study. 
Number of participants 
Paternal age (yrs) 
Paternal education (%) 
tow 
intermedióte 
high 
Maternal age (yrs) 
Primiparae (%) 
Maternal Education (%) 
low 
intermediate 
high 
Gestational age (wks) 
Birth weight (g) 
Apgar score < 9 at S min (%) 
%PIH 
%PAH 
Delivery complications (%) 
Proteinuria present (%) 
Maximal diastolic tension (mmHg) 
measured in week 
59 
30.4 (0.5) 
25 4 (5.7) 
45 8 (6 5) 
28.8 (5.9) 
28.1 (0.5) 
69.0(6.1) 
39 0 (6.3) 
39.0 (6 3) 
22.0 (5.4) 
37.3 (0.5) 
2589(136) 
25.9 (7.8) 
55.9 (6.5) 
40.7 (6.4) 
58.9 (6.6) 
66.7(9 6) 
113 (1.8) 
28 4(1.3) 
61 
29.9 (0.4) 
29.5 (5.8) 
37.7 (6.2) 
32.8 (6.0) 
27.7 (0 4) 
57.4 (6.3) 
31.1(5 9) 
50.8 (6.4) 
18.0(5.1) 
36.4 (0.6) 
2710(121) 
5.4 (3.7) 
55.7 (6.4) 
41.0(6.3) 
56.7(6.4) 
46 2(13.8) 
105(1.5) 
29.1 (1.3) 
82 
304(0 6) 
39.0 (5.4) 
31.7(5.1) 
29.3 (5.0) 
27.5 (0.4) 
76.3 (4.8) 
45.1 (5.5) 
36.6 (5.3) 
18.3(4.3) 
38.3 (0.3) 
2775 (96) 
2 0(002) 
85.4 (3.9) 
13.4(3 8) 
53 8 (5.6) 
42.9 (8.4) 
104(0.8) 
35.5 (0.4) 
93 
30.2 (0.4) 
29.0(4.7) 
40.9 (5 1) 
30.1 (4.8) 
27.8 (0.4) 
53 3 (5.2) 
34.4 (4.9) 
50.5 (5.2) 
15.1 (3.7) 
39.6 (0.3) 
3367 (63) 
1.9(0 02) 
1.1(0 01) 
1 1(0 01) 
50 5 (5 2) 
18.2(8.2) 
78(1.0) 
34.0(1.2) 
Comparability of populations 
Table 2 gives an overview of some characteristics of the women participating in the 
study. The two medically treated populations were most alike with respect to the distri-
bution of most potential confounders. Only the severity of disease was different between 
the labetalol group and the other groups. The labetalol group seemed to include the most 
severe cases of pregnancy hypertension. The bed rest group differed much more from the 
labetalol group than the methyldopa group, with hardly any overlap in the distribution of 
the gestational ages at first admission because of hypertension. Birth weight was lowest in 
the labetalol group as previously reported in the literature. More children were small for 
their gestational age in this group than in any of the other groups. The paternal factors 
were similarly distributed. 
Comparability of exposure 
Some information on the different treatment regimes is given in table 3. The week 
of starting with the treatment varied strongly over the groups. The methyldopa group was 
treated earlier than the labetalol group. A breakdown by the year of treatment showed that 
obstetricians tended to start treatment with labetalol earlier in more recent years. The bed 
rest alone group was treated much later than either of the medically treated groups. The 
blood pressures in the methyldopa group remained at a lower level, presumably due to 
earlier start of treatment. In addition, more women received another antihypertensive 
treatment concomitant with methyldopa mostly because of deteriorating hypertension. 
91 
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i 
Labetalol Methyldopa Bed rest Nomi 
Table 3 Characteristics of 
the treatments m the four 
groups ofimmen in the 
study. 
Start treatment in gestational week 
Other treatments for PIH/PAH (%) 
bed rest 
magnesium sulfate 
benzodiazepines 
26.1 (1.4) 
49.2 
1.9 
10.2 
20.1 (1.6) 
50.8 
1.6 
82 
34.0 (0.5) 
100.0 
0.0 
6.1 
-
1.1 
0.0 
0.0 
92 
The outcomes for the four groups are presented in table 4. The iQ-score was similar 
for all groups. The concentration score, however, varied over the groups. No statistically 
significant difference in concentration scores was found when the bed rest group was 
taken as reference (^=0.51) whereas there was an indication for an effect when the methyl-
dopa group was taken as the reference (p=o.ocj). The conclusions would thus vary accord-
ing to the reference group. The labetalol group included statistically significantly more 
children with an attention deficit disorder-like syndrome, according to information from 
their teacher, than any of the other groups included in this study. Finally, prenatal expos-
ure to labetalol would seem to prevent sleeping disorders in the child if methyldopa was 
chosen as the reference group. 
Discussion This study suggests that the choice of a reference group in pharmaco-epidemio-
logical studies may seem to be simple in theory but by no means straightforward in 
practice. The basic requirements for the use of either of the options as reference group are 
not always met. 
In the present study on long-term developmental side-effects of prenatal exposure 
to labetalol, both the non-exposed reference group (the bed rest group) and the compar-
ably non-exposed reference group (the methyldopa group) had some drawbacks. The bed 
rest population was not comparable to the labetalol group in several aspects: the women 
Table 4 Developmental 
outcome measures, corrected 
for age at testing if 
necessary. 
Concentration score* 
IQ score (RAKIT) 
Cross motor score 
Fine motor score 
Memory task 
visual* 
associative* 
auditive* 
Sleep well (%) 
Attention Deficit (%) 
Language score 
* Normalised, mean = 
- -
100, sd 
Labetalol 
110.3(3.9) 
106.6(2.1) 
18.0(0.7) 
50.8(1.5) 
17.1 (0.7) 
12.0(0.4) 
5.0 (0.3) 
96.6 (2.4) 
17.0(4.9) 
59.8 (4.8) 
= 15. High scores 
* High score indicates better memory 
Methyldopa 
103.2(2.5) 
107.3(2.1) 
17.0 (0.7) 
53.1(1.4) 
16.6(0.6) 
12.3(0.4) 
5.3 (0.3) 
89.7 (4.0) 
8.2(3.5) 
59.5 (2.6) 
Bed rest 
107.6(1.9) 
106.4(1.6) 
18.6(0.5) 
52.0(1.2) 
16.2(0.6) 
12.1 (0.3) 
5.6 (0.2) 
97.5(1.8) 
4.9 (2.4) 
60.4 (2.9) 
indicate low concentration 
Norm 
100.2(2.1) 
107.1 (1.5) 
18.5(0.5) 
54.8(1.1) 
15.2(0.5) 
12.4(0.3) 
5.5 (0.2) 
97.8(1.6) 
9.7(3.1) 
63.3 (2.4) 
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were more often primiparae, had more often pregnancy induced hypertension as opposed 
to pregnancy aggravated hypertension, and had lower educational levels. Their illness was 
of later onset and of less severity, while treatment started much later than in the labetalol 
group. The methyldopa population was better comparable to the labetalol population as 
regards the various population characteristics. On the other hand, treatment with labetalol 
was different from treatment with methyldopa in more aspects than only the chemical 
used. Treatment was started earlier in the methyldopa group, and more additional 
treatments were used in this group. Thus, the exposure contrast included factors other 
than the chemical given. Furthermore, methyldopa seemed to influence sleep in the 
exposed children (in accordance with a case report [12]). Methyldopa therefore may not 
have been a placebo for all aspects of development addressed in this study. 
Apart from the comparability of information, of populations and of exposure of the 
responders, there is the possibility of differential non-response. In this study, only about 
65% of the potential participants that were contacted were actually included in the study. 
Thus there was ample opportunity for differential respons. Differential response according 
to outcome is probable. We know of at least one mentally retarded subject who was not 
included in the study because he was unable to complete the tests. There does not seem to 
be a reason for believing that more of this non-response occurred in one group than in 
another. 
Table 1 showed that 'norm' mothers were the least likely to participate in the study. 93 
It seems unlikely that these mothers participated only if their children were better or worse 
than children of mothers in the other groups. In conclusion, for valid pharmaco-
epidemiological research more emphasis should be put in the design to comparability of 
effects in addition to comparability of populations and information. Without such 
comparability the results of studies are difficult to interpret. 
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4.7 Comments on chapter IV 
The studies described in this chapter add empirical support to the opinion that a 
case-referent approach is cumbersome if the effects of prenatal exposure to medical drugs 
are evaluated with respect to their side-effects on children's CNS development Our results 
indicate that it is difficult to retrieve information on the use of medical drugs several years 
after a pregnancy has been completed As the information about a specific woman's drug 
use during pregnancy obtained from pharmacists and GPS did not match, these sources of 
information do not substantiate the information provided by the woman herself, because it 
is not clear which source is the best and how to combine the information from the various 
sources Our questionnaire on drug use during pregnancy produced imprecise and biased 
results, which indicates that there is a large degree of measurement error if any of these 
sources of information on medical drug use during pregnancy are employed several years 
afterwards Only computerized pharmacies and highly educated women seemed to recall 
the use of specific medical drugs during pregnancy with reasonable accuracy For some 
medical drugs, exposure may be retrievable several years after a pregnancy 
The error in the measurement of the use of medical drugs may be so large that real 
effects are obscured and empirical evidence for differential recall is present This sheds 
serious doubt on the suitability of the case-referent design for studies on behavioural 
teratology 95 
With respect to cohort studies, it has been recognized that the selection of tests to 
obtain outcome measurements is not straightforward There is no consensus about which 
functions are important, or about the way these outcomes should be measured A set of 
criteria facilitated a well-founded choice of appropriate tests We show that the theoretical 
differences between different reference groups are relevant in practice because the results 
of specific studies and the conclusions drawn from them depend on the reference group 
chosen The more practical drawbacks connected to the cohort design, such as loss to 
follow-up, can only be evaluated in specific studies 
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5.1 Medical drug use during pregnancy and 
behavioural characteristics of the children at 
the age of eight years* 
PCM Pasker-de ¡ong, CA Zielhuis, TKAB Eskes, FJM Cabreéis, WS Ni/dam 
Abstract Objective To study a possible association of medication during pregnancy with 
behavioural characteristics in the child 
Methods Medical drug use during pregnancy was studied m a hospital cohort of 978 
women who had a singleton pregnancy in Nijmegen, the Netherlands, in 1983 In 1991-92, 
the participants with hve-born children were sent a standardised checklist on child 
behaviour 
Results In the analyses, 531 responses could be used In boys, prenatal exposure to 
analgesics was associated with internalizing syndromes (schizoid, depressed and 
uncommunicative), while in girls, prenatal exposure to analgesics was related to the 
(externalizing) aggressive syndrome Furthermore, exposure to hormones was related to 
depressed behaviour in girls No other prenatal drug exposure was associated with 
behaviour 
Conclusions Prenatal exposure to hormones may influence the behaviour of the female 
offspring Exposure to analgesics during pregnancy seems to be associated with 
behavioural characteristics in both boys and girls, although the type of behaviour differed 
between sexes More research is necessary on the nature of these associations and the exact 
prepara hons involved to be able to identify which analgesics and hormones might better 
not be used during pregnancy 
Introduction The use of medication during pregnancy occurs much more frequently than 
medical handbooks advise For instance, some 80 per cent of pregnant women at low nsk 
for pregnancy complications used at least one drug in the Netherlands m 1984 [1] Even if 
iron and vitamins were excluded, 50% of pregnant women were still exposed to 
medication, mostly analgesics, antacids, antibiotics and dermatological preparations [1] 
For high-risk pregnancies, these figures are even higher The effects of the use of most 
medication during pregnancy on the fetus are only partly known Morphological effects 
are being studied with reasonable vigour, especially in laboratory animals Functional 
effects, however, are hardly ever studied in humans, while the results of animal 
experiments are not easily extrapolated to human functions 
Behavioural disorders are probably the most frequent functional problems in 
children In 1986, Verhuist reported a prevalence of 7% for severe behavioural problems 
and of 25% for moderate and severe problems combined, as measured with the Child 
Behavior CheckList in a survey among Dutch children of 8 and 11 years old [2] In 
Blackburn, England, prevalences of psychological disorders were measured in boys and 
girls aged 13 or 14 years It was found that 20 8% of the boys showed moderate or severe 
behavioural disorders (neurotic, conduct or psychotic disorders), while 13 6% of the girls 
had moderate or severe disturbances [3] Rutter et al conducted a survey of the prevalence 
* Submitted for publication 
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of psychological disorders in 10-year-old children in two geographical areas (an inner 
London borough (ILB) and an Isle of Wight (row) sample) through an interview with the 
parents. He reported that 12% of the children in the iow sample and 25.4% of the children 
in the ILB sample had psychiatric behavioural disorders, mostly emotional or conduct 
disorders [4]. Achenbach reported that the prevalence of behavioural disorders was 
highest in children with low socio-economic status (SES) and lowest in children with high 
SES [5]. 
It has been shown before that medication during pregnancy may have an impact 
on the development of behaviour in the child. Cohen [61 observed irritability and 
restlessness in infants born to mothers who were taking anti-psychotics during pregnancy. 
Several other drugs which are suspected of having an adverse effect on behavioural 
development, are sex hormones [7], antihypertensives 18], Phenytoin [9,10], and Pheno-
thiazine [11]. In animal experiments, effects were also found after exposure to Diazepam 
[12] and barbiturates [13]. As several drugs affect brain function, it may be justified to 
expect effects purely on the basis of their pharmacological properties [14]. 
This paper describes the results of a study on medical drug use during high-risk 
pregnancy and delivery and the subsequent behaviour of the children at the age of 7 and 
8 years. This is, to our knowledge, the first study in which the effects of a wide variety of 
medical drugs are evaluated in a group of children selected in a consistent way. 
Population and In 1983, a study was conducted on drug use during pregnancy in a population of 
methods 1000 women who registered consecutively for prenatal care at the department of Obstetrics 
and Gynaecology of the University Hospital Nijmegen, the Netherlands [15]. Drug use 
from the last menstrual period to and including delivery was covered. At each prenatal 
visit, information was collected on the drugs used in the intermediate period. The women 
were requested to write down the medication they had used in the periods between the 
visits which occurred between weekly and once a month. After delivery, the record was 
completed and adjusted by means of a thorough but structured interview which covered 
the whole pregnancy and delivery. If there was any doubt about the type of drugs, 
prescriptions (if any) were requested from the pharmacy. 
A questionnaire on child behaviour (CBCI. ([i6]) was mailed to the 978 women with 
a singleton pregnancy and live birth seven to eight years after delivery. The CBCL was 
developed by Achenbach for use in the USA. It was translated into Dutch and validated for 
the Netherlands by Verhuist [17]. The CBCL is designed to describe the behavioural 
problems and competencies of children aged 4 to 16 years. The questionnaire is to be filled 
in by the parents and consists of two parts. The first part assesses social competence. The 
second part, which consists of some 120 questions on certain forms of behaviour, detects 
signals about behavioural problems in general as well as specific behavioural syndromes. 
These syndromes can be categorised into externalizing and internalizing problems. Extern-
alizing problems reflect antisocial, aggressive, undercontrolled behaviour. Internalizing 
problems reflect fearful, inhibited overcontrolled behaviour. The behavioural syndromes 
vary by gender. All behaviours scored by the parents are added up to calculate a total 
behavioural problem score. A very high score on the CBCL does not necessarily have any 
clinical implications [17]. However, low scores did not occur in children referred for 
further clinical tests. The CBCL actually reflects the ideas of the parents about the behaviour 
Table!. Comparison 
of responden and non-
responders, means and 
(standard deviations). 
Maternal age in years 
Gravidity 
Gestational age in weeks 
Birth weight in grams 
Mean number of drugs used 
Apgar at 5 min >8 % 
Primary indication for hospital delivery 
Secondary indication for hospital delivery 
No medical indication for hospital delivery 
Responden 
n=SÎ1 
28.3 (4.4) 
2.1(1.2) 
39.5 (2.3) 
3288 (677) 
3.2(2.8) 
94.0 (0.2) 
67.0 (2.5) 
24.9(3.8) 
8.1 (4.2) 
Nonresponders 
n=447 
27.8 (4.9) 
2.0(1.3) 
38.5 (3.8) 
3048(839) 
3.2(2.7) 
87.5 (0.4) 
64.9 (2.8) 
26.0(4.1) 
9.2(4.5) 
Ρ value 
difference 
0.08 
0.48 
<0.01 
<0.01 
0.90 
<0.01 
>0.05 
>0.05 
>0.05 
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and competencies of their child. In this study, only the behaviour part of the Dutch version 
of the questionnaire was used. 
All the mothers in the original cohort were sent a CBCL and a questionnaire for 
retrospective assessment of drug use (the results of the validation study on this 
questionnaire were presented earlier [t8]). The covering letter stated that we were 
studying the associations between medical drug use during pregnancy and the functional 
development of the child. 
Possible confounding factors were covered for half the study population. 
Questions were included about the educational level of the parents, alcohol use during 
pregnancy, smoking during pregnancy and diseases in the child which could possibly 
account for behavioural problems. For all the women, information about pregnancy-
related potential confounders (length of gestation, birth weight, complications during 
pregnancy or delivery, maternal age) was collected from the medical records. 
In the analyses, we used the mean standard scores for behaviour to assess any 
differences in outcome among children exposed and non-exposed to a chemical from a 
drug group. The association between the drug groups that were associated with the total 
behavioural problem score, and specific behavioural syndromes occurring in at least ten 
children, were studied in more detail. 
Results The CBCL was sent to 978 women. At least 15% of them had moved to an unknown 
address. A total of 531 responses (54% of the original population) could be used in the 
analyses. Some characteristics of the responders and nonresponders are given in table 1. 
Responders and nonresponders were similar with regard to the number and type of drugs 
used. Among the responders, there was a higher proportion of children with high Apgar 
scores, higher birth-weight and longer pregnancies. 
The mean overall scores on the behavioural problem scale for exposed and non-
exposed children are given in figures 1 (boys) and 2 (girls) for some selected groups of 
drugs. Prenatal exposure to psychopharmaceuticals was associated with the total 
behavioural problem score in both boys and girls. Boys who had been exposed to 
analgesics (mostly acetyl salicylic acid (ASA) and paracetamol) during pregnancy had 
higher behavioural problem scores than boys who had not been exposed to these drugs 
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Figure h Mean total 
behavioural problem scores 
m boys prenataUy ''-TP°¡icl' 
or unexposed to certain 
groups of drugs. 
Figure 2. Mean total 
behavioural problem scores 
m girls prenatally exposed 
or unexposed to certain 
groups of drugs. 
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during pregnancy. Girls who had been exposed to other psychopharmaceuticals (mostly 
general anaesthetics and sleeping pills) had higher behavioural problem scores than 
unexposed girls. Furthermore, genital tract drugs (oxytocics and tocolytics) were 
associated with the total score in boys and hormones (mostly corticosteroids, insulin and 
oestrogens) with the total score in girls. The mean total scores of girls exposed to medical 
drugs were higher (although not always significantly) than those of non-exposed girls for 
all groups of drugs studied. 
The effects of the pregnancy-related potential confounders on the association 
between drug groups and total behavioural problem score were evaluated with linear 
CASE STUDY 1 
702 
Psychopharmaceuticals 
No psychopharmaceuticals 
analgesics 
no analgesics 
other psychopharmaceuticals 
no other psychopharmaceuticals 
Hormones 
No hormones 
Genital tract medication 
No genital tract medication 
'p<0.05 
Table 2. Comparison of 
exposed and non-cxposcd to 
some drug groups for birth 
weight, Apgar score and 
duration of pregnancy 
(mean and sd). 
Gestational 
boys 
38.8(3.1) 
39.5 (1.9)* 
38.6 (3.2) 
38.9 (3.4) 
38.5 (3.4) 
39.5 (2.0)* 
38.1 (3.2) 
38.9 (3.4) 
38.3(3.5) 
39.1 (3.2)* 
age 
girls 
39.5 (2.5) 
40.0 (1.7) 
39.1 (3.2) 
39.4 (2.9) 
39.0 (2.8) 
40.1 (1.7)* 
37.6 (3.5) 
39.5 (2.8)* 
38.8 (3.5) 
39.7 (2.5)* 
Birth weight 
boys 
3199(865) 
3430(573)* 
3157(806) 
3245 (798) 
3142(956) 
3409 (585)* 
3008 (882) 
3246 (790) 
3065 (850) 
3327 (750)* 
girls 
3108(723) 
3330 (54B)* 
3131 (742) 
3127(719) 
2975 (794) 
3335 (536)* 
2762(913) 
3171 (686)* 
3014(784) 
3206 (669)* 
Apgars 
boys 
79.9 
94.9* 
85.4 
89.9 
73.6 
94.2' 
87.2 
89.1 
85.1 
91.3* 
8 % 
glris 
89.9 
94.9 
94.8 
92.4 
87.2 
94.7* 
80.0 
94.3* 
91.2 
94.1' 
regression analysis. Some of these potential confounders are presented in table 2 in relation 
to exposure to the drugs that were associated with the total score. After correction for birth 
weight, Apgar score and duration of pregnancy, the association between genital tract 
drugs and the behavioural problem score disappeared. This association was therefore not 
studied in more detail. None of the other crude associations changed materially when 
corrected for confounding. In the subset of 258 women for whom information about other 
potential confounders was available, we calculated the crude and adjusted associations 
between drugs and total behavioural problem scores. None of the potential confounders 
from this subset substantially changed the estimates after inclusion in the analyses. 
Groups of drugs that were associated with the total score were studied with 
respect to specific behavioural syndromes. The results are listed in tables 3 (boys) and 4 
(girls). The main findings in boys were an association between psychopharmaceuticals 
(especially analgesics) and schizoid, depressed and uncommunicative behaviour (intern-
alizing syndromes). In girls, prenatal exposure to analgesics (mostly ASA and paracetamol) 
seemed to be related to aggressive behaviour and exposure to hormones (corticosteroids, 
insulin and oestrogens) was related to depressed behaviour. There was no association 
between 'other psychopharmaceuticals' and any behavioural syndrome in the girls, while 
there was a clear association with the total score. 
Discussion This study explored associations between exposure to medication during 
pregnancy and behaviour of children. It revealed an association between prenatal 
exposure to analgesics and behaviour of boys and girls. Moreover, exposure to hormones 
during pregnancy was associated with behaviour in girls. Correction for potential 
confounders did not alter these associations substantially. The association between genital 
tract drugs and the behaviour of the child appeared to be due to the effect of premature 
birth. 
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Table 3. Crude Relative 
Risks (95% Cl) for specific 
behavioural syndromes 
(with more than 10 cases 
present) associated with 
prenatal exposure to 
psychopliarmaceuttcals in 
boys (n-V2). 
Table 4. Crude Relative 
Risks (95% CD for specific 
bclinvioural syndromes 
(with more than 10 cases 
present) associated with 
prenatal exposure to 
psychopliarmaceuticals and 
hormones in girls (n=259). 
Behavioural 
syndromes 
Schizoid 
Depressed 
Uncommunicative 
Obsessive 
Social withdrawal 
Hyperactive 
Aggressive 
behavioural 
syndromes 
Depressed 
Social withdrawal 
Hyperactive 
Aggressive 
22 
10 
19 
14 
17 
14 
15 
14 
15 
13 
10 
Psychopharmaceutlcals 
all 
159 
2.0 
(0.9-4 6) 
3.3 
(0.9-12.5) 
1.3 
(0.5-3 0) 
0.8 
(0.3-2.3) 
1.3 
(0.5-3.1) 
0.8 
(0.3-2.3) 
1.6 
(0.6-4.3) 
analgesics 
58 
2.6 
(1.1-5.7) 
3.7 
(1.1-12.3) 
2.2 
(0.9-5.2) 
1.5 
(0.5-4.5) 
1.5 
(0.6-4 2) 
2.1 
(0.7-5.9) 
1.3 
(0.4-4.1) 
Psychopharmaceutkals 
all 
105 
1.1 
(0.4-3.1) 
17 
(0.6-4.5) 
1.7 
(0.6-5.0) 
34 
(0.9-13.0) 
analgesics 
60 
0.9 
(0.3-3.1) 
1.7 
(0.6-4.7) 
1.0 
(0.3-3.5) 
3.3 
(1.0-11.1) 
other 
76 
1.5 
(0.6-3.4) 
1.1 
(0 3-4 2) 
09 
(0.3-2.5) 
1.0 
(0.3-3.2) 
0.8 
(0.3-2.4) 
0.7 
(0.2-2.5) 
1.7 
(0.6-4.7) 
other 
68 
1.1 
(0 4-3.5) 
1.0 
(0.3-3.1) 
1 8 
(0.6-5.2) 
1.9 
(0.5-6.5) 
Hormones 
12 
3.9 
(1.4-11.0) 
0.5 
(0.1-3.7) 
1.3 
(0.3-5.6) 
0.8 
(0.1-6.0) 
103 
Several critical remarks can be made about the study regarding the possibility of bias. 
Response was only moderate, but there was no evidence that there was a higher 
response among users of drugs than among nonusers, or that the mothers of children with 
behavioural problems were over-represented. As the mean number of drugs used and the 
type of drugs were very similar for the responders and nonresponders, it does not seem 
likely that selection bias occurred. 
In this study, the information about drug use was recorded prospectively, without 
any knowledge of the outcome of pregnancy. Therefore, information bias on exposure can-
not have occurred. Information bias on outcome information is not likely either because the 
study was presented as a study on 'medical drug use and functional development7. No drug 
was specifically named and no expectations given as to the type of disturbances to be expected. 
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We did not have information on all the women for all the confounders, but only 
the pregnancy-related confounders birth weight, length of gestation and Apgar score were 
found to be of importance. However, correction for these confounding variables did not 
materially change the estimated association between analgesics and behaviour or between 
hormones and behaviour in girls. Parental attitudes and upbringing were not assessed, 
although these are likely to be related to the behaviour of the child, and might be related to 
the (type of) drug use during pregnancy. Confounding bias because of these co-variates 
therefore cannot be excluded. 
Finally, it should be stressed that in this type of non-experimental study, it is 
hardly possible to separate the effects of the drugs used from the effects of the diseases for 
which the drugs were used. Moreover, combinations of medication which were common 
in this population, confuse the interpretation to a certain extent. Analyses of the effect of 
exposure to aspirin versus exposure to paracetamol was not possible because most women 
had used both drugs. 
Despite these critical remarks, it does not seem likely that our findings can be 
explained by artifacts. The associations between analgesics and hormones and behavioural 
characteristics of the child seem genuine. 
In the literature, the use of aspirin has been related to decrements in intelligence 
Í04 and attention [19]. Klebanoff could not repeat those findings [20]. Effects on behaviour of 
exposed offspring have not been reported before. No conclusive human studies have been 
published to our knowledge to give a priori credibility to the association between prenatal 
exposure to analgesics and specific behavioural characteristics. However, animal experi-
ments have related exposure to salicylates with behavioural disturbances and learning 
impairment in rat offspring [21,22], especially when iron was given as well [23I. All the 
women in the present study had been given iron supplements during pregnancy. A 
chelation mechanism was suggested for the teratogenicity of salicylates [23]. However, sali-
cylates may also affect the blood flow through the fetal brain. The proportion of cardiac out-
put distributed to the brain decreased after salicylate exposure in the fetus of the sheep [24]. 
Hormones have been connected with behavioural disturbances. Especially the sex 
hormones have been found to influence sexual behaviour in the offspring [7]. Most 
hormones in this study were corticosteroids and insulin. Administration of dexamethasone 
to rats depleted the number of receptors in the hippocampus and cerebellum, and 
influenced motor co-ordination and behaviour [25,26]. 
Although the clinical importance of the functional changes in behaviour of 
children is not yet fully understood, the results of this study do confirm that the intake of 
specific medications during pregnancy may have an effect on the function of the central 
nervous system. Developmental outcomes should be studied in the pre-marketing phase of 
new drugs. Further research is urgently needed to evaluate the effects of all concurrent 
drugs used in pregnancy in more detail so as to be able to identify those with a functional 
teratogenic potential. In the meantime, more conservative prescription and consumption 
behaviour should be advised. 
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6.1 Medical drug use during pregnancy and the 
IQ of the exposed child* 
PCM Pasker-de ¡ong, BWjH Pennmx, M Vn/heid, QM Doggen, H van der Vlugt 
Abstract An explorative case-referent study was performed on the association between 
medical drug use during pregnancy and the IQ of the exposed child There were 66 cases 
with an IQ of 85 or less and 238 referents with an IQ of 90 or more, aged 6 to 13 years and 
referred to the neuropsychology department of the university of Brabant Information on 
medical drug use was collected by mailing questionnaires to the mothers, general 
practitioners and gynaecologists After adjustment for maternal education, all adverse 
effects of a particular drug group on a child's IQ seemed to disappear However, for 
antibiotics, genital tract medications and tocolytics, maternal education proved to be an 
effect modifier Significantly increased ORS were found for these drugs in the group of 
highly educated mothers There was no apparent explanation for this finding 
Introduction Medical drug exposure dunng pregnancy is very common Nearly all the studies on 
drug use dunng pregnancy have shown that 70% or more of all pregnant women take at 
108 least one drug[i] In the Netherlands, drug use was studied in a cohort of low-nsk 
pregnancies [1] Medication was used by 877% of the women under the supervision of a 
gynaecologist and by 59 8% of the women under the supervision of a midwife The top-five 
medications were analgesics, antacids, vitamins, antibiotics and dermatological preparations 
The effects of medical drugs on the developing fetus and infant are virtually 
unknown Numerous effects may be expected, depending on the drug taken, the dose and 
the gestational age on exposure Some drugs have the potential to interfere with brain 
development both in animals and m humans Disturbances of brain development form the 
basis for functional pathology which appears as functional and behavioural disorders 
during maturation or even m childhood [2,3] Examples of drags which may produce these 
functional disorders are anh-psychotics, barbiturates, sex hormones, corticosteroids, anti-
convulsants, Clonidine and ntodnne [2,4-7] These drugs are suspected of having an 
adverse effect on functional development, which may result in e g overactivity of the 
child, impaired social interaction in groups, attention disorders, learning problems, 
sleeping problems and intelligence (IQ) decrements All of these may cause lifelong disabi-
lity which senously affects the social position of the child 
Few studies have investigated the association between medical drugs and a child's 
IQ However, some examples are present Children prenatally exposed to hydantom anti-
convulsants, such as phenytoin, appeared to have lower IQ scores at seven years of age 
than matched controls [81 Gaily carried out a prospective study on 148 children from 
epileptic mothers who had used anti-epileptic drugs during pregnancy and 105 control 
children He found that the mean IQ at 5 5 years was significantly lower in the study group 
than in the control group [9] Gaily also found that significantly more children from 
epileptic mothers had some type of specific cognitive dysfunction than control children 
* Submitted for publication 
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However, the increased risk was associated with maternal secures but not with exposure 
to anti-epileptic drugs [io] 
In a study on the long-term effects of intra-utenne medroxyprogesterone exposure 
on human progeny, it was concluded that MPA has no effect on the intellectual devel­
opment of youngsters aged 13 to 19 [11] 
In 1987, Pytkowicz Strcissguth studied maternal aspirin use during the first half of 
pregnancy in 421 women and found that exposure was significantly related to IQ 
decrements in the children (AIQ=8) at four years of age [12] Klebanoff could not confirm 
the finding in a similar study on 19,226 pregnancies and concluded that an adverse effect 
of aspirin exposure on IQ was unlikely [13] 
Polowczyk et al [14] reported the findings from a follow-up on trial participants 
A statistically non-significant decrease was found in the IQ of children bom from preg­
nancies treated with ntodnne as compared to matched controls Recently, the Canadian 
preterm labour investigators group reported on a double blind randomized controlled 
clinical trial on the treatment of preterm labour with ntodnne or a placebo [15] They 
assessed the outcome of pregnancy and found a statistically non-significant increase in 
performance on the Baylcy Developmental Scales m the treated children at the age of 
eighteen months 
So far little is known about adverse effects of other medical drugs on the IQ of the 109 
exposed child when they are used during pregnancy The purpose of the present explor­
ative study was to investigate the association between medical drug exposure during 
pregnancy and the IQ of exposed children at the age of 6 to 13 years 
Materials and The TAN (Ambulatorium for Neuropsychology in Tilburg, the Netherlands) is a 
methods neuropsychology department of the university of Brabant which specializes m tests for 
learning and behavioural problems About 1250 persons, mostly children, were tested 
between 1980 and 1992 From this population we selected all the children aged 6 to 13 
years whose IQ was measured with the WISCR (Wechsler Intelligence Scale for Children 
Revised) or the WPPSI (Wechsler Preschool and Primary Scale of Intelligence) This age 
group was chosen because most intelligence disorders will have been diagnosed at 
pnmary school age 
All the children had to meet the following entena 
β not adopted or living with a foster family, b the biological mother could still be 
contacted, с always gone to school in the Netherlands, d no evidence of gross neurological 
disease which might cause changes in brain function, such as spina bifida or a brain 
tumour 
The selected children were divided in two groups The case group consisted of 
76 children with an IQ of 85 or less and the referent group consisted of 279 children with an 
IQ of 90 or more Children with an IQ of between 85 and 90 were excluded from the study 
to increase the degree of contrast 
The mothers of the 355 selected children were invited by telephone to participate 
in the study In total, 75 mothers of cases and 275 mothers of referents agreed to participate 
and were mailed a questionnaire After four weeks, a reminder was sent to the mothers 
who had not yet responded Two weeks after the reminder, the remaining non-responders 
were contacted by telephone 
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The questionnaire had previously been validated [16,17] a n d adjusted and exten-
ded for this study. The questionnaire contained questions about medical drug use and 
complications during pregnancy and their timing, possible confounders and variables 
which might influence the recall and reporting of medical drug use. To complete the data 
on medical drug use during pregnancy, we also asked the participants' permission to 
contact their general practitioner and gynaecologist. The GPS and gynaecologists were sent 
a short questionnaire, which consisted of questions about which drugs were prescribed 
and any complications which occurred during pregnancy and delivery. The information 
collected from the GPS and gynaecologists was added to the data collected from the 
mothers. 
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To evaluate the association between medical drug use during pregnancy and a 
child's iQ, drug exposure was compared in the case and referent groups. Too few data 
were available on the timing and dosage of medication to be able to include these variables 
in our analyses. Drug (sub)categories were defined according to the classification system in 
the Dutch Pharmacotherapcutical Compass 1984 [18]. In each drug category we considered 
no use at all versus any use. Only drug groups used by a minimum of 10 women were in-
cluded in the analyses. Odds Ratios were calculated. The following potential confounders 
were examined for any possible influence on the estimated association between drug use 
and IQ: birth weight, gestational age, complications during pregnancy, maternal age, 
maternal work during pregnancy, educational level of both parents, and maternal diet, 
alcohol use and smoking habits. The potential confounders which relevantly changed the 
exposure ORS were included in the final model as actual confounders. Finally the adjusted 
ORS were computed. 
Results Of the 355 mothers who were telephoned, 350 agreed to participate. Of these, 
304 (86% of 355) returned the questionnaire completely filled in. Of the 207 GPS and 
149 gynaecologists we contacted, 145 (70%) and 115 (86%) returned the postal question-
naire in time, respectively. 
A description of the case and the referent groups is given in table 1. The case group 
consisted of 66 children with a mean IQ of 78 (ranging from 47 to 85). The mean age of the 
cases at the time of this study was 12.3 years and 71 per cent were boys. In this group, 
Table 1. Comparison of 
several characteristics of 
cases and referents. Means 
and (standard deviations). 
IQ 
Age (yrs) 
Male gender (%) 
Maternal education: 
low 
middle 
high 
Number of drugs during pregnancy 
Cases 
H=66 
77.9 (7.5) 
12.3 (3.4) 
71 
46 
37 
17 
2.27 (2.2) 
Referents 
n=2J8 
107.5(11.3) 
13.6 (3.4) 
79 
24 
35 
42 
2.30 (1.7) 
I 
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Table 2. Crude and adjusted 
ORs for the relation between 
drugs used (considered as 
no use at all versus any use) 
by more than 10 women and 
the IQ of the exposed child. 
Drag group 
CNS medications 
hypnotics/sedatives 
analgesia/antipyretics 
anti-emetics 
Local anaesthetics 
during delivery 
Iran 
Cardiovascular medications 
Intestinal medications 
Respiratory medications 
Genital tract medications 
oxytocics 
tocolytics 
ovulation stimulation 
Antibiotics 
Vitamins and minerals 
Hormones 
* among referents (n=23S) 
44 exposed ' 
30.3 
7.3 
23.5 
4.2 
15.0 
40.4 
4.6 
17.7 
3.4 
37.4 
21.9 
13.3 
5.9 
9.7 
20.4 
9.7 
crude 
OR 
1.00 
1.06 
1.08 
0.36 
0.48 
1.01 
0.65 
0.74 
0.90 
1.16 
1.56 
1.21 
1.04 
1.29 
0.48 
1.29 
90% a 
0.61-1.65 
0.44-2.53 
0.62-1.90 
0.06-2.06 
0.21-1.09 
0.63-1.62 
0.18-2.33 
0.38-1.42 
0.24-3.37 
0.73-1.85 
0.93-2.59 
0.63-2.31 
0.40-2.73 
0.63-2.64 
0.24-0.97 
0.63-2.64 
adjusted 
OR 
0.95 
0.96 
1.07 
0.29 
0.53 
1.09 
0.53 
0.69 
0.72 
1.08 
1.45 
1.09 
0.91 
1.21 
0.58 
1.07 
90%σ 
0.57-1.59 
0.39-2.35 
0.60-1.91 
0.05-1.68 
0.23-1.22 
0.67-1.77 
0.14-1.98 
0.35-1.35 
0.19-2.80 
0.67-1.75 
0.86-2.46 
0.56-2.12 
0.33-2.48 
0.58-2.54 
0.28-1.21 
0.51-2.23 111 
81.8 per cent of the mothers had used at least one medical drug, with an average of 
2.3 drugs per person. The referent group consisted of 238 children and their mean IQ was 
108 (ranging from 90 to 143). The mean age in the referent group was 13.6 years and 79 per 
cent were boys. Almost 85 per cent of the mothers had used at least one medical drug, with 
an average of 2.3 drugs per person. Thus the extent of drug use was similar for the cases 
and referents. 
Crude odds ratios were computed for the drug categories which were used by at 
least 10 women (table 2). Vitamins and minerals appeared to be negatively related to IQ 
(OR=O.48, 90% ci 0.24-0.97). For oxytocics, a positive association was found, although not at 
the 5% significance level. No other drug categories showed any relation with the IQ of the 
exposed child. 
Maternal education was the only potential confounder which differed significantly 
between the cases and referents and substantially changed some of the exposure ORS. The 
mothers of the cases had received less education than the mothers of the referents (table 1). 
There were no differences between the cases and the referents regarding most of the 
variables which could influence the recall of medical drug use (time between pregnancy 
and reporting, number of pregnancies, number of children and birth order). After adjust­
ment for maternal education through logistic regression analysis, several of the odds ratios 
but not all of them showed some change (table 2). The 'protective' association between 
vitamins and minerals with IQ remained (although weakened, OR = 0.58) as well as the 
tendency for a 'harmful' association with oxytocics (OR = 1.45). 
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Table 3 OR, (95% CI) ¡лг 
level of maternal education 
for the drug groups m 
which mah mal education 
M s an effect modifiLr 
Maternal 
education 
Low 
Middle 
High 
CNS 
medications 
„ _ 
0 39 (0 1 1 2) 
1 72 (0 7 A 5) 
1 50 (0 4 5 6) 
Antibiotic 
medications 
. 
0 24 (0 0 2 1) 
1 49 (0 4 5 3) 
6 99 (1 4 34 5) 
Genital tract medications 
All Tocolytics Oxytocics 
1 2 2 ( 0 5 3 0 ) 0 7 7 ( 0 2 2 7 ) 2 1 9 ( 0 8 5 9 ) 
0 46 (0 2 1 3) 0 52 (0 1 2 5) 0 85 (0 3 2 6) 
3 9 7 ( 1 1 1 4 5) 6 37(15 26 3) 1 5 6 ( 0 4 6 5 ) 
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Some of the drug groups showed an interaction with maternal education in their 
association with disease status, suggesting effect modification (table 3) The ORS for 
tocolytics and antibiotics were highest in the group of highly educated mothers, while the 
OR for CNS medications was low (OR=O 39) in the mothers with low education In the drug 
groups not presented, no interaction was noticed or the numbers were small 
Discussion This study did not show any relation between medical drug use during pregnancy 
and the child's IQ For some drugs a weak association was tentatively suggested, especially 
for oxytocics In addition, the ORS for cvs medications, genital tract medications and 
antibiotics were found to be statistically significantly increased in the highly educated 
mothers but not in the mothers with a low education The use of vitamins seemed to 
protect against a low IQ in the child Before making any deductions with respect to these 
findings several limitations of this study should be borne m mind 
First, it should be stressed that in observational studies, it is almost impossible to 
separate the effects of the drugs used from the effects of the reasons for which the drugs 
were taken This may play a role especially regarding the association between oxytocics or 
tocolytics and the IQ of the child The reasons for taking these drugs were complications 
during delivery which may be related to IQ decrements in the child 
Second, underreporting of medical drug use may have occurred m this study To 
improve the overall sensitivity, we combined the information obtained from the mothers 
with information from the GPS and gynaecologists The underreporting was probably non-
differenfaal (masking real effects as a result), especially after controlling for maternal 
education Recall bias is unlikely because the referents also had functional disorders 
Third, it is considered possible that a proportion of our referent group had 
functional disorders which might be due to medical drug use during pregnancy [19] This 
might have reduced the ORS for the relation between medical drug use and child's IQ [19] 
Therefore, we subdivided the referents into classes according to the (subjective) probability 
that their disorders were caused by medication during pregnancy We repeated the 
analyses with the referents who had the lowest probability, such as children with brain 
disorders caused by accidents or disease The magnitude of the ORS remained the same 
Finally, the number of users in the various drug categories was generally small In 
the drug groups used by less than 17% of the population, which were numerous, the 
power did not exceed 70 per cent It would have been difficult to detect increased risks in 
these groups so we have not presented the results for these groups 
These limitations could all have led to the masking of existing effects This might 
explain the fact that hardly any of the ORS were statistically different from unity, but does 
not explain the interaction with maternal education Several explanations for this 
modification effect present themselves 
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First of all it is possible that there was a difference in the type of preparations taken 
by the women in the three educational groups One or several of the preparations from a 
drug group may enhance the risk of IQ decrements in the exposed child These prepara­
tions could be taken preferentially by a particular educational subgroup of the mothers 
Information on the exact preparations used was incomplete so we could not explore this 
possibility 
The modification effect of maternal education may have also been introduced by 
decreasing misclassihcation over the educational groups Our validation study showed 
that recall was better among the more highly educated women [17] Misclassificahon 
might have masked the effects among the less educated mothers but not or to a lesser 
extent among the highly educated mothers 
Finally, less educated mothers may stimulate their children to a lesser extent so 
that children who have a potentially high IQ would not actually achieve it, whereas with a 
highly educated mother they would A possible effect of drug use on a child's potential IQ 
might thus only be measurable in children who achieve their full potential IQ 
In view of the above-desenbed limitations, we still have to conclude that it is 
unlikely that methodological artefacts explain the associations found in this study 
Although the effects may not be large, it might still be possible that drugs used during 
pregnancy have a true effect on the IQ of the exposed child 113 
It should be noted that in the literature, antibiotics have not yet been considered to 
be relevant in the etiology of mental retardation From the tocolytics (genital tract 
medication), only Ritodnne has been studied in relation to the functional development and 
IQ of exposed children, with no or only marginal effects [14,15] The credibility of a true 
increased risk for tocolytics of six, is therefore not very high Although the value of this 
study may be restricted, the results add to the concern raised in previous reports I4-8I The 
development of the brain and its capacities, and the role of the parents, is complex 
Pharmacons and other external factors may well influence the process 
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and functional development of the child at 
the age of four through ten years* 
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ТКАВ Eskes, PR Hem 
Abstract As recent studies have shown that treatment of moderate pregnancy induced 
hypertension does not improve pregnancy outcome, the potential detrimental long-term 
side-effects on the developing central nervous system might be a reason to refrain from 
medical treatment of pregnancy hypertension We therefore studied all liveborn children 
prenatally exposed to labetalol because of maternal hypertension born in one of the twelve 
participating hospitals between 1-1-1983 and 31-12-1987 Children exposed to methyldopa, 
children exposed to maternal hypertension treated only with clinical bed rest, and children 
neither exposed to maternal hypertension nor to antihypertensive medication ('norm') 
were studied as referent groups In 1992 and 1993 when the children were four through ten 
years of age, functional development was measured with several standard developmental 
tests The score on the concentration test was worse in the children exposed to labetalol 
116 (»=59) than in those exposed to methyldopa (и=6і), bed rest (и=8г) or no hypertension 
(11=93) Moreover, children exposed to labetalol were more often classified as inattentive by 
their teachers As birth weight was lowest in children exposed to labetalol as compared to 
methyldopa, bed rest and norm, birth weight might be an intermediary factor in the 
association of labetalol with concentration decrements Test scores on other dimensions of 
Central Nervous System development were not significantly different between the groups 
Labetalol exposure in utero seemed to negatively affect the concentration of the child at 
primary school age 
Introduction About seven percent of pregnant women will experience a significant rise in blood 
pressure during pregnancy (Pregnancy Induced Hypertension (PIH) or Pregnancy 
Aggravated Hypertension (глн)) There is no doubt about the necessity of medical 
intervention for women whose diastolic tensions rise to 110 mmHg or more [14] In these 
cases, treatment leads to a diminished risk of major complications of hypertension and to 
improved pregnancy outcome [6,7,14,15] However, the question has been raised whether 
treatment is necessary m more moderate and light cases of pregnancy induced 
hypertension, with diastolic tensions between 90 and 110 mmHg, especially if no protein-
urea is present Pregnancy outcome has been found to be similar after bed rest only as 
compared with treatment with nifedipine [21], atenolol [4], methyldopa [23] or labetalol 
[13,22] in chronic or mild hypertension If treatment does not improve pregnancy outcome 
but only improves maternal status, knowledge of the long-term sequelae of prenatal 
exposure is necessary for rational treatment of PIH/PAH balancing the risks and benefits 
Of some antihypertensive drugs, the long-term sequelae have been studied in the human 
but information is scanty Sleeping disturbances after prenatal exposure to Clonidine, 
a centrally acting agent, have been reported from a cohort study [5] Functional 
development was similar at four year follow-up of children bom in a large clinical trial on 
the effectiveness of methyldopa, also a centrally active antihypertensive drug, versus no 
anti-hypertensive treatment [12] Ten out of fourteen children exposed to labetalol were 
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developing normal at the age of ых months [6] No comparison was made for this outcome 
with children treated otherwise No follow-up studies on the functional sequelae of 
prenatal exposure to other antihypertensive medications have been published In rats, 
early postnatal exposure to propranolol was associated with reduced bram weight [24] but 
not with altered behavioural development The same holds for atenolol and Clonidine [18] 
Losula7ine impaired functional development in rats [11] However, the developmental 
tests varied between the studies and inconsistent results may just reflect these differences 
Since 1984, the treatment of first choice in the Netherlands has been labetalol, 
a combmed alpha and beta blocking agent The question has been raised whether this 
agent is negatively associated with functional development of children exposed in utero 
In the penod between 1983 and 1987, Dutch obstetricians gradually switched from 
methyldopa to labetalol as treatment of first choice after reports on side-effects associated 
with exposure to methyldopa that were absent with labetalol As it took some four years 
before the majority of obstetricians had switched from methyldopa to labetalol, the situation 
in that period had many characteristics of a natural experiment Whether a hypertensive 
pregnant woman received treatment with methyldopa or with labetalol in this period 
depended predominantly on the attending obstetrician It should be noted that methyldopa 
is generally considered to have no side-effects for the fetus even at long-term The safety of 117 
labetalol for the fetal central nervous system development has not been established 
We conducted a historical cohort study of the functional development of children 
bom from a mother treated with methyldopa or labetalol because of pregnancy 
hypertension To be able to relate the outcomes in these groups to 'normal expectations', 
a non-hypertensive reference group was included as well A bed rest group was included 
m the study to analyse the effect of hypertension per se 
Population and The departments of Obstetrics and Gynaecology of twelve hospitals in the 
methods Netherlands participated in the study The hospital records of all women whose diastolic 
tension had exceeded 90 mmHg at least once during pregnancy and who delivered in one 
of these hospitals between 1-1-1983 and 31-12-1987 were reviewed for the study (я = 4000) 
They were selected via the hospital registry or via the files of the Dutch Obstetrics Registry 
All women treated with methyldopa (Aldomet ®) or labetalol (Trandate ®) for PIH or PAH 
were included in the study together with a sample, matched on delivery date, of the 
women treated with clinical bed rest because of hypertension Finally, a group of women 
without a medical indication for hospital delivery was selected from the hospital files, 
matched on delivery date as well Only women aged between 20 and 35 years, with 
singleton pregnancies who delivered from a live bom child after at least 32 weeks gestation 
and who had not suffered from diabetes or epilepsy in this pregnancy were eligible 
Finally, 540 mother-child pairs were selected for inclusion in the study 99 labetalol, 
102 methyldopa, 154 bed rest, and 184 pregnancies without a medical indication for 
obstetric supervision (Norm) 
The 540 women were sent a letter from the department where they had delivered, 
with a request to participate in the study One reminder was sent to all non-responders and 
addresses were traced (if possible) when a letter was returned as being undehverable 
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Women who agreed to participate were contacted by telephone to make an 
appointment. All children whose parents agreed to participate were tested at the children's 
home address by one of six trained child-psychologic test-assistants. The following 
developmental aspects were assessed: 
The child's Concentration (Bourdon-Vos [28]), IQ (Shortened RAKIT [2]), Memory 
(visual memory: subtest of RAKIT [2], verbal memory: ten-words-test [27], associative 
memory: verbal word pair associations [27]), Gross motor development (subtest of Hamm 
Marburger Körper Koordinationstest für Kinder [29]), Fine motor development (prick-test 
[27D, and Language development (Mommers one-minute test [30]). 
Information about the pregnancy and the early development of the child was 
obtained from the parents using a standardised questionnaire. Behaviour of the child was 
scored by the parents (CBCL) as well as by the teacher of the child (TRF) [26]. 
In the analyses, we compared the various outcomes in the Iabetalol group with 
those in the methyldopa group. The results in the bed rest group are given to provide a 
comparison with what would be expected if only (less severe) hypertension were present. 
The results in the Norm group are given to provide a comparison with what would be 
expected if no hypertension had been present during pregnancy. 
118 Results In total, 416 of the 540 women selected for the study returned an answer. Of these, 
299 agreed to participate. Two of the women changed their mind and two were not 
included for practical reasons. Thus, 295 subjects were left for analysis. Of the 124 women 
who did not respond, about half were found by a telephonic check not to be living at the 
address the letter had been sent to. If we excluded these women (since they had not had 
the possibility to agree to participate), 63% of the women who had been invited actually 
participated in the study. 
Some characteristics of the participants, refusers and non-responders are given in 
table 1. Refusers tended to have had longer pregnancies, with higher birth weight of the 
children. Since more 'Norm' women refused to participate, this is not surprising. Birth 
weight and length of gestation were comparable for the participants, the refusers and the 
non-responders in the four subgroups. 
For the participants, more information about the women and the pregnancy (severity of 
Participants 
295 
2908(53) 
38.2 (0.2) 
27.7(0.2) 
60.2 
60.4 
53.6 
50.0 
6.7(01) 
Refusen 
119 
3093(85) 
39.0 (0.2) 
26 9 (0.4) 
18.4 
15.8 
24.8 
25.3 
6.9 (0.1) 
_ _ 
Non-responders 
124 
3142(77) 
38 6 (0.2) 
26.1 (0.4) 
21 4 
23.8 
21.6 
24.7 
7.1 (0.1) 
Table 1. Characteristics 
of participants, 
non-participants and 
non-responders. 
Number 
Birth Weight 
Gestational age 
Maternal age 
Croup: 
Iabetalol (n = 98) 
methyldopa (n =101) 
bed rest (n= 153) 
norm(n= 1S6) 
Age of the child on Jan 1,1993 
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Table 2 Characteristics of 
the four groups of women in 
the study 
Number of participants 
Maternal age yean 
Pnmiparae % 
Education low 
intermediate 
high 
Birth weight g 
Proportion 5GA % 
Length of gestation wk 
Maximal DBP mmHg 
in week 
Apgarscore <9 % 
Start treatment wk 
Other medical 96 
treatments for PIH ι» 
Ubetalol 
59 
28 1 (0 5) 
69 0(61) 
39 0 (6 3) 
39 0 (6 3) 
22 0 (5 4) 
2589(136) 
67(3 7) 
37 3 (0 5) 
113(1 8) 
28 4 (1 3) 
25 9 (7 8) 
26 1 (1 4) 
27 1 (5 8) 
1 4 (0 08) 
SCA = Small tor Gestational Age 
Methyldopa 
61 
27 7 (0 4) 
57 4 (6 3) 
31 1 (5 9) 
50 8 (6 4) 
180(5 1) 
2710(121) 
7 7(3 7) 
36 4 (0 7) 
105(1 5) 
29 1 (1 3) 
5 4 (3 7) 
20 1 (1 6) 
42 6 (6 3) 
1 3 (0 06) 
Bedrest 
82 
27 5 (0 4) 
76 3 (4 8) 
45 1 (5 5) 
36 6 (5 3) 
18 3(4 3) 
2775(96) 
17 1 (4 3) 
38 3 (0 4) 
104(0 8) 
35 5 (0 4) 
2 0 (0 02) 
34 0 (0 5) 
51 2 (5 5) 
1 2 (0 05) 
Norm 
93 
27 8 (0 4) 
53 3 (5 2) 
34 4 (4 9) 
50 5 (5 2) 
151(3 7) 
3367(63) 
0 
39 6 (0 3) 
78 (1 0) 
34 0 (1 2) 
1 9 (0 02) 
-
2 2 (1 5) 
1(0) 
hypertension, treatments and complications) is presented in table ι The mothers in the 
labetalol group were more often pnmiparae than the mothers in the methyldopa group As 
expected, the labetalol group and the methyldopa group were most comparable in all 
aspects of hypertension and the occurrence of pregnancy complications However, in the 
methyldopa group women were treated earlier in the pregnancy so that their maximal 
diastolic tension remained at a lower level This may reflect a change in treatment protocol, 
associated with the replacement of methyldopa by labetalol as the treatment of first choice 
Some early developmental hallmarks are presented in table 3 Children exposed to 
labetalol and children exposed to methyldopa were equally fast They were a little slower 
in their development than the children born from a 'norm' pregnancy The bed rest group 
was fastest in its early development After correction for duration of pregnancy the 
difference between the medically treated and the norm groups disappeared The bed rest 
group remained faster than the other groups However, all children developed within the 
time boundaries for Dutch children [25] 
The developmental outcome at school age for the four groups is given in table 4. 
The scores were adjusted for age at testing where appropriate as the labetalol group was 
119 
Table 3 Early development 
of the children m the study 
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Age at first roll over 
Age at first crawl 
Age at first sit 
Age at first stand 
Age at first walk 
CASE STUDY 3 
Labetalol 
6 0 (0 4) 
9 4 (0 3) 
8 5 (0 3) 
10 7(0 4) 
151(0 5) 
Methyldopa 
5 6 (0 3) 
9 1 (0 3) 
8 5 (0 3) 
10 6(0 3) 
14 9(0 3) 
Bedrest 
5 2 (0 3) 
8 9 (0 2) 
77(0 2) 
9 6 (0 2) 
13 7(0 2) 
Norm 
55(0 2) 
8 9 (0 2) 
8 2 (0 2) 
10 2(0 2) 
14 5 (0 3) 
Labetalol Methyldopa Bed rest Norm 
Concentration score 
IQ (RAK1T) 
Cross motor 
Fine motor 
Memory task 1@ 
2ff 
3$ 
Sleep well (%) 
Attention Deficit (%) 
Language 
110.3(3 9) 
106 6(2.1) 
18.0(07) 
50 8(1.5) 
17.1 (07) 
12.0(0 4) 
5.0 (0.3) 
96.6 (2 4) 
17 0(4.9) 
59.8 (4.8) 
103.2(2.5) 
107 3(2.1) 
17.0(07) 
53.1 (1.4) 
16.6(0.6) 
12.3(0.4) 
5.3(0.3) 
89.7(4 0) 
8.2(3.5) 
59.5 (2.6) 
107.6(1.9) 
106.4(16) 
18.6(0.5) 
52 0(1.2) 
16.2(0.6) 
12.1 (0.3) 
5.6 (0.2) 
97.5(1.8) 
4.9(2.4) 
60 4 (2.9) 
100.2(2.1) 
107.1 (1.5) 
18.5(0.5) 
54.8(1.1) 
15 2(0.5) 
12.4(0.3) 
5.3(0 2) 
97 8(1.6) 
9.7(3.1) 
63.3 (2.4) 
@ Visual memory 
Tabic 4. Developmental ft Associative memory 
outcome measures. S Auditive memory, including long-term memory or learning task 
younger than the methyldopa group. The scores on the concentration test were higher (i.e. 
120 worse, ^=0.03) in the labetalol group than in the 'norm' group. The methyldopa group had 
concentration scores closer to the norm group and the bed rest group had intermediate 
results. The labetalol group had the lowest score on the fine motor development test. It was 
significantly lower only than that in the 'norm' group (/7=0.04). The proportion of children 
classified as 'Attention Deficit Disordered' according to the criteria of the American 
Psychiatric Association DSM-III classification |i] on the basis of information from the 
teacher was significantly higher in the labetalol group than in the other groups (р=о.од, 
p=0.02 and p=o.ocj, respectively). Furthermore, there was a tendency for the children 
exposed to labetalol to have decreased memory, especially on the auditive memory task 
which included long-term memory. Children who were prenatally exposed to methyldopa 
were reported by their parents to sleep less well than any of the other children (table 5). The 
groups did not differ in other aspects of functional development of the CNS. 
There were several potential confounders. Alcohol use during pregnancy by the 
mother and vision problems and brain concussion in the children were equally frequent in 
the four groups and were therefore not studied further. Correction for maternal education, 
severity of the maternal disease (proteinuria), otitis media in childhood, and parity of the 
mother by means of linear or logistic regression analysis where appropriate did alter the 
Table 5. Developmental 
outcome measures, corrected 
for confounding by maternal 
education, partly and otitis 
media in childhood. 
Concentration 
Attention Deficit 
Long term memory 
Cross Motor 
Fine Motor 
Labetalol 
110.0(3.5) 
17.4 (3.8) 
5.1 (0.3) 
18.2(07) 
51.0(1.5) 
Methyldopa 
103.5(2.5) 
8.1 (3.8) 
5.2 (0.3) 
16.8(07) 
53.0 (1 5) 
Bedrest 
108.3(2.5) 
5.7(3.3) 
5.7 (0.2) 
187(0.6) 
51.8(1.2) 
Norm 
99 9(2.1) 
9.1(31) 
5.4 (0.2) 
18.2(0.5) 
54.9(1.2) 
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association between labetalol and concentration decrements in the children to some extent. 
The corrected results are given in table 6. After correction, the labetalol children still had 
concentration problems more often and were more often classified as attention deficited. 
Discussion This study suggests that exposure to labetalol during pregnancy may affect the 
concentration as estimated several years later. Furthermore, attention deficits were also 
more frequent among these children. The birth weight was also lowest in the labetalol 
group. Low [8| suggested that reduced birth weight may be part of the causal chain in 
behavioural teratology. For this reason, we did not correct for birth weight as a confounder 
in the analyses. 
As no differences were found between the labetalol group and the other groups for 
other developmental aspects, concentration might either be specifically sensitive to the 
effects of labetalol or it may be one of the aspects of neural development that is most 
sensitive to the effects of labetalol. However, to exclude the possibility that the present 
findings arose from bias, sources of bias should be considered. 
The size of this study was large enough to detect relevant differences in concen-
tration scores, iQ scores, and the other outcome measures (i.e. more than one standard 
deviation difference in means) if they had been present. With a participation rate of 63%, 
the question of differential participation over the four groups and over the outcome is of 121 
importance. The baseline characteristics of the participants, refusers and non-responders 
were similar for the four groups. Differential participation in the four groups is therefore 
unlikely. On the other hand, it is very likely that participation did depend on develop-
mental outcome of the children. We know of at least one woman who did not participate 
because her child was mentally too retarded to be examined. However, this selective 
participation is likely to have occurred equally frequently over the four groups. 
We regarded methyldopa as a medical drug without effects on the functional 
development of the exposed child. This is disputed by Ounsted [12] who indicated that 
methyldopa might reduce a small negative effect of pregnancy hypertension on the 
development of the child. In this study, the hypertension alone group (bed rest) did not 
have worse outcomes than the methyldopa group. Shimohira [20] related sleeping 
problems and delayed motor development in a child to its exposure to methyldopa during 
pregnancy. The effect on sleep also seen in the present study may be mediated through the 
noradrenergic receptors in fetal brain [3,20]. 
In the literature, no studies on the long-term effects in the human of prenatal 
exposure to labetalol have been presented. However, several ways of action may be 
postulated for labetalol to cause the effects found. Labetalol may affect the child's 
behaviour and brain development through its effect on birth weight. It may also affect 
blood flow through the placenta. Labetalol increased the placental vascular resistance in 
exposed women while exposure to methyldopa decreased the resistance (16]. However, 
this was not found in another study [9]. 
The developmental hallmarks were all attained at similar ages in the labetalol and 
methyldopa group. The faster development in the bed rest group as compared to the other 
groups was unexpected and may be due to chance. 
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This study suggests that labetalol is not safe for the developing fetus in all aspects 
A detrimental effect on birth weight has already been described elsewhere [22] and was 
confirmed in this study In addition, we found a detrimental effect on 'concentration', also 
showing up in the proportion of children classified as attention deflated by their teachers 
Furthermore, there was a tendency for the children exposed to labetalol to have decreased 
memory function, especially on the memory task 3 which included long-term memory 
The behavioural teratogenic effects of labetalol is not unlikely beforehand as effects of 
exposure during pregnancy have been reported both on birth weight and on placental 
blood flow Restricted use of this drug may be warranted, especially now that the 
beneficial effects of treatment on pregnancy outcome have been questioned 
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Discussion and Conclusions 
The combination of medical drugs and pregnancy is in principle inadvisable. 
However, studies on drug use during pregnancy show that the combination is far from 
uncommon. A study presented in this thesis (chapter 2) on 1000 children bom at a 
university hospital clinic in the Netherlands showed that prenatal drug exposure had 
occurred in at least 70% per cent of these newborns. The number of drugs per mother and 
the character of drug use depended to a large extent on the method of data collection. This 
must be kept in mind when interpreting the data on the frequency and intensity of drug 
use. However, there is no doubt that prenatal exposure to medical drugs does occur 
frequently. In pregnancies at low risk for pregnancy complications, the top five medication 
were analgesics, antacids, vitamins, antibiotics and dermatological preparations in the 
Netherlands in 1984-85. 
The teratological sequelae in the human after prenatal exposure to medical drugs 
are generally unknown before a drug is marketed. Chapter 3 presents a review of the 
literature on the functional effects of prenatal exposure to medical drugs. The results of 
premarketing animal experiments may give an indication of the effects (not) to be 
expected, but extrapolation does not give straightforward answers. Research into humans 
is scarce with the exception of potential associations between anti-epileptic medication or 
psychopharmaceuticals and functional development. Premarketing studies on humans 
126 generally exclude pregnant women. Restricting premarketing research to non-pregnant 
women is ethically correct, but if marketed drugs are also going to be used by pregnant 
women, some information should be collected about the (behavioural) teratogenic 
consequences of prenatal exposure. Therefore, research into the teratological side-effects of 
drugs should be carried out after a drug has been put on the market. Thorough follow-up 
of women and children exposed to the drug during pregnancy seems to be the best way of 
detecting the effects of exposure as quickly as possible. 
Post-Marketing Surveillance aims at recognizing the side-effects of exposure in a 
systematic way after a drug is put on the market. However, the Post-Marketing 
Surveillance system as it functions today in most countries is incomplete as it relies 
predominantly on voluntary reporting systems in which exposure measurement is 
restricted and information on potential confounding variables is absent. The present set-up 
of Post-Marketing Surveillance will not raise questions about the association between 
prenatal exposure and conditions diagnosed later in life, because these are not reported. 
Moreover, significant but subclinical retardation of intellectual, behavioural or motor 
development are not detected through such a system of voluntary case reports. Registries 
of congenital malformations have similar drawbacks: the reporting is voluntary and 
follow-up is restricted to the first year of life. Functional sequelae of prenatal exposure 
cannot be studied routinely through either system. To make Post-Marketing Surveillance a 
more effective system, it should not only collect information about suspected side-effects 
on a voluntary basis, but also systematically collect information about the outcome of 
pregnancy, the development of the exposed offspring and any future disorders. However, 
this would be costly and may not be acceptable to the mothers who received drugs. 
As systematic Post-Marketing Surveillance cannot be introduced on a larger scale 
for teratogenic as well as other side-effects, information about the behavioural 
teratogenicity of drugs for human fetuses can only come from ad hoc epidemiological 
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studies on the functional sequelae of prenatal exposure after a drug has been marketed and 
indications of potentially harmful effects have been raised Several epidemiological 
designs can be considered for such post-marketing assessments of side-effects The case-
referent design is highly efficient, but it is only valid if exposure and confounder 
information can be obtained at the rune the outcome is diagnosed We found that in most 
instances this was not the case, as exposure measurement via questionnaires several years 
after birth yielded imprecise information (chapter 4 3) Furthermore, there were indications 
of information bias, while maternal education seemed to modify the assessment or effects 
of prenatal exposure {chapter 4 4) Prospective cohort studies are preferable from a validity 
point of view, but long-term follow-up makes this design expensive and unpractical 
Historical cohort studies combine the advantages of both designs, but are only possible if 
exposure of the fetus/child to the drug can be ascertained from valid sources (other than 
the mother) and if loss to follow-up is small (and reasons for termination are known) The 
validity of the measurement of confounders should be kept in mind m all designs 
A promising source of information on prenatal exposure to medical drugs in 
developed countries may be the pharmacist's administration, now that over 90% of the 
pharmacies in the Netherlands have automated their administration (chapter 42) To be 
useful for historical cohort studies on functional teratology, these pharmacy dispensary 
files should be kept for five to ten years minimum Exposure or treatment information 
could also be recorded in the Dutch Obstetrics Registry (LVR) or the Dutch Neonatal 127 
Registry which will come into existence in the near future In historical cohort studies, the 
choice of the reference group is a point of major importance Our results showed that the 
use of a non-diseased or non-exposed reference group may introduce potential sources of 
bias (chapter 4 6) The choice of a reference group treated for the disease with a drug other 
than the exposure of interest may not solve the problem as treatments differ in more 
respects than the chemical alone This lack of unidimensionahty of the exposure contrast is 
a large problem in non-expenmental pharmaco-epidemiological studies 
This thesis adds evidence to the belief that the drugs that are presently being used 
during pregnancy may affect the functional development of the exposed child (cMpters 5,6 
and γ) 
A follow-up study of 978 children bom in the St Radboud university hospital in 
1983-84 suggested an association between analgesics and internalizing behaviour in boys 
and between hormones and aggressive behaviour in girls (chapter 5) As the nature of the 
study was explorative, these findings have to be replicated to exclude the possibility of a 
chance finding Furthermore, follow-up was incomplete and this may have affected the 
results In a case-referent study on the association between prenatal exposure to medical 
drugs and mental retardation, a high maternal education and exposure to antibiotics and 
tocolytics were associated with mental retardation in the child (chapter 6) However, this 
finding may be an artifact, resulting from misclassificahon of exposure (chapter 44) In a 
historical cohort study on the functional development of children prenatally exposed to 
either labetalol or methyldopa because of maternal pregnancy hypertension, an association 
was found between exposure to labetalol and attention deficits in the children, and 
between exposure to methyldopa and sleeping disorders in the children (chapter 7) 
Although these findings are suggestive of a long-term side-effect of prenatal exposure to 
antihypertensive medications, more research is necessary to establish the genuineness of 
the findings 
DISCUSSION AND CONCLUSIONS 
In effective Post-Marketing Surveillance, information on the treatment regimes 
(not only the treatment), and for all the treatments given during pregnancy for an illness, is 
of interest. The length of the follow-up of exposed children should depend on the expected 
period in which adverse outcomes occur or are judged to be relevant. Thus, follow-up 
could include school achievements, diseases occurring during childhood, adolescence and 
even adulthood, and reproductive performance. Preferably, follow-up should make use of 
existing pathways as much as possible. For instance, the infant welfare programme and 
school health programmes are well-organised in the Netherlands, thus providing a 
framework for nearly complete follow-up. Such monitoring programmes should cover 
many outcomes of interest measured and documented in a standardized way. In addition, 
ad hoc measurements of the outcome status of prenatally exposed children and a 
comparably non-exposed group could be carried out. This would help to tailor studies to 
the anticipated outcomes associated with the type of exposure under study. The number of 
exposed children who are followed-up can be adjusted to the maximum acceptable risk for 
the adverse effect under study. An obligation to follow at least the first η children exposed 
to a new drug with standard procedures for f years could be included in the regulations. 
The results of a study are only of real use to the clinician confronted with diseases 
occurring during pregnancy if both the risks and benefits associated with a particular 
therapy in a particular situation were studied against estimates of the risks and benefits of 
128 alternative treatments, the alternatives being either chemical, physical or conservative. 
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S A M E N V A T T I N G 
(Hoofdstuk 1) Dit proefschrift probeert antwoord te geven op vier vragen die van belang zijn 
voor onderzoek naar de gedragsteratogemateit van geneesmiddelen 
ι Welke geneesmiddelen worden het meest frequent gebruikt tijdens de zwangerschap7 
2 Van welke medicijnen valt een effect te verwachten, en wat voor effect is dat7 
3 Wat zijn de beste onderzoeksmethoden om de gedragsteratogemateit van genees­
middelen te bestuderen, theoretisch zowel als praktisch gezien7 
4 Zijn deze onderzoeksmethoden uit te voeren in de praktijk en geeft dergelijk onderzoek 
bruikbare informatie over de effecten van specifieke groepen geneesmiddelen7 
(Hoofdstuk 2) Uit onderzoek blijkt dat in de hele wereld inclusief Nederland veel vrouwen tijdens 
de zwangerschap geneesmiddelen gebruiken Omdat de onderzoeken verschillen in opzet, 
onderzoeksgroep en methoden, zijn de resultaten moeilijk te interpreteren In hoofdstuk 2 2 
wordt beschreven dat 50 procent van de verschillen in percentage geneesmiddelen 
gebruikende zwangere vrouwen russen studies kan worden toegeschreven aan verschillen 
in methoden van informatieverzameling Verschillen in de definitie van 'geneesmiddelen' 
en in de onderzochte populatie zijn ook verantwoordelijk voor verschillen m de resultaten 
Hoofdstuk 2 3 beschrijft een prospectief onderzoek naar geneesmiddelengebruik 
tijdens de zwangerschap onder vrouwen die begeleid werden door een gynaecoloog 
(71=332) en vrouwen die begeleid werden door een verloskundige («=250) wanneer geen 
130 medische indicatie bestond Het onderzoek vond in Nederland plaats in 1984 en 1985 Het 
geneesmiddelengebruik werd nagevraagd bij ieder bezoek. Meer vrouwen onder begelei­
ding van een gynaecoloog gebruikten geneesmiddelen (bijna negentig procent) dan 
vrouwen onder begeleiding van een verloskundige (zestig procent) Staalpillen en 
plaatselijke verdoving voor inknippen werden niet meegeteld Uit medisch oogpunt is het 
feit dat geneesmiddelen worden gebruikt interessanter dan om hoeveel vrouwen het gaat 
Vanuit farmaco-epidemiologisch oogpunt is het meest interessant welke geneesmiddelen 
het meest worden gebruikt De meest gebruikte geneesmiddelen waren pijnstillers, 
middelen tegen brandend maagzuur, vitaminen, antibiotica en zalfjes en smeerseltjes 
Om de verschuivingen m de tijd te onderzoeken in het soort en de hoeveelheid 
geneesmiddelen die worden gebruikt tijdens de zwangerschap hebben we informatie 
bestudeerd die was verzameld in Zweden tussen 1980 en 1983 Het geneesmiddelen-gebruik 
werd geschat met behulp van de antwoorden op vragen naar het gebruik van bepaalde 
middelen die aan zwangere vrouwen werden gesteld We vergeleken de resultaten van onze 
meting met die van eerdere onderzoeken in Zweden (hoofdstuk 2 4) In het meest recente 
onderzoek gebruikte twee derde van de vrouwen tenminste een geneesmiddel Staalpillen 
en middelen die bij de bevalling werden gebruikt zijn niet meegeteld Pijnstillers werden het 
meest gebruikt, gevolgd door antibiotica De hoeveelheid gebruikte geneesmiddelen (en met 
name het gebruik van pijnstillers en psychopharmaca) was afgenomen sinds de zestiger 
jaren en was gehjkgebleven sinds het eind van de zeventiger jaren In het begin van de jaren 
tachtig werden zwangere vrouwen gestimuleerd 'drogistenj'middelen te gebruiken als zij 
verkouden waren of moetsen overgeven Verdere beperking van het geneesmiddelen­
gebruik lijkt daarom mogelijk 
(Hoofdstuk 3) De tweede vraag ging om de teratogeniciteit van de geneesmiddelen die tijdens de 
zwangerschap het meest worden gebruikt Wij hebben de nadruk gelegd op de gedrags-
teratogene effecten aangezien deze misschien voorkomen in situaties waar zichtbare 
afwijkingen met voorkomen 
Een overzicht van de literatuur liet zien dat er weinig onderzoek is gedaan naar de 
gedragsteratogemciteit bij mensen van geneesmiddelen die op de markt zijn De genees-
middelen waarvan een effect te verwachten valt zijn psychofarmaca en dan speciaal de 
anti-epilephca, en hormonen Er was geen informatie beschikbaar over de effecten op de 
functionele ontwikkeling van prenatale blootstelling aan antacida, antibiotica, zalfjes en 
huidpreparaten, of de meeste vitaminenpreparaten 
Met zo'n beperkte kennis is een aanvulling door specifieke studies op het gebied 
van de functionele teratologie van geneesmiddelengebruik tijdens de zwangerschap 
wenselijk Aangezien Post Marketing Surveillance op dit moment niet voldoet en regi-
straties van aangeboren afwijkingen geen functionele stoornissen registreren, zal zulk aan-
vullend onderzoek een ad hoc karakter hebben 
(Hoofdstuk 4) De derde onderzoeksvraag was wat de beste onderzoeksstrategien zijn voor het 
doen van onderzoek naar de functionele effecten voor het kmd van geneesmiddelen-
gebruik tijdens de zwangerschap Om deze effecten te bestuderen op een epidemiologische 
manier zijn twee studieopzetten denkbaar Case-referent onderzoek en Cohort onderzoek 
Gerandomiseerde onderzoeken zouden het meeste bijdragen aan de kennis, maar het is 
onethisch om bijwerkingen te bestuderen met behulp van clinical trials 
De Case-referent opzet is alleen valide wanneer de blootstelling (het gebruik van 
geneesmiddelen tijdens de zwangerschap) en confounders accuraat kunnen worden 
bepaald op het moment dat de effecten worden gemeten Daarom hebben wij de volledig-
heid en de toegankelijkheid van verschillende bronnen van informatie over het gebruik 
van geneesmiddelen bestudeerd Huisartsen en apothekers stuurden informatie over de 
geneesmiddelen die zij tijdens de zwangerschap aan de deelnemers van een onderzoek 
naar mentale retardatie hadden voorgeschreven of geleverd Bovendien werd informatie 
verzameld uit de ziekenhuis status en via een gestructureerd interview met de ouders De 
informatie van de moeders was het meest uitgebreid Apothekers en huisartsen gaven niet 
dezelfde informatie over het gebruik van de soorten geneesmiddelen Bovendien waren 
veel apothekers niet in staat de gevraagde informatie te leveren aangezien zij hun gege-
vens met langer dan zes jaar bewaarden (hoofdstuk 4 2) 
In een tweede onderzoek stuurden we een vragenlijst naar het geneesmiddelen-
gebruik tijdens de zwangerschap aan vrouwen die zeven a acht jaar eerder hadden deel-
genomen aan een onderzoek naar het geneesmiddelengebruik hjdens de zwangerschap 
De herinnering van het geneesmiddelengebruik was verre van compleet Anaesthehca 
werden het best herinnerd Tachtig procent van de blootgestelde vrouwen wist zich de 
blootstelling nog te herinneren Voor de meeste groepen geneesmiddelen werd maximaal 
de helft van de blootgestelde vrouwen geïdentificeerd (hoofdstuk 43 en 44) Een 
vragenlijst over het gedrag van het kind werd ook ingevuld en wij hebben de mogelijkheid 
van differentiële herinnering bestudeerd De fout in de herinnering bleek af te hangen van 
het gedrag van het kind Recall bias was dus aanwezig Dit zou kunnen leiden tot valse 
associaties russen geneesmiddelengebruik en het gedrag van het kind (hoofdstuk 4 4) 
De cohort opzet is valide wanneer een referentiegroep wordt gekozen die zo goed 
mogelijk lijkt op de blootgestelde groep voor wat betreft de relevante eigenschappen Dit is 
met eenvoudig aangezien behandelingen veranderen m de tijd en, belangrijker nog, 
aangezien de behandeling afhangt van de indicatie voor behandeling zoals de ernst van de 
ziekte (hoofdstuk 4.6). Cohort onderzoeken zijn in principe geschikt maar langdurige 
follow-up en de meting van de effecten zijn vaak duur en onpraktisch. Historische cohort 
onderzoeken kunnen alleen worden uitgevoerd voor geneesmiddelen waarvan de 
bloostelling in het verleden goed genoeg is gedocumenteerd. 
Beide onderzoeksopzetten werden in de praktijk uitgeprobeerd. 
(Hoofdstuk 5) In een follow-up onderzoek van 1000 kinderen die waren geboren in een aca-
demisch ziekenhuis werd een gedragsvragenlijst (CBCL, Child Behaviour Checklist) in-
gevuld door de ouders. Prenatale blootstelling aan analgetica was geassocieerd met 
gedragsveranderingen in jongens en meisjes terwijl blootstelling aan hormonen was 
geassocieerd met depressief gedrag in meisjes. Follow-up van 1000 kinderen was van 
beperkte waarde omdat slechts een beperkt aantal kinderen tijdens de zwangerschap was 
blootgesteld aan specifieke geneesmiddelen. Een survey-type onderzoek moet erg groot 
zijn om genoeg informatie te leveren over minder frequent gebruikte geneesmiddelen. 
In een case-referent onderzoek naar de prenatale blootstelling aan geneesmiddelen 
en mentale retardatie (cases met een IQ van minder dan 80 en referents met een IQ van 
meer dan 90) werd een associatie gevonden tussen blootstelling aan antibiotica en mentale 
retardatie in kinderen van hoog opgeleide ouders. De informatie over blootstelling was 
verzameld via de ouders, de huisartsen, de apothekers en de ziekenhuizen waarin de 
vrouwen eventueel bevielen. De gevonden associatie russen blootstelling aan antibiotica 
en mentale retardatie in kinderen van hoog-opgeleide ouders kan kunstmatig zijn. De 
resultaten van case-referent onderzoeken moeten voorzichtig worden geïnterpreteerd aan-
gezien de meting van de blootstelling aan geneesmiddelen ruimte laat voor (grote) fouten. 
(Hoofdstuk 7) Een historisch cohort onderzoek liet een effect zien van prenatale blootstelling aan 
antihypertensieve medicatie op de concentratie van kinderen. Geen van de andere ontwik-
kelingsaspecten verschilde russen de kinderen die aan labetalol waren blootgesteld en de 
kinderen die aan methyldopa waren blootgesteld. Kinderen die prenataal waren bloot-
gesteld aan methyldopa hadden meer moeite met slapen dan de andere kinderen in het 
onderzoek. De aan labetalol blootgestelde kinderen werden vaker door hun onderwijzer 
geklassificeerd als hyperactief met concentratie- en aandachtstoomissen. Historisch cohort-
onderzoek is uitvoerbaar maar het is duur om de functionele ontwikkeling van kinderen te 
bepalen en als veel ouders zijn verhuisd russen de bevalling en het moment van onderzoek 
kost het veel tijd en moeite om de nieuwe adressen te achterhalen. 
(Hoofdstuk 8) Hoewel epidemiologisch onderzoek naar de gedragsteratogeniciteit van genees-
middelen mogelijk is zou meer de nadruk moeten worden gelegd op de verbetering van 
Post-Marketing Surveillance. Een verbetering van Post-Marketing Surveillance zou zijn dat 
de eerste η prenataal aan een geneesmiddel blootgestelde kinderen gedurende hun leven 
worden gevolgd, waarbij η afhangt van het maximaal aanvaardbare risico. Een betere vast­
legging van blootstelling aan geneesmiddelen tijdens de zwangerschap zou de moge­
lijkheden voor non-experimenteel (epidemiologisch) onderzoek naar gedragsteratologie 
aanmerkelijk verbeteren. Geautomatiseerde administratie van afgeleverde geneesmiddelen 
bij de apotheker zou een belangrijke rol kunnen spelen in toekomstig onderzoek. Follow-up 
zou kunnen worden uitgevoerd via bestaande metingen zoals de consultatiebureaus en de 
schoolgezondheidsdiensten die uitvoeren. 
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D A N K W O O R D 
Zoals vnjwel ieder in zijn of haar dankwoord meldt, wordt het schrijven van een 
proefschrift zelden eenzaam op een zolderkamertje gedaan Veel mensen dragen aan het 
geheel een steentje bij 
Het fundament voor dit proefschrift werd gelegd door Professor JP Vanden-
broucke, die mij het eerste beetje plezier aan de Epidemiologie deed beleven en mijn keuze 
voor de Genetica wist terug te draaien Dat het fundament een vervolg kreeg is ook te 
danken aan mijn begeleiders m Lyon Dr Annie Sasco en Dr Rodolfo Saraca 
Toen ik in Nijmegen аап het promotieproject begon, zou het onderzoek zich richten 
op ijzersupplehe, zinkstatus en de ontwikkeling van het kind Dat hier nu een heel ander 
proefschrift voor u ligt is te danken aan de ruimte die ik kreeg van mijn begeleiders 
(Professor Tom Eskes, Professor Fons Gabreels, Dr Chiel Hekster, Dr Jenny Copius 
Peereboom en Dr Ir Gerhard Zielhuis) om het onderzoek naar eigen inzicht m te richten 
Een groot gedeelte van dit proefschrift werd geschreven met behulp van informatie 
verzameld door anderen 
Hoofdstuk twee is geheel met behulp van eerder verzamelde informatie geschreven 
Voor het beschikbaar stellen van hun gegevens wil ik Geert Berghs en Esmeralda Spanjaards, 
138 Wies Nijdam en Professor Eskes, and ofcourse Gunnar Ahlborg hartelijk danken 
De hoofdstukken vier, vijf en zes zijn geschreven met de informatie die door 
stageaires werd verzameld De extra handen die ik via hen kreeg kwamen buitengewoon 
goed van pas Marlou Prevoo, Henriette Nienhuis, Annette Huismans, Mary Bems, Yvonne 
van Duynhoven, Anja Hammink, Canne Doggen, Brenda Penninx en Martine Vrijheid, met 
alleen hebben jullie de gegevens verzameld, ook werd ik door het begeleiden van jullie 
stages veel wijzer Hoofdstuk zes zou bovendien onmogelijk zijn geweest zonder de 
medewerking van het Tilburgs Ambulatorium voor Neuropsychologie, waarvan Professor 
van der Vlugt hoofd is 
Het zevende hoofdstuk tenslotte, had met zo in dit proefschrift gestaan als het 
Prae ven tiefonds had besloten geen subsidie te verlenen, de gynaecologen* geen deel­
nemers hadden aangeschreven of geen informatie hadden gegeven over de zwangerschap, 
Ethische Commissies nog langzamer waren geweest met het nemen van besluiten over al 
eerder goedgekeurd onderzoek of de deelnemers geen deelnemers waren geweest Bij het 
opzetten van dit laatste onderzoek kreeg ik veel medewerking van Claire Assman-
Hulsmans van het Interdisciplinair Kinder Neurologisch Centrum, van Professor van der 
Vlugt van het Tilburgs Ambulatorium voor Neuropsychologie en van Dr Ρ Hem van het 
instituut voor Obstetne en Gynaecologie Anne-Petra Rozendal, Gerti van Vorst, Jolanda 
Sloots, Ingnd Comehssen, Marjo de Groot en Alexandra Benschop zijn het hele land 
doorgereisd op zoek naar de deelnemers en hun kinderen Annehes Pellegrino was nog 
fanatieker dan ik m het bewaken van de planning en het verzamelen en opbellen van de 
deelnemers, en Leo van Rossum deed alle klussen die anders zouden zijn blijven liggen 
Mw Abma-Hill heeft bovendien een groot gedeelte van het proefschrift herschreven 
zodat het engels echt Engels werd 
Hoewel ik mij aan de discussies over de zin van het leven op iedere eerste vnjdag 
van de maand heb onttrokken, hielden mijn collega's op de afdeling en daarbuiten mijn ogen 
open voor alles wat er buiten geneesmiddelen, zwangerschappen en epidemiologie op de 
wereld is Ook ik moet straks zorgen voor een E-mail verbinding met de afdeling 
Twee mensen speelden het laatste jaar een belangrijke rol in het ontstaan van dit 
proefschrift 
Gerhard, ab stok-achter-de deur, vraagbaak, kalmeringsmiddel en knbsch lezer 
(hoeveel pennen heb je de afgelopen jaren versleten7) van door mij gewrochten concepten, 
heb je (gelukkig) je stempel gedrukt op de inhoud van dit proefschrift 
En last but not least Enk, jouw talenten maakten van mijn enorme stapel A-4tjes dit 
prachtige boekwerkje Het lachende kindje' bleek zelfs bij de kas bekend Alleen daarvoor al 
mijn dank Voor al het andere kan ik je met schriftelijk danken en dat probeer ik dus ook met 
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Glossary* 
Bias - Deviation of results of a study or inferences drawn from the results of a study 
so that an incorrect view of the truth is obtained. 
Case-Referent study - Study of a population that can be classified by the occurrence 
or presence of a disease and by a history of an exposure hypothesized to cause the disease. 
Census - Complete enumeration of characteristics of a total population. 
Cohort study - Study of a population that can be classified by exposure or non-
exposure and that will be followed-up for the occurrence of a disease hypothesized to be 
caused by the exposure. 
Confidence Interval - A range of values that indicates the range of possible values of 
a statistical index compatible with the data on the basis of chance fluctuations with a 
specified probability. 
Confounding - A situation in which a measure of the effect of an exposure on risk is 
740 distorted because of the association of exposure with other factors that influence the 
disease studied. 
Cross sectional study - Study in which a population is classified according to 
presence of exposure and of disease at the same moment in time in the lives of members of 
a study population. 
Determinant - Any factor, whether event, characteristic, or other definable entity, 
that brings about change in a health condition, or other defined characteristic. 
Effect Modifier - A factor that modifies the effect of a determinant under study. 
Exposure - Proximity and/or contact with a source of a disease agent in such a 
manner that effective transmission of the agent or harmful effects of the agent may occur. 
incidence rate - The number of new cases of a disease, divided by the number of 
persons in a population times the amount of time the population has been under 
observation (incidence density) or the proportion of persons in a population developing 
the disease in a specified time period (cumulative incidence). 
Multifactorial - A combination of causes or alternative combinations of causes may 
be required to produce the disease: There is not a single cause that always produces the 
disease in everyone exposed. 
Odds - Measure that indicates how more likely it is that an event occurs than that an 
event does not occur. 
* Based In part on List |M. A dictionary of epidemiology. Oxford University Press, New York; 1988 
Odds Ratio - The odds of being exposed if diseased divided by the odds of being 
exposed if not diseased (in case-referent studies). 
Outcome - All identified changes in health status that may stem from exposure to a 
causal factor. 
Post-Marketing Surveillance - Approach to the monitoring of drug use after 
approval for marketing, monitoring the occurrence of serious adverse reactions associated 
with licenced drugs or biologic products used in normal medical practice, and initiating 
selected epidemiologic studies to estimate risk or test specific hypotheses. 
Power - Probability of detecting an association with at least an arbitrarily chosen 
p-value between exposure and outcome under study if such an association would exist. 
Prevalence rate - The proportion of persons having a disease or attribute at a 
specified point in time. 
P-value - Probability of a study resulting in a specific or more extreme estimate of an 
association (e.g. Relative Risk = 2) under the null hypothesis of no effect (i.e. RR = 1). The 
usual levels of probability below which an association is considered not to be resulting 
from chance and, hence, to be 'statistically significanf are ρ = 0.05 and ρ - o.oi. These levels 
are completely arbitrarily chosen. 
Relative Risk · The risk of developing a disease if exposed as contrasted to the risk of 
developing the disease if not exposed. 
Sample - Enumeration of characteristics of part of a population so as to be able to 
describe the characteristics of the total population. 
Study base - Amount of population time classified according to the presence or 
absence of exposure and studied for the occurrence of disease. 
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